










The handle http://hdl.handle.net/1887/21013  holds various files of this Leiden University 
dissertation. 
 
Author: Duyvenvoorde, Hermine van 
Title: Genetic causes of growth disorders 
Issue Date: 2013-06-25 




enetic causes of grow




omslag_hvanduyvenvoorde.indd   1 20-05-13   12:59
Genetic causes of 
growth disorders
Hermine van Duyvenvoorde
hoofdstuk 0.indd   1 18-05-13   17:29
ISBN:  978-94-6203-382-5
Cover design, lay-out: Esther Beekman (www.estherontwerpt.nl)
Cover image: iStockphoto.com
Printed by: CPI - Koninklijke Wöhrmann BV, Zutphen, The Netherlands
For publication of this thesis financial support from the Department of Pediatrics, the 
Department of Endocrinology and Metabolic Diseases, and the Department of Clinical 
Genetics of the Leiden University Medical Center, Ipsen Farmaceutica B.V. and  
the ‘Nederlandse Vereniging voor Calcium- en Botstofwisseling’ (NVCB) is gratefully 
acknowledged.
© 2013 H.A. van Duyvenvoorde, Rijnsburg, the Netherlands.
All rights reserved. No part of this publication may be reproduced in any form or by any 





de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 25 juni 2013
klokke 13.45 uur
door
Hermine Agatha van Duyvenvoorde
geboren te Katwijk
in 1981
hoofdstuk 0.indd   3 18-05-13   17:29
Promotiecommissie
Promotores:  Prof. dr. J.M. Wit
  Prof. dr. H.B.J. Karperien (Universiteit van Twente)
  Prof. dr. A.M. Pereira Arias
Copromotor:  Dr. M. Losekoot
Overige leden:  Prof. dr. E. Bakker 
  Prof. dr. M.H. Breuning
  Prof. dr. J.A. Romijn (Universiteit van Amsterdam)
hoofdstuk 0.indd   4 18-05-13   17:29
hoofdstuk 0.indd   5 18-05-13   17:29



















Chapter 1  General introduction
Part A Candidate gene approach 
Chapter 2  Short stature associated with a novel heterozygous mutation in the insulin-like 
growth factor 1 gene 
The Journal of Clinical Endocrinology & Metabolism 2010;95(11):E363-367
Chapter 3  The severe short stature in two siblings with a heterozygous IGF1 mutation is not 
caused by a dominant negative effect of the putative truncated protein
 Growth Hormone & IGF Research 2011;21(1):44-50
Chapter 4   Homozygous and heterozygous expression of a novel mutation of the acid-labile 
subunit 
 European Journal of Endocrinology 2008;159(2):113-120
Part B Combined candidate gene and whole genome approach 
Chapter 5   Two short children born small for gestational age with insulin-like growth factor 1 
receptor haploinsufficiency illustrate the heterogeneity of its phenotype  
The Journal of Clinical Endocrinology & Metabolism 2009;94(12):4717-4727
Chapter 6  Genetic analysis of short children with apparent growth hormone insensitivity
 Hormone Research in Paediatrics 2012;77(5):320-333
Part C Whole genome approach 
Chapter 7  Copy number variants in patients with short stature
 Submitted
Part D Combined whole genome approach and functional studies 
Chapter 8  A novel activating mutation in the kinase homology domain of  
natriuretic peptide receptor-2 causes extremely tall stature without skeletal 
deformities
 Submitted
Chapter 9 General discussion 
Chapter 10 Summary 
 Samenvatting 
Chapter 11 Curriculum Vitae 
 List of publications
hoofdstuk 0.indd   7 18-05-13   17:29
1
hfst 1.indd   8 20-05-13   10:32
General introduction1
hfst 1.indd   9 20-05-13   10:32
Chapter 1  | General introduction
10
General introduction
Normal body growth can be defined as the progression of height, weight, and head 
circumference in line with established standards for a given population. It starts at 
conception and proceeds through various developmental stages, controlled by genetic, 
environmental, psychosocial and nutritional factors (1;2).
Growth can be divided into four stages: fetal life, infancy, childhood and puberty. Fetal 
growth is mainly regulated by insulin-like growth factors (IGFs; IGF-I and IGF-II) and insulin, 
and environmental factors (nutrition, maternal factors, and placental function) have a 
larger impact than genetic factors. In the second trimester of fetal life growth velocity is at 
its maximum. In infancy (up to ~3 years) nutritional factors, the growth hormone (GH)-IGF-I 
system, as well as genetic factors play a role. In the first two to three years the child seeks 
its own growth channel, which is highly correlated with target height (gender-corrected 
mid-parental height). In childhood (from 3 years to puberty) growth continues at a lower 
and gradually diminishing rate, with a small growth spurt during mid-childhood. In this 
phase growth is predominantly under the influence of GH and thyroid hormone. Puberty is 
characterized by a growth spurt followed by a rapid decrease of growth velocity followed 
by fusion of the epiphyseal plate (growth plate), thereby terminating growth. Besides GH 
and IGF-I, estrogen is the main determinant of pubertal growth and epiphyseal fusion in 
boys and girls. Boys have a later onset of pubertal growth than girls, which gives them 
an additional two years of prepubertal growth. This, together with the greater amplitude 
of pubertal growth in boys, leads to a difference of 12-13 cm in adult height between the 
sexes. There is a wide variation in pubertal timing within each sex, but the net result is a 
comparable adult height in early and late maturers (2).
Height is a highly heritable and classic polygenic trait, and to a lesser degree influenced 
by environmental factors. It is estimated that about 80% of the variation in adult height 
among individuals is due to genetic factors (3). The GH-IGF-I axis is an important regulator 
of longitudinal growth. Genetic defects in this axis have been shown to be responsible 
for abnormal growth, and can have a large influence on adult height. These mutations, 
however, are rare and do not explain the ‘normal’ variation in height among people. Due to 
new techniques, such as genome-wide association studies (GWAS), 180 genes associated 
with height have been identified, and studies on even larger cohorts have suggested that 
there are at least 700 genes associated with height (Visscher, personal communication). 
While the individual contribution of each of these genes on height is small, the cumulative 
effect of all these genes is estimated to determine ~10% of the variance. This thesis focuses 
on the detection of genetic defects in the GH-IGF-I axis and on the results of whole genome 
SNP-arrays and next-generation sequencing to identify novel genes influencing height.




Genetic defects in the GH-IGF-I axis in short stature
The GH-IGF-I axis is the most important system regulating longitudinal growth. The first 
somatomedin hypothesis was formulated in 1957 and since then it has been updated due 
to new insights. The term somatomedin is derived from the hypothesis that GH (also 
known as somatotropin) does not exert its effects directly on tissues but only through 
an intermediary substance, first named sulfation factor, later somatomedin, and finally 
IGF. This hypothesis was later shown to be only partially correct. The latest version of the 
somatomedin hypothesis will be explained here.
GH is produced in and secreted by the pituitary. GH secretion is regulated by the 
hypothalamic factors GH releasing hormone (GHRH) and somatostatin. The pulsatile 
fashion of GH secretion is regulated by an interaction between these hormones. Another 
potent stimulator of GH secretion is ghrelin. This is an appetite stimulating peptide 
produced mainly by the stomach; plasma levels increase before meals and decrease 
thereafter (4). Ghrelin binds to its receptor, the growth hormone secretagogue receptor 
(GHSR1a), which is highly expressed in the brain and in the pituitary, resulting in GH 
secretion. Binding of GH to the transmembrane receptor (GHR, a cytokine receptor that 
lacks intrinsic kinase activity), which exists as a pre-assembled non-functional dimer 
(5), is followed by conformational changes leading to stabilization of the dimer and 
induction of signal transduction through the recruitment and activation of Janus kinase 
2 (JAK2) (6;7). An important intermediary of the complex activated signaling pathways 
is Signal Transducer and Activator of Transcription 5b (STAT5b). STAT5b is recruited to the 
intracellular domain of the activated GHR and subsequently phosphorylated (activated) by 
JAK2. Phosphorylated STAT5b forms a homodimer and translocates to the nucleus, where 
it binds to GH-responsive elements (GHRE) in DNA and activates transcription of target 
genes, including IGF1, IGFBP3 and IGFALS. 
IGF-I can be synthesized by almost any tissue in the body, in an autocrine and paracrine 
fashion, but circulating (endocrine) IGF-I is mainly produced in the liver (8). Approximately 
80–90% of circulating IGFs form a 150 kDa ternary complex with IGFBP-3 or -5 and the 
acid-labile subunit (ALS) (9), 10–15% are bound in a 40–50 kDa binary complex to IGFBPs, 
whereas less than 1% is found in the free form (10). The 150 kDa complexes cannot cross 
the capillary endothelial barrier, which prolongs the half-life of IGFs, IGFBP-3, and IGFBP-5 
in the circulation (9;11;12). This seems to play an important role in the regulation of the 
bioavailability of IGFs to the tissue compartments. When carried in ternary complexes, the 
half-life of IGF-I is more than 12 h, much longer than that of binary bound IGF-I (30–90 
min) and free IGF-I (~ 10 min) (13). IGF-I binds to the extracellular domain (α-subunit) of the 
tetrameric (α2β2) transmembrane IGF-I receptor (IGF1R, a tyrosine kinase receptor), leading 
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to autophosphorylation of the intracellular tyrosine kinase domain (β-subunit). This results 
in recruitment of cytoplasmic components of downstream signaling pathways, including 
the PI3K/Akt and MAPK/Erk pathways, ultimately leading to cell proliferation, survival and 
growth (6;14). 
The original somatomedin hypothesis proposed that GH binding to its receptor 
stimulated IGF-I production by the liver, which independently affected growth (15). Since 
then new insights made clear that: 1) IGFs and the GHR are expressed in most tissues; 
2) GH also has local (direct) effects independent of those mediated by the increase in 
circulating IGF-I; 3) IGF-I cannot be the sole mediator of GH action because IGF-I repletion 
does not fully restore the deficits found in GH insensitivity; 4) some of the IGF effects 
oppose the known actions of GH; and 5) both locally produced and circulating IGF-I are 
important growth mediators. This led to the latest somatomedin hypothesis (2007); “the 
augmentative/counteractive hypothesis”, which implies that IGFs enhance (augment) the 
anabolic actions of GH while reducing (countering) its potentially undesirable effects of 
hyperglycemia (gluconeogenesis) and depletion of lipid stores (lipolysis) (16).
In the following paragraphs the genetic defects in various components of the GH-IGF-I axis 
causing growth disorders are summarized.
GHRH
Although it is considered to be a candidate gene, to date no GH releasing hormone (GHRH) 
gene mutations or deletions causing isolated GH deficiency (IGHD) have been described 
(17;18). 
GHRHR
The GH releasing hormone receptor (GHRHR) belongs to the G protein-coupled receptor 
(GPCR) superfamily characterized by a seven transmembrane domain structure. Mutations 
in the GHRHR have been estimated to account for 10% of the patients with autosomal 
recessive familial IGHD. The phenotype of these patients include proportionate short 
stature, normal intelligence, variable anterior pituitary hypoplasia, normal GHRH and 
GHBP levels, undetectable or very low GH levels, low IGF-I and IGFBP-3 levels, absent or 
subnormal GH response to stimulation tests and a good response to exogenous GH. The 
presence of an intermediate phenotype has been hypothesized in heterozygous carriers, 
although they do not show signs of IGHD (19-21). 
GHSR1a
The GHSR is a member of the GPCR superfamily. There are two isoforms of GHSR: GHSR1a 
which is active and GHSR1b which is truncated and has no known biological activity. The 




GHSR1a is a constitutive active receptor which stimulates GH secretion after binding to 
Ghrelin. Homozygous and heterozygous mutations in the GHSR1a, causing a decrease in 
the constitutive activity, have been identified in patients with idiopathic short stature 
(ISS), IGHD, and constitutional delay of growth and puberty. Familial analysis suggests a 
dominant mode of inheritance with incomplete penetrance (22-25).
GH1
IGHD can also be caused by a mutation or deletion of the GH1 gene. Heterozygous missense 
mutations in the GH1 gene can lead to the secretion of biologically inactive GH, resulting 
in GH insensitivity (GHI). Clinical characteristics include severe short stature, normal or 
slightly increased GH levels, low IGF-I levels, and a good response in terms of growth and 
circulating IGF-I to exogenous GH. However, normal statured family members carrying 
the same mutation have been described, suggesting a variable penetrance (6;20;26). In 
one case a homozygous missense mutation of the GH1 gene was described, leading to the 
absence of the disulfide bridge Cys-53 to Cys-165, resulting in reduced binding affinity for 
the GH receptor (GHR) and subsequently activation of the JAK2/STAT5 signaling pathway. 
Similar to the cases with heterozygous missense mutations, both growth and circulating 
IGF-I responded well to exogenous GH. The parents of the patient, who were heterozygous 
carriers of the mutation, had normal height (27). 
Homozygous deletions of the GH1 gene have also been described in patients with 
IGHD. These patients usually have birth weight and length in the normal range but 
experience severe postnatal growth retardation with a height SDS less than -4.5. The 
sizes of the deletions vary, with 6.7 kb occurring most frequently. The remaining deletions 
include 7.6, 7.0 and 45 kb. The deletions arise at meiosis via unequal recombination and 
crossing over within the GH-gene cluster. Patients with homozygous GH1 deletions 
and frameshift mutations frequently develop anti-GH antibodies during exogenous 
GH treatment. However, this is an inconsistent finding, even within families (6;20). 
 The genetic defects in the GHRHR, GHSR1a, and GH1 gene causing IGHD, as described 
above, are relatively rare causes of short stature. 
GHR
Defects in the GHR gene lead to Laron syndrome, also called GH insensitivity syndrome 
(GHIS) or classical GH insensitivity. Since 1966, more than 250 patients have been described 
worldwide. Clinical characteristics include a mean birth length of -1 SDS or lower (indicating 
some GH dependency during late pregnancy), severe postnatal growth retardation, 
normal head circumference and very low circulating IGF-I, IGFBP-3 and ALS levels despite 
increased GH secretion. In most families this disorder is inherited in an autosomal recessive 
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fashion, including homozygous or compound heterozygous mutations. Deletions, 
missense, nonsense and splice site mutations have been reported. Milder phenotypes of 
GH insensitivity caused by GHR mutations (including splice site, compound heterozygous, 
and heterozygous dominant negative mutations) have also been described, illustrating the 
heterogeneous phenotype in this disorder (6;20;28).   
STAT5B
Molecular defects in GH signal transduction pathways appear to be very rare. To date, 7 
different homozygous STAT5B gene mutations have been described, including insertions, 
deletions, and missense and nonsense mutations. The phenotype of these patients include 
autosomal recessive inheritance, normal birth weight and length, followed by postnatal 
growth failure and severe GH resistance (also against exogenous GH), normal head 
circumference, delayed puberty in most cases, and in all cases except one a severe immune 
disorder. Biochemical profiles show normal or elevated GH secretion, very low circulating 
IGF-I, IGFBP-3 and ALS levels (also after GH stimulation), and in all cases elevated serum 
prolactin. A heterozygous defect may lead to a mild decrease in height SDS, but this has 
still to be confirmed by data from additional heterozygous carriers (6;7;28). 
IGF1
Only 6 mutations in the IGF1 gene have been described so far. The first reported patient had 
a homozygous deletion of exon 4 and 5 of the IGF1 gene, resulting in severe intrauterine and 
postnatal growth failure, microcephaly, mental retardation and sensorineural deafness. 
Circulating IGF-I was undetectable and IGFBP-3 and ALS were normal, but GH was 
elevated (29). In the second patient with the same phenotype, a homozygous nucleotide 
substitution located in the upstream core polyadenylation signal at the 3’ untranslated 
region in exon 6 of IGF1 was reported (30), but the same variant was subsequently found 
in unaffected children, thus probably is a polymorphism (31). The third and fourth reported 
cases both showed homozygous missense mutations that reduced the affinity of IGF1 for 
its receptor (32;33). The third case had a similar clinical phenotype as the first reported case, 
but the biochemical profile differed to some extent: circulating IGF-I was elevated, as well 
as GH and ALS, and IGFBP-3 was normal (32). Remarkably, the fourth case had a similar but 
milder phenotype compared to the previous reported patients, including milder growth 
deficiency, microcephaly, and intellectual impairment, and normal hearing. Circulating 
IGF-I concentrations differed according to the immunoassay used, and IGFBP-3 and ALS 
levels were in the upper normal range or above (33). The difference between these two 
cases consists of a difference in reduced binding affinity for the IGF1R; case 3 had a 90-fold 
decreased affinity compared to a 2- to 3-fold decreased affinity in case 4. This partially 




diminished IGF-I activity had marked consequences for growth and development (6;32-35). 
Family members who were heterozygous carriers of the IGF1 defect have a modest decrease 
of height and head circumference (29;32;36). The fifth and sixth reports concerned families 
with a heterozygous mutation in the IGF1 gene associated with severe short stature (37-
39). In none of the 3 index cases in the two reports deafness was observed. Microcephaly, 
intellectual impairment and intrauterine growth failure was observed at a variable 
degree, but not present in all cases. Circulating IGF-I was low and IGFBP-3 was normal in 
all index cases (37-39). In the first report, two children with severe short stature and a 
maternally derived novel heterozygous frameshift mutation in exon 3 of the IGF1 gene and 
their relatives were described, and a dominant negative effect of the putative truncated 
protein was hypothesized. This was however not supported by subsequent functional 
studies. The cause of the growth failure was speculated to be a combination of partial IGF-I 
deficiency, placental IGF-I insufficiency, and other genetic factors (38;39). The most recent 
report described a large kindred with severe short stature, in which a novel heterozygous 
splicing mutation in intron 4 of the IGF1 gen was found to segregate with short stature. 
There were however other family members who were short but wild-type for IGF1, thus it 
remains unclear whether the growth retardation in this family is due to more than the IGF1 
mutation alone (37). 
IGFALS
The IGFALS gene encodes for the soluble protein ALS, a member of the leucine-rich repeat 
superfamily. The proteins belonging to this family are characterized by their ability to 
participate in protein-protein interactions (12). ALS is synthesized primarily in the liver and 
regulated by GH (40). Molecular defects in the IGFALS gene appear to be more frequent 
compared to the other candidate genes for primary IGF deficiency, besides the GHR 
gene. Since the first report of a homozygous IGFALS mutation (41), a total of 16 unique 
homozygous or compound heterozygous mutations in 21 patients with ALS deficiency 
have been described (42;43). The different types of IGFALS mutations include missense and 
nonsense mutations, frameshift mutations with premature stop codons, and in-frame 
duplications resulting in the insertion of extra amino acids (6;44). The phenotype of these 
patients includes autosomal recessive inheritance, extremely low levels of circulating ALS 
with inability to form the ternary complex with IGFBP-3 and IGF-I, severely reduced levels 
of IGF-I together with even more profoundly reduced IGFBP-3 levels, and a mild growth 
retardation apparently out of proportion to the degree of IGF-I and IGFBP-3 deficits, 
with the possibility of reaching a normal adult height. Pubertal delay in boys and insulin 
insensitivity are common findings, but not present in all cases. Studies in family members 
who were either heterozygous carriers of the IGFALS mutation or had a homozygous wild-
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type IGFALS gene showed that heterozygosity resulted in approximately 1.0 SDS height 
loss in comparison with wild-type, whereas homozygosity or compound heterozygosity 
for IGFALS mutations resulted in a further height loss of 1.0 to 1.5 SDS, suggestive of a 
gene-dosage effect (43). An important lesson learned from these families is that local IGF-I 
appears to be more important for growth than circulating IGF-I. 
IGF1R
Heterozygous and compound heterozygous defects (mutations or deletions) of the IGF1R 
gene, causing IGF-I resistance, have been described several times since the first report 
of 2 children with short stature and unexplained intrauterine growth retardation with a 
compound heterozygous or heterozygous IGF1R mutation (45). Clinical characteristics of 
patients with a heterozygous or compound heterozygous IGF1R mutation include small 
birth size, short stature, small head circumference, and relatively high circulating IGF-I 
levels (>0 SDS) (6;28;46-48). Until recently, homozygous mutations in the IGF1R gene had 
not been described. First, these were thought to be lethal, because igf1r -/- mice die shortly 
after birth (46;47), but homozygosity for a hypomorphic IGF1R mutation has recently be 
associated with a similar phenotype as observed in (compound) heterozygous damaging 
mutations (49). In patients with a heterozygous deletion of the IGF1R and surrounding 
genes (most times a 15q terminal deletion) additional clinical manifestations can be seen, 
including developmental delay, and facial, cardiac and limb abnormalities, probably caused 
by haploinsufficiency of one of the surrounding genes (6;28;46-48;50).  
Genetic defects in the GH-IGF-I axis in tall stature
Tall stature can be caused by excessive GH secretion in childhood. In most of these 
children the excessive GH secretion results from a pituitary adenoma or hyperplasia. 
This is extraordinarily rare in early childhood, and its frequency only slightly increases 
in adolescence. A pituitary adenoma can be part of a genetic condition predisposing to 
pituitary and other tumors. Multiple endocrine neoplasia type 1 (MEN1), Carney complex 
type 1 (CNC1), familial isolated pituitary adenomas (FIPA) and McCune-Albright syndrome 
(MAS) are genetically determined endocrine-related tumor syndromes resulting in 
excessive GH secretion (51-53). MEN1 and CNC1 are autosomal dominant disorders caused 
by germline mutations in the MEN1 tumor suppressor gene and the PRKAR1A gene, 
respectively. Mutations in the CDKN1B gene (alias p27/KIP1) are associated with a MEN-
1- like syndrome. FIPA can be caused by inactivating mutations in the AIP gene, but the 
remaining predisposition genes are largely unknown. MAS is caused by a somatic mutation 
in the GNAS1 gene, thus this is a genetic, but not inherited, disorder (51-53). 
Sotos syndrome which is characterized by tall stature, craniofacial features and mental 




retardation is caused by haploinsufficiency of the NSD1 gene, either caused by a mutation 
or deletion (54-57). In a recent study a significant association was demonstrated with 
the Mitogen-Activated Protein Kinase (MAPK) pathway, which is part of the downstream 
signaling pathways of the GH and IGF-I receptors. Phosphorylation studies in skin fibroblasts 
demonstrated a possible diminished activity state of the MAPK/ERK pathway and the 
hypothesis was proposed that deregulation of the MAPK/ERK pathway in Sotos syndrome 
results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and 
may be a determining factor in statural overgrowth and accelerated skeletal maturation 
(58). The MAPK/ERK signaling pathway is an important regulator of cell differentiation, 
proliferation and apoptosis and has been implicated in many human diseases. Activating 
mutations in this pathway have been identified as the causative factor in a number of 
short stature syndromes, such as Noonan, Costello and LEOPARD syndrome (59). 
Duplication of the IGF1R caused by a trisomy of 15q26-qter is frequently associated with 
tall stature, mental retardation and often macrocephaly (60;61). Cell proliferation studies 
on skin fibroblasts of a patient with three copies of the IGF1R gene showed accelerated 
growth, and IGF1R phosphorylation and binding were increased, while cells of a patient with 
only one copy of the IGF1R gene showed slower growth and decreased phosphorylation 
and binding, compared with controls (62). There seems to be a gene dosage effect of the 
IGF1R gene, causing tall stature when increased and short stature when decreased.
Strategies to identify genetic defects
There are different strategies and techniques that can be used to search for a genetic defect 
causing a growth disorder, or any other congenital syndrome. One of these is the candidate 
gene approach. By thoroughly investigating the clinical and biochemical phenotype of the 
patient and compare this to the medical literature, one or more candidate genes can be 
selected. Sanger sequencing and/or multiplex ligation-dependent probe amplification 
(MLPA) analyses to identify mutations and/or copy number variations of these genes can 
be performed to investigate the presence of a genetic defect.
If the candidate gene approach does not result in a causative genetic defect or if there is 
no candidate gene, another approach is a whole genome single-nucleotide polymorphism 
(SNP) array to identify copy number variations or uniparental disomy. Microdeletions 
and -duplications, with a size >10 kb, can be identified with this technique and can result 
in the identification of novel genes involved in the regulation of longitudinal growth. 
 The most recent available technique in identifying genetic defects is next-generation 
sequencing. With this technique the whole genome or whole exome (only the part of 
the genome coding for genes) can be sequenced. With this high-resolution technique 
mutations of single nucleotides can be detected. Instead of sequencing one candidate 
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gene, all genes in the human genome are sequenced and analyzed for the presence of 
a mutation, inversing the search strategy and increasing the probability to identify new 
genes involved in longitudinal growth. However, this approach also brings new challenges, 
such as how to establish the pathogenicity of the detected genetic defect.
Outline of this thesis
In this thesis, we aimed to identify genetic causes of growth disorders, using different 
search strategies. We further aimed at studying genotype-phenotype correlations, in order 
to increase the understanding of the regulation of longitudinal growth.
Chapter 1 presents a general introduction and the outline of this thesis.
A. Candidate gene approach
The first family with a heterozygous mutation in the IGF1 gene associated with severe 
short stature is described in chapter 2, followed by functional analysis of the mutant 
IGF-I in chapter 3. 
Three brothers with short stature, microcephaly and ALS deficiency due to a homozygous 
mutation in the IGFALS gene and their family members are described in chapter 4. In this 
report we propose that there might be a gene-dosage effect, resulting in some negative 
effect on height and head circumference in heterozygous carriers.
B. Combined candidate gene and whole genome approach
In chapter 5 we describe the results of a study in 100 children born small for gestational 
age (SGA) with persistent short stature in which we examined 18 growth-related genes 
with MLPA for possible aberrations. This resulted in 2 patients with a heterozygous 
15q terminal deletion including the IGF1R gene. A subsequent review of the literature 
shows that small birth size, short stature, small head size, relatively high IGF-I levels, 
developmental delay, and micrognathia are the main predictors for an IGF1R deletion. 
Chapter 6 describes the genetic analysis of short children with apparent GH insensitivity, 
combining two different search strategies; the candidate gene and whole genome 
SNP array approach. Patients were divided into three groups based on their height 
and circulating IGF-I levels. The group including children with severe short stature 
and IGF-I deficiency (lowest height and circulating IGF-I levels) revealed three patients 
with two novel heterozygous STAT5B mutations, in two of them combined with novel 
heterozygous IGFALS variants. 




C. Whole genome approach
In chapter 7 the use of the whole genome SNP array approach in patients with ISS is 
described, in an effort to identify rare variants that may cause short stature. In 22.1% of 
the included families potentially pathogenic CNVs which may be associated with short 
stature were identified, although their precise role remains unclear.
D. Combined whole genome approach and functional studies
In chapter 8 the use of whole exome sequencing in a patient with extreme tall stature 
is described, identifying a heterozygous mutation in the NPR2 gene. Functional studies 
using the synthetic derived mutant NPR2 protein and skin fibroblast of the patient 
revealed increased basal and stimulated NPR2 activity, indicative for an activating 
mutation which results in extremely tall stature.
Chapter 9 provides a general discussion on the findings described in this thesis, including 
future perspectives, followed by a summary in English and in Dutch in chapter 10.
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Abstract
Context: Homozygous IGF1 deletions or mutations lead to severe short stature, deafness, 
microcephaly and mental retardation. Heterozygosity for an IGF-I defect may modestly 
decrease height and head circumference.
Objective: The objective of the study was to investigate the clinical features of heterozygous 
carriers of a novel mutation in the IGF1 gene in comparison with noncarriers in a short 
family and to establish the effect of human GH treatment.
Subjects: Two children, their mother, and their maternal grandfather carried the mutation 
and were compared with two relatives who were noncarriers.
Results: The two index cases had severe short stature (height SD Score −4.1 and −4.6), 
microcephaly, and low IGF-I levels. Sequencing of IGF1 revealed a heterozygous duplication 
of four nucleotides, resulting in a frame shift and a premature termination codon. The 
mother and maternal grandfather had the same IGF1 mutation. Adult height (corrected for 
shrinking and secular trend) and head circumference SD Score of carriers of the paternally 
transmitted mutation was −2.5 and −1.8, in comparison with −1.6 and 0.3 in noncarriers, 
respectively. After 2 yr of GH treatment, both index cases exhibited increased growth.
Conclusions: Heterozygosity for this novel IGF1 mutation in children born from a mother 
with the same mutation, presumably in combination with other genetic factors for short 
stature, leads to severe short stature, which can be successfully treated with GH.




Insulin-like growth factor-I (IGF-I) plays a critical role in the regulation of pre- and postnatal 
growth and development in humans and rodents (1;2). Prenatal IGF-I production is largely 
growth hormone (GH) independent, and is mainly affected by placental sufficiency, fetal 
nutrition, and insulin (3). Postnatally IGF-I production and secretion is predominantly 
regulated by GH and nutrition (1). IGF-I can be synthesized by almost any tissue in the body, 
but circulating IGF-I is mainly produced in the liver (4).
A total IGF-I deficiency caused by a homozygous IGF1 deletion or missense mutation, 
leads to severe intrauterine and postnatal growth failure, microcephaly, mental 
retardation, and sensorineural deafness (5;6). In another patient with the same phenotype, 
a homozygous nucleotide substitution located in the upstream core polyadenylation 
signal at the 3’ untranslated region in exon 6 of IGF1 was reported (7), later shown to be a 
polymorphism (8). Recently a fourth patient was described with a homozygous missense 
IGF1 mutation (9), exhibiting intrauterine and postnatal growth failure, microcephaly, mild 
intellectual impairment, but normal hearing.
There is some evidence that heterozygosity for an IGF1 defect is associated with a 
modest decrease of height. The eight heterozygous carriers of the IGF1 deletion had a 
height between −0.6 and −2.1 SD Score (SDS), and serum IGF-I was below the normal range 
in five (5;10). The nine heterozygous carriers of the missense mutation showed a subtle, 
but statistically significant, inhibition of intrauterine and postnatal statural and cranial 
growth (6).
In this report we describe two children with severe short stature and a maternally 
derived novel heterozygous mutation in exon 3 of the IGF1 gene and their relatives. All 
subjects provided written informed consent.
Materials and Methods
Clinical, radiological, and audiometric measurements
A full physical examination was performed as described previously (11). Bone mineral 
density was measured by dual-energy x-ray absorptiometry using the Hologic Scanner 
(QDR 4500; Hologic, Waltham, MA) at the lumbar spine and femoral neck. Z-scores were 
calculated as a function of age, sex, and ethnicity for a matched population using the 
Hologic reference database. Hearing ability at different sound frequencies (500−4000 Hz) 
was measured with an AC40 clinical audiometer (Interacoustics, Eden Prairie, MN).
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Biochemical measurements
Plasma acid-labile subunit (ALS), IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, IGFBP-3, 
IGFBP-4, and IGFBP-6 were determined as described previously (6). Serum insulin levels, 
after an overnight fast, were determined by a semiautomatic luminescence method 
(Immulite 1000; Siemens Medical Solutions Diagnostics, Los Angeles, CA). GH levels are 
expressed as micrograms per liter (conversion rate 1 μg/liter = 3.0 IU, standard World Health 
Organization international standard 98/574).
Molecular studies with genomic DNA of the family members
Genomic DNA was isolated from whole blood (12). All exons of IGF1 (GenBank accession 
number NM_000618) were sequenced as described previously (6).
For the analysis of single-nucleotide polymorphisms, the Affymetrix GeneChip human 
mapping 262K NspI array (Affymetrix, Santa Clara, CA) was used. Detection of copy number 




Clinical and biochemical features are shown in Table 1. Adult height SDS is corrected for 
shrinking and secular trend (15).
Index case III-1 was born after an uncomplicated 40-wk pregnancy. There were feeding 
difficulties in infancy, slow motor development, poor growth, and delayed bone age (2.5 yr 
at 5.9 yr) (Supplemental Fig. 1A). She had a prominent forehead, thin lips, and fine eyebrows. 
IGF-I was low, but GH maximum during two provocation tests was normal (10.7 μg/liter, 
normal >6.7 μg/liter). At an IGF-I generation test (1), baseline plasma IGF-I was −2.7 SDS and 
IGFBP-3 was 0.3 SDS. Only on the highest GH dose IGF-I normalized (−0.6 SDS).
Her younger brother (index case III-2) was born after an uncomplicated 42-wk pregnancy. 
Besides cow milk allergy and asthma, there were no medical problems, except poor growth 
and delayed bone maturation (Supplemental Fig. 1B). He had a prominent forehead. Plasma 
IGF-I was low and the peak GH response to arginine borderline (5.6 μg/liter).
Case II-3, the father of the index cases, had a height of −1.3 SDS, a head circumference 
(HC) of −1.0 SDS and normal IGF-I and IGFBP-3.
Their mother (case II-2) had feeding problems in infancy and poor growth. At 8.5 yr, height 
SDS was −3.0 (16), and the GH peak after exercise was 11.5 μg/liter. Breast development 
started at 11.3 yr at a height of 131.0 cm, and pubertal height gain was only 16.2 cm.
The mother’s sister (case II-1) was also short as a child (height SDS −2.0) (16). Her pubertal 
growth spurt started at 9.75 yr at a height of 128.0 cm, and pubertal height gain was 




28.5 cm. The GH peak after exercise was 6.3 μg/liter.
Their maternal grandfather (case I-1), born in 1941, was admitted to the hospital in the 
first 6 months for failure to thrive. Since 32 yr of age, he is known with poor bone quality, 
overweight, early dementia, chronic diarrhea, headache, reflux esophagitis due to a hernia 
diaphragmatica, gout, and a cataract. Reportedly his father, as well a several members of 
his father’s family, was short.
Case I-2, the probands’ maternal grandmother, had always been healthy without any 
medication.
Molecular studies with genomic DNA of the family members
Sequence analysis of IGF1 of cases I-1, II-2, III-1, and III-2 revealed a heterozygous duplication, 
indicated as +/−, of four nucleotides, resulting in a frame shift at position 35 of the mature 
IGF-I protein and a premature stopcodon (c.243_246dupCAGC, p.Ser83GlnfsX13) (http://
www.hgvs.org/mutnomen/recs-prot.html). The other family members did not carry the 
mutation (+/+) (Fig. 1).
Sequence analysis of FGFR3 in cases II-2, III-1 and III-2 and SHOX in cases II-2 and III-1 
showed no abnormalities. Case III-2 showed a 47,XYY karyotype. His sister (case III-1) and 
father (case II-3) had a normal karyotype.
Single-nucleotide polymorphism array analysis showed an interstitial deletion 
(rs13073496 to rs1119180) of about 0.4 Mb on chromosome 3q26.1 in cases I-1, II-1, II-2, III-1 and 
III-2. All these subjects, except case II-1, are also heterozygous carriers of the IGF1 mutation 
(Fig. 1). The deleted area does not contain any genes or noncoding RNAs. None of the known 
variations in the Database of Genomic Variants in this region (http://projects.tcag.ca/
variation/) had 100% overlap with this deletion.
Comparison of clinical and biochemical features between carriers and noncarriers of the 
IGF-I mutation
Carriers of the IGF1 mutation tended to have a lower height SDS (−3.4 vs. −1.6, P = 0.172) and 
had a significantly lower HC (−1.9 vs. 0.3, P = 0.002). In case II-2, bone mineral density was 
normal. Tone audiometry in the two probands was normal. In carriers plasma IGF-I was 
lower than in noncarriers (P = 0.004).
Response to GH treatment
Both index cases received GH (1.4 mg/m2/day) (Supplemental Fig. 1), which was well 
tolerated. After 2 yr, height SDS in case III-1 increased by +1.0, she remained prepubertal, 
and plasma IGF-I rose from −2.6 to +0.6 SDS. IGFBP-3 increased from −0.4 to +0.5 SDS
In case III-2 height SDS increased by +1.5 SD, IGF-I from −2.4 to +0.3 SDS, and IGFBP-3 from 
−1.0 to +0.3 SDS.
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I-1 II-2 III-1 III-2 I-2 II-1
IGF1 gene +/− +/− +/− +/− +/+ +/+
Gender M F F M F F
Age (yr) 65.2 35.5 8.2 6.2 64.5 37.2
Birth weight (kg) [SDS] n.a.  2.8 [−1.6] 2.3 [−2.9] 3.3 [−1.2] 4.0−5.0 3.0 [−1.1]
Birth length (cm) [SDS] n.a. 47 [−1.6] 44 [−3.8] 50 [−1.0] n.a. 48 [−1.1]
Height (cm) [SDS]a 164 [−1.4] 147.2 [−3.5] 108.9 [−4.1] 98.7 [−4.6] 153.2 [−1.2] 156.5 [−2.0]
HC (cm) [SDS]* 54.7 [−1.8] 52.5 [−1.7] 47.8 [−2.4] 49.0 [−1.6] 55.5 [0.1] 56.0 [0.4]
BMI (kg/m2) [SDS] 28.6 [3.5] 31.3 [4.7] 14.1 [−1.3] 13.5 [−1.6] 27.0 [2.7] 40.0 [8.8]
Sitting height: height [SDS] 0.54 [1.7] 0.55 [2.2] 0.55 [1.6] 0.57 [2.5] 0.53 [0.7] 0.55 [1.7]
IGF-I (ng/ml) [SDS] 66 [−2.0] 87 [−1.8] 76 [−2.3] 35 [−2.6] 126 [0.6] 131 [−0.4]
IGF-II (ng/ml) [SDS] 529 [1.6] 599 [1.7] 640 [2.0] 542 [1.4] 665 [3.0] 719 [2.8]
IGFBP-1 (ng/ml) [SDS] b 23 5 143 [0.3] 378 [1.3] 62 7
IGFBP-2 (ng/ml) [SDS] 143 [−0.6] 83 [−1.7] 155 [−1.3] 288 [0.2] 244 [0.5] 81 [−1.7]
IGFBP-3 (mg/liter) [SDS] 2.0 [0.1] 2.8 [0.8] 3.6 [1.2] 2.1 [0.1] 3.3 [2.0] 2.7 [0.7]
IGFBP-4 (ng/ml) [SDS] 242 [1.1] 212 [0.6] 109 [−1.4] 117 [−1.1] 184 [−0.1] 133 [−0.9]
IGFBP-6 (ng/ml) [SDS] 252 [1.0] 148 [0.2] 83 [−1.1] 89 [−0.3] 131 [−0.9] 141 [0.0]
ALS (mg/liter) [SDS] 16.6 [−0.1] 22.8 [0.3] 20.1 [1.1] 11.5 [−0.4] 20.7 [1.2] 24.8 [0.7]
Insulin (IU/liter) c 8.5 22.2 < 2.0 < 2.0 < 2.0 9.6
To convert IGF-I to nanomoles per liter, multiply by 0.131; to convert IGF-II to nanomoles per liter, multiply by 0.134; 
to convert ALS to nanomoles per liter, multiply by 15.8; to convert IGFBP-1 to nanomoles per liter, multiply by 0.033; 
to convert IGFBP-2 to nanomoles per liter, multiply by 0.032; to convert IGFBP-3 to nanomoles per liter, multiply by 33.3; 
to convert IGFBP-4 to nanomoles per liter, multiply by 0.038; to convert IGFBP-6 to nanomoles per liter, multiply by 
0.034. n.a., Not available; BMI, body mass index; ALS, acid-labile subunit.
 a Adult height SDS is corrected for shrinking and secular trend by the equations of Niewenweg et al. (15).
b  Normal range for nonfasting subjects is 24−57 ng IGFBP-1 per milliliter. After overnight fasting there is an average
5-fold rise in normal individuals. IGFBP-1 SDS values are not available for adults older than 24 yr.
c Normal range for healthy subjects after overnight fasting is less than 25 IU/liter.
* Statistical difference between heterozygous and wild-type family members.
Table 1  Clinical features and biochemical characteristics of the heterozygous and noncarriers





Pedigree of the family. The heterozygous carriers of the IGF1 mutation are indicated with a 
diagonally striped right half of the symbol and the noncarriers are indicated with a filled black 
right half. The carriers of the 3q26.1 deletion are indicated with a white left half of the symbol and 
the noncarriers are indicated with a filled black left half. On the right, the different combinations 
of wild-type (WT) or mutant (MT) IGF1 and deleted or normal 3q26.1 is explained. On the left the 
generation number is indicated and the family number is indicated below each individual.
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Discussion
We have shown that heterozygosity for a maternally derived IGF1 frameshift mutation is 
associated with severe short stature and microcephaly. The probands’ mother, who inherited 
the same mutation from her father, was less short than the two probands. However, she 
was still shorter and had a smaller HC and lower plasma IGF-I than her sister, who is not 
carrying the mutation. This suggests that the combination of maternal and fetal IGF-I 
deficiency may have had a larger effect on growth than fetal IGF-I deficiency alone, similar 
to previous observations in a family with an IGF1R defect (11). Most carriers had feeding 
difficulties in infancy, comparable with that observed in patients with homozygous IGF1 
and heterozygous IGF1R defects (5;6;11;17). Biochemically, GH secretion was not elevated, 
similarly to observations in children with IGF-I receptor defects (17) and mice with brain-
targeted inactivation of igf1r (18). Long-term GH treatment of the probands resulted 
in a good growth response. Mutant IGF-I was synthesized and used for several in vitro 
experiments. It could not bind to the IGF-I receptor or antagonize the growth-promoting 
effect of IGF-I. It could bind to IGFBPs but was not incorporated into 150-kDa complexes 
(data not shown). Details will be reported elsewhere.
We hypothesize that the severe short stature in the two probands might be caused by a 
cumulative effect of three factors: 1) IGF1 haploinsufficiency; 2) placental dysfunction due 
to maternal IGF1 haploinsufficiency; and 3) other genetic factors associated with (mild) 
short stature.
The first part of our hypothesis is supported by the observation that case II-2 was in 
childhood 1 SD and in adulthood 1.5 SD shorter than her wild-type sister (case II-1). Indirect 
support comes from our previous study showing that heterozygosity for a missense IGF1 
mutation leads to a 0.6 SD lower height, as well as an inhibition of intrauterine and cranial 
growth (6;19). The heterozygous carriers of an IGF1 deletion also exhibited reduced height 
(5;10). The difference between pubertal height gain in cases II-2 and II-1 suggests that IGF-I 
deficiency may have a strong impact on pubertal growth.
The second part is based on the observation that birth length (−3.8 SDS) and childhood 
height (−4.1 SDS) of case III-1 is 1−2 SD lower than of her mother (−1.6 and −3.0 SDS, 
respectively). It is further supported by our previous observations in a family with an IGF1R 
mutation (11), in which the proband’s length was much more affected than in her mother, 
who did not inherit the mutation maternally. Some more indirect evidence for such effect 
of maternal IGF-I deficiency on placental and fetal growth includes the strong correlation 
between the rate of IGF-I increase during pregnancy and placental weight (11). Furthermore, 
placentas from intrauterine growth retardation pregnancies are characterized by decreased 
expression of IGF-I receptor and associated signal transduction proteins (11).
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chapterWith respect to the third part (other genetic factors), we have found no other gene 
defects in this family, except for an interstitial deletion on chromosome 3q26.1 in most 
cases. There is no evidence linking this region to short stature. Interestingly, the male 
proband has a 47,XYY karyotype, known to be associated with tall stature. This may have 
mitigated the negative effect of IGF-I deficiency on intrauterine growth and may have 
increased his growth response to GH.
In conclusion, our observations suggest that maternally and paternally derived IGF1 
haploinsufficiency leads to a height loss of 2 and 1 SD, respectively, and to a smaller HC, 
in comparison with wild-type relatives. In combination with a familial predisposition for 
short stature, this can lead to a height far below the normal range, which can be treated 
successfully with GH.
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Plasma levels of IGF-I, IGF-II, IGFBP-1, -2, -3, -4 and -6 were determined as described 
previously (1). ALS was measured by a commercially available ELISA (Diagnostics Systems 
Laboratories, Inc., Webster, TX). With the exception of IGFBP-1 for adults older than 24 
years, smoothed references based on the LMS method were available for all parameters 
allowing conversion of patient data to SDS values (1). For the adult members of the family 
plasma IGFBP-1 concentrations after an overnight fast were compared with a reference 
group of 6 healthy adult controls. Levels of insulin were determined in serum, obtained 
after an overnight fast, by a semi-automatic luminescence method (Immulite 1000; 
Siemens Medical Solutions Diagnostics, Los Angeles, CA).
Molecular studies with genomic DNA of the family members
Genomic DNA was isolated from whole blood according to the salting out procedure 
described by Miller et al (2). All exons of IGF1 (GenBank accession number NM_000618) were 
PCR amplified and sequenced as described previously (1). The various primer sequences are 
available upon request.
For the analysis of single-nucleotide polymorphisms (SNPs), the Affymetrix GeneChip 
human mapping 262K NspI array (Affymetrix, Santa Clara, CA) was used. This SNP array is 
capable of genotyping approximately 262,000 SNPs, with a ~12 kb resolution. The assay 
was performed according to the manufacturer’s protocol, beginning with 250 ng DNA. 
Detection of copy number changes was performed using Copy Number Analyser for 
GeneChip (CNAG) version 2.0 (www.genome.umin.jp/), using a reference set of minimal 5 
and maximal 10 control DNAs (3;4).






Growth curves of the index cases. The dots represent height measurements, the squares 
represent bone age measurements, and GH treatment is indicated below the curves. 
The growth curves of index cases III-1 and III-2 are shown in panels A and B, respectively. 
S
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Abstract
Objective: While in previous studies heterozygosity for an Insulin-Like Growth Factor 1 (IGF1) 
defect only modestly decreased height and head circumference, we recently reported 
on two siblings with severe short stature with a maternally transmitted heterozygous 
duplication of 4 nucleotides, resulting in a frame shift and a premature termination codon 
in the IGF1 gene. In this paper we describe the structural and functional characteristics of 
the putative truncated IGF-I protein. 
Design: Two children, their mother and maternal grandfather carried the mutation. In 
addition, two family members who were not affected were included in the study. Mutant 
(MT) IGF-I was synthesized in oxidized and reduced form using two methods. Neutral gel 
filtration studies were carried out with wild-type (WT) and synthetic MT IGF-I. Binding 
analysis of synthetic MT IGF-I to the IGF1R and insulin receptors were performed with 
EBNA-293 cells, stably transfected with the IGF-I receptor, and IM9 cells. L6 cells were used 
to examine the mitogenic potency and the potential antagonizing effect of synthetic MT 
IGF-I by [3H]-thymidine incorporation assays.
Results: In the sera of both the carriers and non-carriers  the proportion of 125I-IGF-I that 
was associated with the 150 kDa complex was somewhat less (varying between ~37 and 
~52%) than in normal pooled serum (~53− ~ 63%) and, instead, slightly increased amounts 
of radioactivity were eluted in the 40−50 kDa fraction (consisting of binary IGF−IGFBP 
complexes) or remained unbound. Synthetic MT IGF-I did not bind to the IGF-I receptor, 
nor antagonize the growth-promoting effect of IGF-I. It did bind to IGFBPs, but was barely 
incorporated into 150 kDa complexes. Because in all cases WT IGF-I immunoreactivity was 
recovered in one peak, corresponding to the MW of WT IGF-I, i.e. ~7.6 kDa, an interaction of 
circulating truncated mutant peptide with WT IGF- I is very unlikely. 
Conclusions: There is no evidence that the severe short stature associated with 
heterozygosity for this novel IGF1 mutation in children born from a mother with the same 
mutation is caused by a dominant negative effect of the truncated protein. We speculate 
that the growth failure is caused by a combination of partial IGF-I deficiency, placental 
IGF-I insufficiency, and other genetic factors. 
Introduction
IGF-I is a highly conserved, single-chain polypeptide consisting of 70 amino acids, organized 
into four peptide domains: A, B, C and D. The B-domain and the first A domain helix are 
mainly responsible for binding to IGFBPs. The A-, B- and C- and, to a lesser extent, the 
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D-domain contribute substantially to IGF binding to its receptor (IGF1R) (1-8). The A domain 
also contains residues involved in low affinity binding to the IGF2R (4-9). The IGF-I pro-
hormone contains an additional carboxy-terminal E peptide that is cleaved in the Golgi 
apparatus before secretion (10).
Approximately 80−90% of circulating IGFs form a 150 kDa ternary complex with IGFBP-3 
or -5 and the acid-labile subunit (ALS) (11), 10−15% are bound in a 40−50 kDa binary complex 
to IGFBPs, whereas less than 1% is found in the free form (12). The 150 kDa complexes cannot 
cross the capillary endothelial barrier, which prolongs the half-life of IGFs, IGFBP-3, and -5 
in the circulation (11, 13, 14). This seems to play an important role in the regulation of the 
bioavailability of IGFs to the tissue compartments. When carried in ternary complexes, the 
half-life of IGF-I is more than 12 h, much longer than that of binary bound IGF-I (30−90 min) 
and free IGF-I (~10 min) (15).
In mice IGF-I plays a major role in pre- and postnatal growth (16-17). Recent studies 
revealed that autocrine and paracrine IGF-I appears crucial for early postnatal and pubertal 
development of cortical bone, while circulating IGF-I, responsible for the endocrine effect, 
is mainly important for growth after puberty. In autocrine and paracrine IGF-I deficient 
mice high levels of serum IGF-I can permit postpubertal “catch-up” growth (18-20). 
IGF-I is also needed for normal pre- and postnatal growth in humans, as shown by 
severe dwarfism in three patients with well documented homozygous IGF1 defects, caused 
by the deletion of exons 4 and 5 (21), a missense mutation (22) and a missense mutation 
with a milder phenotype (23). There may be a fourth case (24), but although the patient’s 
phenotype was very similar, the presumed genetic aberration in the polyadenylation site 
at the 3’UTR in exon 6 was later found to occur also in healthy controls (25). Patients with 
a homozygous IGF1 defect exhibit severely affected intrauterine growth (about −4 SDS), 
whereas postnatally height SDS varies between −6.9 and −8.5, and head circumference 
between −4.0 and −8.0 SDS. Heterozygosity for an IGF1 mutation or deletion may be 
associated with a mild height loss (in the order of 1 SD), but can present as short stature if 
occurring in a family with genetic predisposition for decreased height (22).
We recently reported on two siblings with severe short stature carrying a heterozygous 
duplication of four nucleotides in IGF1, resulting in a frame shift at position 35 of the mature 
IGF-I protein and a premature stop codon (c.243_246dupCAGC, p.Ser83GlnfsX13) (26). In 
the present paper we describe the laboratory studies that we performed to investigate 
whether this heterozygous mutation could cause such severe phenotype, either directly or 
by interfering with the biological action of WT IGF-I, in particular whether the truncated 
mutant IGF-I may exert a dominant negative or antagonistic effect on the function of wild-
type IGF-I.
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Clinical features, growth curves and plasma levels of IGFs, various IGFBPs and ALS of the 4 
carriers of the IGF1 mutation, as well as the pedigree, have been reported previously (26). In 
short, the first index case was a 8.2 year old girl (III-1) born small for gestational age (birth 
weight −2.9 and birth length −3.8 SDS) who presented with severe postnatal short stature 
(height −4.1 SDS) and microcephaly (head circumference −2.4 SDS). Her 6.2 year old brother 
(III-2) had a birth weight and length of −1.2 and −1.0 SDS, respectively, a height of −4.6 SDS, 
and a head circumference of −1.6 SDS. Their mother (II-2) carried the same mutation and 
had a height SDS of −3.5 and a head circumference of −1.7 SDS, and the affected maternal 
grandfather (I-1) had a height of −1.4 SDS (corrected for age and secular trend) (27) and a 
head circumference of −1.8 SDS. The unaffected maternal grandmother and aunt were less 
short (−1.2 and −2.0 SDS) and had a normal head circumference (0.1 and 0.4 SDS). Serum 
IGF-I SDS of the 4 carriers was approximately −2 SDS, significantly lower than in non-
carriers (P = 0.004). For both carriers and non-carriers of the IGF1 mutation serum levels of 
IGFBP-1, -2,-3, -4 and -6, as well as those of ALS, were within the respective normal ranges, 
i.e. between −2 and +2 SDS (26). Case III-2 showed a 47,XYY karyotype. 
Synthesis of mutant IGF-I 
The biological properties of mutant (MT) IGF-I were tested with synthesized peptides. 
Since the B-domain of MT IGF-I contains two unpaired cysteine residues, and it is unknown 
whether the cysteines remain reduced or become oxidized (in case the peptide is stably 
expressed in vivo), both oxidized and reduced forms were prepared, and used in the various 
experiments. 
One batch of the oxidized mutant peptide was prepared (Dr. L. Schäffer, Novo Nordisk 
A/S, Maaloev, Denmark) by solid phase peptide synthesis on Tentagel S RAM resin using 
Fmoc chemistry on a Liberty microwave synthesizer according to the manufacturer’s 
instruction. The formation of disulfide bridges was accomplished by treatment of the 
peptide with 2% iodine in N-methylpyrrolidone for 1 hour prior to cleavage. The peptide was 
cleaved from the resin with trifluoroacetic acid/water/triisopropylsilane (95%:2.5%:2.5%) 
and purified by standard RP-HPLC. 
Another batch of oxidized peptide, as well as a batch of reduced peptide, was prepared 
in the laboratory of Prof. J. D. Wade (Howard Florey Institute, Melbourne, Australia). Region-
selectively S-protected A- and B-chains were synthesized separately as their C-terminal 
amides using the continuous flow Fmoc-SPPS method as previously reported (28), using an 
automatic PerSeptive Biosystems Pioneer peptide synthesizer (Massachusetts, USA) (29). 
The identities of the crude peptides were confirmed by MALDI-TOF MS. Subsequently, the 
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mutant IGF-I peptide was prepared by sequential region-selective disulfide bond formation 
between the two chains also as previously described (28,29). Following a final RP-HPLC 
purification step, overall yield of mutant IGF-I was 5.01 mgs (9.5% relative to crude starting 
B-chain) which was satisfactory given the multiple steps involved in its preparation.
We show the results obtained with the peptides prepared by Prof. J.D. Wade but 
identical results were obtained with the one prepared by Dr. L. Schäffer. 
Neutral gel filtration studies with WT and synthetic MT IGF-I 
The different molecular-size classes of endogenous IGF-I (i.e. 150 kDa, 40–50 kDa, and 
unbound, free form) in plasma were determined by neutral gel filtration through a 
1.6×60 cm Superdex 200 Hiload column, as described previously (30). Prior to column 
chromatography, each serum sample (250 μl) was incubated with 100 μl of ~100,000 cpm 
of either 125I -WT hIGF-I or 125I- MT IGF-I being dissolved in 50 mM sodium phosphate buffer 
pH 7.4, containing 0.2% BSA, 10 mM EDTA and 0.05% (w/v) Tween-20, for 17 h at 4°C. The 
various molecular size classes of complexes were eluted from the column at a rate of 1.2 
ml/min using 0.05 M NH4HCO3 buffer pH 7.4. The 125I content of each 1.2 ml fraction was 
counted in a gamma counter. 
In order to investigate the ability of synthesized MT IGF-I to compete for incorporation 
into ternary and binary complexes, 250 μl aliquots of pooled normal human serum were 
incubated with 100 μl of the same amount of 125I radiolabeled WT recombinant IGF-I in the 
presence of increasing concentrations of either recombinant wild-type IGF-I or synthetic 
MT IGF-I, as described above. The distribution of 125I-IGF-I among the various molecular-size 
classes in each aliquot of serum was determined after separation by S200 gel filtration.
The possibility that WT IGF-I and eventually naturally existing MT IGF-I in serum 
interacted, for example by forming higher MW dimers or multimers, was investigated by 
Sephadex G-50 exclusion chromatography of Sep-Pak C18 extracts of sera from carriers 
and non-carriers. The 1.5×90-cm column was calibrated with lactalbumin (14.5 kDa), hIGF-II 
(7.5 kDa), and insulin-B (3.5 kDa). Acetic acid (0.1 M) was passed in a descending direction 
at a rate of 4.8 mL/h, and ~3 mL fractions were collected, dried and reconstituted in 50 
mM sodium phosphate buffer pH 7.4, containing 0.2% BSA, 10 mM EDTA and 0.05% (w/v) 
Tween-20. In each column fraction the IGF-I immunoreactivity was determined by RIA (31). 
Cell lines
Binding analysis of synthetic MT IGF-I to the IGF1R and insulin receptors was performed 
with EBNA-293 stably expressing the IGF-I receptor (gift from Dr. J. Whittaker, Case 
Western Reserve University, Cleveland, Ohio) and IM9 human lymphocytes, respectively. 
The rat myoblast cell line (L6) used for thymidine incorporation was kindly provided by Bo 
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Falck Hansen, Novo Nordisk, Denmark. These cells express ~175,000 IGF-I receptors per cell 
and no insulin receptors (Sajeed, W. and De Meyts, P., unpublished data).
EBNA 293 cells transfected with the IGF-1 receptor 
The EBNA-293 cells are human embryonic kidney (HEK) cells expressing Epstein-Barr 
nuclear antigen (EBNA-1) which are stably transfected with the IGF-I receptor (EBNA293t 
IGF-IR), kindly provided by Dr. J. Whittaker (Case Western Reserve University, Cleveland, 
Ohio) (32). The cells were cultured in DMEM high glucose with Glutamax-1 supplemented 
with 10% FBS, 100 U/ml Penicillin-Streptomycin (all from Gibco, Invitrogen, USA). 250 μg/ml 
Hygromycin B (Sigma-Aldrich, USA) and 400 μg/ml Geneticin (Gibco, Invitrogen, USA) were 
added to the media for selecting the stably transfected cells. The cells were grown at 37°C 
in 5% CO2 humidified atmosphere. Cells were sub-cultured three times a week by washing 
the cells in 10 ml PBS w/o calcium and magnesium (Gibco, Invitrogen, USA), detaching the 
cells from the culture flask with 2 ml 0.05% Trypsin-EDTA (Gibco, Invitrogen, USA), followed 
by resuspending in 8 ml fresh media.
IM9 cells
The IM9 human lymphoblast cell line (American Type Culture Collection (ATCC), USA) is 
derived from a patient with multiple myeloma. The cell line carries the Epstein-Barr virus. 
The IM9 cells express about 20,000 insulin receptors (isoform A) per cell and have been 
used for several decades in insulin receptor binding kinetics studies (33). The cells, which 
grow in suspension, were cultured and used as described previously (33).
Rat L6 myoblasts
The L6 WT cells were cultured in 75 cm2 flasks with DMEM (1000 mg/l glucose, Glutamax-1, 
Pyruvate) supplemented with 10% FBS, 100 U/ml Penicillin and 100 μg/ml Streptomycin. 
The cells were grown at 37°C in 5% CO2 humidified atmosphere. The cells were sub-cultured 
three times a week, by washing the cells in 10 ml PBS w/o calcium and magnesium, and 
detaching them by adding 2 ml 0.05% Trypsin-EDTA. Cells were resuspended in 10 ml 
fresh media, and seeded with a split ratio of 1:6 for two days and 1:12 for three days of 
maintenance.
Binding analysis of synthetic MT IGF-I to the IGF1R and insulin receptor
Binding competition between synthetic mutant peptides and 125I-IGF-I (on EBNA293t IGF-
IR cells) and 125I-insulin (on IM9 cells), respectively, as well as accelerated dissociation of 
labeled ligand by cold ligand (negative cooperativity) were studied according to established 
protocols (33, 34).
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[3H]-Thymidine incorporation assay 
[3H]-Thymidine incorporation was used to examine the mitogenic potency of synthetic 
MT IGF-I using the L6 WT rat myoblast cell line. We used a recently developed optimized 
assay on cells synchronized in G0/G1 that gives a robust and highly reproducible response 
to growth factors, as described in detail previously (35).
Results
Mutation analysis
In the two index cases, their mother and maternal grandfather, we found a heterozygous 
duplication of four nucleotides of the IGF1 gene, resulting in a frame shift at position 35 of 
the mature IGF-I protein and a premature stop codon (c.243_246dupCAGC, p.Ser83GlnfsX13) 
(Fig. 1A). If the peptide would be stably expressed in vivo, the mutation should result in a 
truncated C-domain, followed by a tail of 12 residues with an altered amino acid sequence 
showing no homology with the wild-type A- and D-domains (Fig. 1B). Therefore, the 
mutant peptide and wild-type IGF-I protein would have only the B-domain in common. 
Single-nucleotide polymorphism array analysis showed an interstitial deletion not 
containing any gene or noncoding RNAs (26) in all carriers and mother’s sister (II-1).
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Figure 1
A.  DNA sequence chromatogram of the four family members with the heterozygous IGF1 mutation. The arrow 
indicates the duplication of the 4 nucleotides.
B.  Sequence alignment of wild-type human IGF-I and the mutant IGF-I (MT IGF-I).  
The MT IGF1 has a heterozygous duplication of 4 nucleotides at position 247. The duplication leads to an IGF-I 
molecule truncated in its C-domain, which therefore only contains 5 of the 12 residues (Gly30–Ser34) originally 
seen in the C-domain in a wild-type IGF-I molecule. The truncation is followed by a tail of 12 residues with an 
altered amino acid sequence (red colour), that show no homology with the following A- or D-domain observed 
in wild-type IGF-I. Consequently, the MT IGF-I has no A- and D-domain though it still has an intact B-domain.  
The arrows mark the location of the different domains. The dotted arrow marks the altered C-domain, whereas 
the red colour marks the twelve altered residues in the truncated C domain.
A
B
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Neutral gel filtration studies with WT and synthetic MT IGF-I 
After equilibration with 125I-IGF-I, in aliquots (n = 4) of pooled normal control serum a 
substantial part of the radioactivity (~53 – ~63%) was incorporated into the 150 kDa complex 
(Fig. 2A). In the sera of both the carriers and non-carriers the proportion of 125I-IGF-I that 
was associated with the 150 kDa complex was somewhat less (varying between ~37 and 
~52%) and, instead, slightly increased amounts of radioactivity were eluted in the 40−50 
kDa fraction (consisting of binary IGF-IGFBP complexes) or remained unbound (data not 
shown).
Superdex 200 gel filtration column chromatography of normal serum after incubation 
with either 125I-labeled WT hIGF-I or MT IGF-I (reduced form) revealed that the radiolabeled 
mutant peptide is able to bind to IGFBPs in serum but, in contrast to WT IGF-I, is hardly 
incorporated into 150 kDa complexes (Fig. 2A). Similar results were obtained for the oxidized 
form of MT IGF-I (data not shown).
In addition, competition gel filtration experiments were performed in which 125I-WT 
hIGF-I was equilibrated with different aliquots of pooled normal serum in the presence 
of increasing amounts of either unlabeled WT-hIGF-I or MT IGF-I. As shown in figure 2B, 
in contrast to WT hIGF-I, MT IGF-I (reduced form) did not compete significantly with 
radiolabeled ligand for 150 kDa complex formation and only modestly for incorporation 
into 40−50 kDa complexes.  The same results were encountered for the oxidized form of 
MT IGF-I (data not shown).
The results of acid G50 column chromatography of Sep-Pak C18 extracted sera from 
carriers of the IGF1 mutation did not support the possibility that the putative circulating 
truncated mutant peptide forms heteromultimers with WT IGF- I, because in all cases WT 
IGF-I immunoreactivity was recovered in one peak corresponding to the MW of WT IGF-I, 
i.e. ~7.6 kDa (data not shown).
MT IGF-I (both reduced and oxidized) did not show any cross-reactivity in the semi-
automated chemiluminescence IGF-I assay employed (30) nor in an in house RIA (31).
Binding analysis of synthetic MT IGF-I to the IGF1R and insulin receptor
We tested the ability of the reduced and two oxidized preparations of MT IGF-I to compete 
for 125I-WT IGF-I binding to EBNA293t IGF-IR cells, as well as for 125I-insulin binding to IM9 cells 
(oxidized peptide only). No competition was observed in either system at concentrations as 
high as 10 mM, indicating that the peptides do not bind to IGF-I receptors (Fig. 3) or insulin 
receptors (data not shown). Likewise, the peptides did not accelerate the dissociation of 
125I-IGF-I (negative cooperativity) and did not antagonize the negative cooperativity of cold 
IGF-I (data not shown).
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A.  Aliquots of pooled normal serum were equilibrated with either 125I radiolabeled WT hIGF-I  
(• —— •) or synthetic MT IGF-I (reduced form)(□- - -□) , followed by Superdex 200 gel filtration 
column chromatography. 
B.  Distribution of radioactivity among the various molecular weight classes, as determined by 
Superdex 200 gel filtration in aliquots of pooled normal serum that had been equilibrated 
with 125I radiolabeled WT in the absence (• —— •) or presence (Δ- - - -Δ) of increasing amounts 
of unlabeled WT hIGF-I or reduced synthetic MT IGF-I (+ - - - +). Only the highest amounts of 
unlabeled WT hIGF-I and MT IGF-I employed are included in the figure, i.e. 26 pmol and 64 pmol, 
respectively.







Competition of unlabeled IGF-I (A) and reduced (B) and oxidized (C) MT IGF-I for 125I -IGF-I binding 
to EBNA-293 cells stably transfected with the IGF-I receptor. The data are plotted as bound tracer 
(as a fraction of tracer bound without unlabeled ligand), as a function of the concentration of 
competing ligand. IGF-I competes for tracer binding with a high affinity Kd of 1.3 nM, while both 
forms of the MT IGF-I are unable to compete at concentrations as high as 10 mM.
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[3H]-Thymidine incorporation assay 
The MT IGF-I peptides were tested for their ability to stimulate thymidine incorporation 
in L6 myoblasts. The cells showed a robust response to WT IGF-I, while the MT peptides 
showed no effect in the physiological molar range of WT IGF-I (0.13–13 nmol/L) (36). 
Only a very small increase in thymidine incorporation was observed at very high non-
physiological concentrations of MT IGF-I, which is probably an artificial effect since at 
these concentrations there was no binding to the IGF-I receptor. Figure 4 shows data for 
the reduced mutant peptide; similar data were obtained with the oxidized peptides. The 
mutant oxidized and reduced peptides did not antagonize the response to WT IGF-I (data 
not shown).
Figure 4 
[3H]-Thymidine incorporation assay. Dilution series of MT IGF-I (0−10,000 nM) were used to 
stimulate L6 cell proliferation. The data were plotted as MT IGF-I response compared to WT IGF-I 
response at 103 nM in percent, as a function of the MT IGF-I concentration. WT IGF-I was included 
in each assay as a control and data were plotted as percent of WT IGF-I response at 103 nM. Data 
presented display three independent experiments performed in triplicates ± SD. MT IGF-I is not 
able to stimulate mitogenesis in normal physiological concentrations.




In a previous study on a patient with a homozygous missense mutation in the IGF1 gene, 
presenting with severe intrauterine and postnatal growth retardation, microcephaly, and 
sensorineural deafness, we also investigated family members who were heterozygous for 
this IGF1 mutation. These subjects exhibited SDS values for height, head circumference, 
and birth weight that were lower than those for non-carriers from the same family, but still 
within the normal range (22). Hence, it was surprising that the severity of the short stature 
of the two siblings with the heterozygous IGF1 mutation described in the present study 
was, in fact, of a similar order of magnitude as observed in one of the three subjects with a 
homozygous IGF1 mutation (23), though less severe than the patients with a complete loss 
of function of IGF-I (21,22). This finding prompted us to investigate the possible functional 
effects of the putative truncated IGF-I peptide as encoded by the mutated IGF1 gene.
Although we could not establish whether any MT IGF-I was present in the circulation, 
we first hypothesized that in case it would, this truncated peptide may exert a dominant 
negative effect on the biological action of the WT IGF-I. Insulin and IGF-I bind to their 
respective dimeric receptors with a complex mechanism that involves cross-linking of two 
partial binding sites (sites 1 and 2) on each receptor half. Two distinct sites of the ligand are 
involved, leading to high affinity binding (37). We reasoned that while the truncated IGF-I 
clearly lacks the whole set of determinants needed to cross-link the two receptor halves, 
it may still have sufficient affinity to bind to one of the two receptor binding sites, which 
would thus enable it to prevent the cross-linking by native IGF-I, resulting in a dominant 
negative or antagonistic effect.
However, we demonstrated that synthetic MT IGF-I could not bind to the IGF1R or the 
insulin receptor at all and lacked significant mitogenic potency. Moreover, MT IGF-I did 
not show any antagonistic effects on either the binding of WT IGF-I to the IGF1R and the 
insulin receptor or its mitogenic capacity. This result could be explained by the fact that MT 
IGF-I lacks critical A- and C-domain residues involved in receptor binding. Furthermore, it 
likely has a disordered structure with the potential for an abnormal disulfide bond as in the 
oxidized peptide. Thus, the short stature of the carriers of the heterozygous IGF1 mutation 
cannot be attributed to a blockade of WT IGF-I action at the receptor level.
On the other hand, MT IGF-I still does contain various domains important for binding 
to IGFBPs. Therefore, we investigated the possibility that MT IGF-I might tightly bind 
to IGFBPs (including 150 kDa complexes with ALS) in such a way that it would not be 
readily exchangeable with WT IGF-I. In theory, this would lead to a decrease in the half-
life of circulating WT IGF-I (as observed in ALS deficient patients), and, as a consequence, 
deregulation of its bioavailability. However, the results of our gel filtration experiments 
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with both synthesized forms of MT IGF-I did not provide any evidence for this possibility, 
probably due to a disordered structure as discussed above. In addition, there was no 
indication that MT IGF-I directly interacted with WT IGF-I.
The observation that the incorporation of WT 125I-IGF-I into 150 kDa complexes in sera 
from both carriers and non-carriers of the IGF1 mutation appeared to be somewhat less 
than in normal sera is difficult to explain. Subtle individual differences between the serum 
concentrations of the various IGFBPs or ALS may account for this finding, although for all 
the subjects investigated the levels of these proteins were within their normal ranges (26). 
In all members of this family, the serum levels of IGF-II appeared to be either in the upper 
normal range or even elevated (26). A relatively higher endogenous serum IGF-II pool may 
have competed with the WT 125I-IGF-I for 150 kDa complex formation.
Circulating endogenous levels of WT IGF-I (MT IGF-I could not be detected by the IGF-I 
assays employed) in the four heterozygous carriers of the IGF1 mutation were found to be 
significantly reduced, i.e. varying between – 1.8 and – 2.6 SDS (26). In each case, this appears 
to represent about half of that of the corresponding normal mean serum IGF-I level when 
adjusted for age and gender.
We therefore conclude that the severe short stature of the two index cases is not 
caused by a dominant negative or antagonistic effect on the function of WT IGF-I. We 
speculate that the severe short stature might be caused by a cumulative effect of three 
factors: 1) WT IGF1 haploinsufficiency; 2) placental dysfunction due to maternal WT IGF1 
haploinsufficiency; and 3) other genetic factors associated with (mild) short stature (26). 
Our studies showed that MT IGF-I is not able to bind to the IGF1R, therefore we speculate 
that reduced height can be caused by WT IGF1 haploinsuffiency; it seems that the WT copy 
of IGF1 does not produce enough IGF-I to reach normal height. Another factor that may 
contribute to the short stature observed is placental dysfunction due to maternal WT 
IGF1 haploinsufficiency, as discussed in our earlier paper (26). There is a strong correlation 
between the rate of maternal IGF-I increase during pregnancy and placental weight (38). 
Various studies have been performed to investigate IGF-I in intrauterine growth retardation 
pregnancies. Contradicting results have been observed in studies concerning placenta 
IGF-I and IGF1R mRNA and protein expression. Some studies reported increased expression 
of IGF-I and IGF1R in placentas from small for gestational age (SGA) newborns compared 
with appropriate for gestational age (AGA) newborns (39, 41), while other studies showed 
decreased or equal expression. Inconsistencies could be due to differences in the selection 
criteria for IUGR, length of gestation and the methodology used (40, 42). Based on the 
observation that birth length and childhood height of case III-1 is 1−2 SD lower than of her 
mother and our previous observations in a family with an IGF1R mutation (38), in which 
the proband’s length was much more affected than in her mother, who did not inherit the 
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mutation maternally, we hypothesize that IGF-I and IGF1R play an important role in normal 
placental function and consequently in intrauterine growth.
Interestingly, we observed that GH therapy was efficacious in increasing height in 
the first two years of treatment, without adverse events, which may be explained by the 
normalisation of IGF-I availability.
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Abstract
Context: Acid-labile subunit (ALS) deficiency due to homozygous inactivation of the ALS 
gene (IGFALS) is associated with moderate short stature, and in few cases pubertal delay. 
The clinical expression of heterozygosity is unknown.
Objective: To investigate the clinical, laboratory, and radiological features of homozygous 
and heterozygous carriers of a novel mutation in the ALS gene in comparison with non-
carriers.
Subjects: Three short Kurdish brothers and their relatives.
Results: The index cases presented with short stature, microcephaly, and low circulating 
IGF-I and IGF-binding protein-3 (IGFBP-3), and undetectable ALS levels. Two were known 
with a low bone mineral density and one of them had suffered from two fractures. We found 
a novel homozygous ALS gene mutation resulting in a premature stopcodon (c.1490dupT, 
p.Leu497PhefsX40). The IGF-I, IGFBP-3, and ALS 150 kDa ternary complex was absent, and 
ALS proteins in serum were not detected with western blot. IGFPB-1 and IGFBP-2 were low 
and there was a mild insulin resistance. Five heterozygous carriers tended to have a lower 
height and head circumference than five non-carriers, and had low plasma ALS and IGFBP-3 
levels. Bone mineral (apparent) density was low in two out of three homozygous carriers, 
but also in four out of nine relatives.
Conclusions: The clinical presentation of homozygous ALS mutations may, besides short 
stature, include microcephaly. Heterozygous carriers may have less statural and head 
growth, suggestive for a gene dosage effect.




For both humans and rodents, it has been well established that insulin-like growth factor-I 
(IGF-I) plays a critical role in the regulation of intrauterine growth and development and 
postnatal growth and metabolism (1, 2). Total IGF-I deficiency leads to severe intrauterine 
and postnatal growth failure, microcephaly, mental retardation, and deafness (3, 4). Partial 
IGF-I resistance due to heterozygous mutations in the IGF-I receptor (IGF1R) gene results in 
moderate intrauterine and postnatal growth retardation and microcephaly (5-8).
A third defect that is associated with a reduced bioavailability of IGF-I is caused by a 
mutation in the acid-labile subunit gene (ALS). ALS can form, together with IGF-I (or IGF-II) 
and IGF-binding protein-3 (IGFBP-3, or IGFBP-5 for only 10%), a 150 kDa ternary complex. 
Under normal circumstances, 80−85% of circulating IGF-I is retained in this complex (9). 
The 150 kDa complexes cannot cross the capillary endothelial barrier, which prolongs 
the half-life of IGFs, IGFBP-3 and IGFBP-5, in the circulation (9-11). This seems to play an 
important role in the regulation of the bioavailability of IGFs to the tissue compartments.
ALS belongs to the superfamily of leucine-rich repeat (LRR) proteins, characterized by 
their ability to participate in protein−protein interactions. About 75% of the mature protein 
consists of the consensus motif for the LRR superfamily of proteins. These leucine-rich 
domains organize ALS into a doughnut-shaped structure (11, 12). Whereas ALS readily binds 
to binary complexes of IGFs and IGFBP-3, it does not interact directly with free IGFs and 
shows only a very low affinity for unliganded IGFBP-3 (13, 14).
So far, eight patients have been described with mutations in the ALS gene (10, 15-18). All 
cases described were characterized by moderate or mild growth failure, undetectable or 
very low circulating levels of ALS, and markedly reduced plasma concentrations of IGFBP-3 
and IGF-I. In some cases, pubertal delay was noted, and a low bone mineral density (BMD) 
was found in one case (19).
In this report, we describe three brothers of Kurdish origin with short stature and 
microcephaly associated with a novel homozygous mutation in the ALS gene. In addition, 
we have evaluated the clinical and laboratory findings in ten relatives, five of whom were 
heterozygous for the mutation and five non-carriers.
Methods
All subjects described in this paper belong to a consanguineous family of Kurdish origin (Fig. 
1). After mutation analysis, the subjects were divided into ‘patients’ (homozygous carriers), 
heterozygous carriers, and non-carriers. For each homozygous carrier, the medical history 
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as well as the results of previous investigations was retrieved. In 2007, all the subjects were 
again thoroughly investigated. All the subjects provided written informed consent.
Molecular studies
Genomic DNA was isolated from whole blood or buffy coats according to the salting out 
procedure described by Miller et al. (20). All exons of ALS (GenBank accession number 
AF192554) were PCR amplified and sequenced as described previously (4). The various 
primer sequences employed are available upon request.
Figure 1
Pedigree of the family. The patients are indicated in black and the heterozygous carriers are 
indicated in white/black. On the left, the generation number is indicated and the family number is 
indicated below each individual.
Clinical measurements and auxology
Physical examination was performed including measurements of height and sitting height 
with a Harpenden stadiometer and head circumference with a tape measure. Height was 
expressed as standard deviation score (SDS) based on references for Turkish children living 
in the Netherlands (21). Head circumference and sitting height/height ratio were expressed 
as SDS for the Dutch population (22, 23). Differences between homozygous, heterozygous, 
and non-carriers were calculated with ANOVA.




BMD was measured by dual energy X-ray absorptiometry using the Hologic Scanner (QDR 
4500W) at the lumbar spine, femoral neck, and total body. The volumetric bone mineral 
apparent density (BMAD) was calculated using the formula: BMAD (g/cm3) = BMD×(4/
π×width of measurement area in lumbar spine) (24). An estimate of the mean width 
was derived from the scanned area (cm2) divided by the height of L2−L4. z-Scores were 
calculated using the reference data as reported by Fournier et al. (25). Subjects above the 
age of 20 years were compared with the reference data of subjects aged 18−20 years. The 
z-score of the subjects below the age of 9 years could not be calculated because there were 
no appropriate references.
Biochemical measurements
Plasma levels of IGF-I, IGF-II, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-6 were 
determined as described previously (4), and ALS was measured by a commercially available 
ELISA kit (DSL, Inc., Webster, TX, USA) (26). All measurements were expressed as SDS, except 
for IGFBP-1 in adults older than 24 years, which was compared with a reference group of 
six healthy adult controls. The different molecular size classes of endogenous IGF−IGFBP 
complexes in plasma were determined by neutral gel filtration through a 1.6×60 cm Hi-
load Superdex-200 column. Prior to column chromatography, each serum sample (250 μl) 
was incubated with 100 μl of either ~80 000 c.p.m. 125I-hIGF-I or 125I-IGF-II, being dissolved 
in 50 mM sodium phosphate buffer (pH 7.4), containing 0.2% BSA, 10 mM EDTA, and 0.05% 
(w/v) Tween-20, for 17 h at 4°C. The various molecular size classes of complexes were eluted 
from the column at a rate of 1.2 ml/min using 0.05 M NH4HCO3 buffer (pH 7.4). The 125I 
content of each 1.2 ml fraction was counted in a γ-counter. The hIGFBP-3 used in several of 
these experiments was isolated from human plasma according to Martin and Baxter (27). 
Western blotting on serum samples was performed as described previously (28), using an 
antibody against human amino-terminal ALS1-34 (DSL, Inc).
Results
Medical history of the ALS-deficient patients
Patient III-1 was born as the first of four children of consanguineous parents. In the first 
three years, he was short, frequently ill, had many episodes of diarrhea, and showed poor 
appetite and night sweating. At the age of 11.6 years, he moved with his family to the 
Netherlands. At the age of 12 and 14 years, he suffered fractures of the left wrist and arm, 
after minor trauma, and at radiographs, bone density appeared low. Reported pubertal 
onset was at about 14 years of age (mean age at Tanner stage 2 in Turkish adolescents living 
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in the Netherlands is 12.2 years) (21). He had a somewhat dysmorphic face with mandibular 
hypoplasia and a prominent forehead. The growth curve is shown in Fig. 2A.
At the age of 16.1 years, dietary calcium and vitamin D intake appeared low, and 
serum vitamin D25 was slightly decreased, but serum calcium was in the upper normal 
range and parathyroid hormone (PTH) was normal. Vitamin D p.o. for 6 months resulted 
in normalization of D25 levels. A grade I mitral and tricuspid insufficiency was detected 
at cardiologic investigation. The growth hormone (GH) peak after exercise was high (63 
mU/l), IGF-I was very low (−6.9 to −5.0 SDS), and IGFBP-3 extremely low (−12.0 SDS). There 
was a poor response to GH in an IGF-I generation test with two different doses (0.8 and 
1.6 mg/m2 per day for 4 days); only on the higher dose IGF-I increased from 16 to 60 ng/ml. 
IGFBP-3 did not change. 
At the age of 17.8 years, his bone age was adult, and he had reached a final height of 
149.7 cm (−4.2 SDS) (Fig. 2A), indicating a fast progression through puberty, which probably 
led to the poor pubertal height gain (13.3 cm). At the age of 16, 17, and 19 years, total BMD 
and z-scores were 0.81 g/cm2 (−3.3 SDS), 0.89 g/cm2 (−3.9 SDS), and 0.91 g/cm2 (−2.5 SDS) 
respectively, and femoral neck BMD was 0.827 (−1.5 SDS) at 19 years of age.
Patient III-2 moved with his family to the Netherlands at the age of 5 years. At 7 years of 
age, he was seen by an ophthalmologist because of strabismus. His growth chart is shown 
in Fig. 2B. Data on reported pubertal onset and progression are inconsistent. 
Patient III-4 had a reported birth weight of 2.0 kg at an unknown gestational age. He 
remained short in childhood and adolescence (Fig. 2C), but bone maturation was not 
retarded. During infancy, he experienced poor appetite, frequent episodes of diarrhea, 
and night sweating. His left leg was ~5 cm shorter than the right leg, probably due to 
congenital coxa vara by congenital femoral hypoplasia. After an osteotomy, the difference 
was reduced to 3 cm. He had a similar dysmorphic face as patient III-1. Puberty onset was 
reported to have occurred between 12 and 14 years. Total BMD at 6, 10, and 12 years of age 
was 0.68 (−1.3 SDS), 0.76 (−1.2 SDS), and 0.62 (−2.0 SDS) respectively. The GH peak after 
exercise was high (118 mU/l), IGF-I was very low (−4.2 to −3.8 SDS), and IGFBP-3 extremely 
low (< −17 SDS). During IGF-I generation tests, employing GH doses 0.8 and 1.6 mg/m2 per 
day for 4 days, IGF-I levels increased only marginally, from 38 to 46 ng/ml and 44 to 52 ng/
ml respectively. DNA analysis for GH and GHR was normal.




(A−C) Growth curves of patients III-1, III-2, and III-4 (index cases). Target height is 162.0 
cm (−2.1 SDS). Dots represent height measurements, and G2 and G5 indicate Tanner 
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Molecular studies
Sequence analysis of the ALS gene of patients III-1, III-2, and III-4 revealed a homozygous 
duplication of a T nucleotide at position 1490 of the coding DNA, resulting in a frameshift 
and a premature stopcodon (c.1490dupT, p.Leu497PhefsX40; further indicated as −/−) 
(Supplemental Fig. 1). Five relatives were heterozygous carriers of the mutation (+/−) and 
the other five non-carriers (+/+) (Fig. 1).
Clinical, radiological, and biochemical features at recall
Clinical, radiological, and laboratory findings are summarized in Tables 1−3. Mean height 
and head circumference SDS of heterozygotes were 1 and 0.7 SD lower respectively than 
those of non-carriers, but the differences with non-carriers did not reach statistical 
significance (P = 0.25 and 0.13 respectively). The sitting height/height ratio was in the 
upper normal range in most cases, without apparent association with the ALS defect. Two 
homozygous patients exhibited a low BMD and one of them also a low BMAD, but also 
in four out of nine relatives low values were observed. Tone audiometry did not show a 
clinically relevant perceptive hearing loss in the patients or their relatives (data not shown).
In the three patients, ALS was not detected by ELISA, which was confirmed by western 
blotting of patient’s sera (Supplemental Fig. 2). No ALS bands with aberrant molecular 
weights were detected. Fasting glucose levels were normal (5.3, 4.5, and 4.6 mmol/l), but 
insulin was slightly elevated (12, 17, and 14 mU/l), indicating mild insulin resistance. Plasma 
levels of IGFBP-3 were extremely low, and of IGF-I, IGF-II, IGFBP-1, and IGFBP-2 markedly 
reduced. Plasma IGFBP-4 and IGFBP-6, and serum testosterone, follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), and free thyroxine (FT4) levels were normal. In 
heterozygous carriers, plasma ALS and IGFBP-3 were low. In non-carriers, all parameters 
were normal. 
Neutral gel filtration
While in normal control serum, most IGF-I (90%) is associated with the 150 kDa complex (Fig. 
3A); in the sera of the three ALS-deficient patients there was almost no 150 kDa complex 
present. The 40−50 kDa fraction (consisting of binary IGF−IGFBP complexes) was markedly 
elevated and the free 125I-IGF-I peak was reduced (Fig. 3B). Addition of purified hIGFBP-3 to 
these sera did not induce 150 kDa complex formation, while a slightly increased 150 kDa 
peak was observed upon addition to normal serum (data not shown). Similar results were 
obtained with 125I-IGF-II (data not shown). In the sera of heterozygous carriers, the amount 
of the 150 kDa complexes was reduced and that of the 40−50 kDa complexes markedly 
increased (Fig. 3C). Column profiles of sera of the non-carriers were normal.
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Table 1 Clinical features and biochemical characteristics of the homozygous carriers
III-2 III-4 Mean
IGFALS gene −/− −/− −/−
Gender M M M
Age (year) 27.2 21.5 17.0 21.9
 Height (cm) [SDS] 149.7 [−4.2] 153.2 [−3.6] 145.5 [−4.4] 149.5 [−4.1]
Head circumference (cm) [SDS] 52.5 [−3.0] 53.3 [−2.6] 51.2 [−3.2] 52.3 [−2.9]
BMI (kg/m2) 21.2 23.4 21.6 22.1
Sitting height: Height [SDS] 0.54 [2.2] 0.54 [2.0] 0.53 [1.1] 0.54 [1.8]
Total BMD (g/cm2) [z-score] 0.865 1.058 0.793 [−3.3] 0.905
BMD femoral neck [z-score] 0.591 [−2.4] 0.943 [0.1] 0.640 [−2.4] 0.725 [−1.6]
BMD L1−L4 [z-score] 0.625 [−4.2] 0.902 [−1.7] 0.590 [−3.1] 0.706 [−3.0]
BMAD L2−L4 [z-score] 0.209 [−2.8] 0.284 [−0.2] 0.230 [−1.7] 0.241 [−1.6]
IGF-I (ng/ml) [SDS] <12 [< −7.2] 13 [−7.4] 29 [−5.6] 18 [−6.7]
IGF-II (ng/ml) [SDS] 66 [−6.6] 55 [−6.8] 49 [−6.7] 56.7 [−6.7]
IGFBP-1 (ng/ml) [SDS] α  27 12 [−1.5] 9 [−2.2] 16
 
IGFBP-2 (ng/ml) [SDS] 67 [−2.5] 95 [−1.8] 69 [−3.0] 77 [−2.4]
IGFBP-3 (mg/l) [SDS] 0.09 [−18.2] 0.09 [−18.5] 0.10 [−17.6] 0.10 [−18.1]
IGFBP-4 (ng/ml) [SDS] 172 [−0.1] 136 [−0.7] 157 [−0.3] 155 [−0.4]
IGFBP-6 (ng/ml) [SDS] 180 [0.4] 138 [−0.3] 148 [0.2] 155.3 [0.1]
ALS (mg/l) [SDS] <0.07 [< −7.1] <0.07 [< −5.7] <0.07 [< −4.5] <0.07 [< −4.5]
α Normal range for non-fasting subjects: 24−57 ng IGFBP-1 per ml.  After overnight fasting, there is 
an average fivefold rise in normal individuals. IGFBP-1 SDS values are not available for adults 
older than 24 years.
III-1
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Table 2 Clinical features and biochemical characteristics of the heterozygous carriers
II-1 II-2 II-4 III-3 III-5 Mean
IGFALS gene +/− +/− +/− +/− +/−
Gender F M M F M
Age (year) 46.1 52.2 41.6 20.1 7.4 33.5
Height (cm) [SDS] 141.7 [−3.4] 155.5 [−3.2] 154.8 [−3.3] 149.8 [−2.0] 126.3 [0.3 ] 145.6 [−2.3 ]
Head circumference (cm) [SDS] 53.8 [−0.9] 54.0 [−2.2] 55.0 [−1.6] 52.5 [−1.7] 51.6 [−0.4] 53.4 [−1.4]
BMI (kg/m2) 27.2 24.3 27.0 24.4 14.7 23.5
Sitting height: Height [SDS] 0.53 [0.4] 0.54 [2.1] 0.53 [1.2] 0.53 [0.6] 0.53 [−0.4] 0.53 [0.8]
Total BMD (g/cm2) [z-score] 0.974 [−0.9] 0.869 0.986 0.911 [−2.2] 0.751 [0.4] 0.898 [−0.9]
BMD femoral neck [z-score] 0.721 [−0.7] 0.648 [−1.3] 0.855 [0.0] 0.811 [−0.3] 0.732 [1.4] 0.753 [−0.2]
BMD L1−L4 [z-score] 0.805 [−1.7] 0.618 [−3.9] 0.692 [−3.5] 0.865 [−1.4] 0.577 [0.7] 0.711 [−2.0]
BMAD L2−L4 [z-score] 0.307 [−0.4] 0.164 [−4.4] 0.184 [−3.7] 0.308 [−0.4] 0.169 0.226 [−2.2]
IGF-I (ng/ml) [SDS] 99 [−1.1] 73 [−1.5] 86 [−1.6] 141 [−1.8] 73 [−1.4] 94 [−1.5]
IGF-II (ng/ml) [SDS] 352 [−1.0] 305 [−1.8] 305 [−1.7] 308 [−1.5] 296 [−1.1] 313.2 [−1.4]
IGFBP-1 (ng/ml) SDS] α  11 31 5 19 [−1.7] 164 [0.1] 46
IGFBP-2 (ng/ml) [SDS] 184 [0.1] 196 [0.3] 255 [0.9] 278 [1.5] 360 [1.1] 255 [0.8]
IGFBP-3 (mg/l) [SDS] 1.54 [−1.2] 0.93 [−2.9] 0.94 [−3.3] 1.19 [−3.2] 1.05 [−2.9] 1.13 [−2.7]
IGFBP-4 (ng/ml) [SDS] 196 [0.3] 117 [−1.1] 139 [−0.7] 139 [−0.8] 113 [−1.2] 141 [−0.7]
IGFBP-6 (ng/ml) [SDS] 185 [0.8] 176 [−0.3] 159 [−0.3] 147 [0.1] 112 [0.3] 156 [0.1]
ALS (mg/l) [SDS] 9.9 [−2.6] 10.5 [−1.9] 6.0 [−3.6] 9.0 [−3.0] 6.9 [−2.0] 8.5 [−2.6]
α Normal range for non-fasting subjects: 24−57 ng IGFBP-1 per ml.  After overnight fasting, there is an average fivefold
 rise in normal individuals. IGFBP-1 SDS values are not available for adults older than 24 years.
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Table 2 Clinical features and biochemical characteristics of the heterozygous carriers
II-1 II-2 II-4 III-3 III-5 Mean
IGFALS gene +/− +/− +/− +/− +/−
Gender F M M F M
Age (year) 46.1 52.2 41.6 20.1 7.4 33.5
Height (cm) [SDS] 141.7 [−3.4] 155.5 [−3.2] 154.8 [−3.3] 149.8 [−2.0] 126.3 [0.3 ] 145.6 [−2.3 ]
Head circumference (cm) [SDS] 53.8 [−0.9] 54.0 [−2.2] 55.0 [−1.6] 52.5 [−1.7] 51.6 [−0.4] 53.4 [−1.4]
BMI (kg/m2) 27.2 24.3 27.0 24.4 14.7 23.5
Sitting height: Height [SDS] 0.53 [0.4] 0.54 [2.1] 0.53 [1.2] 0.53 [0.6] 0.53 [−0.4] 0.53 [0.8]
Total BMD (g/cm2) [z-score] 0.974 [−0.9] 0.869 0.986 0.911 [−2.2] 0.751 [0.4] 0.898 [−0.9]
BMD femoral neck [z-score] 0.721 [−0.7] 0.648 [−1.3] 0.855 [0.0] 0.811 [−0.3] 0.732 [1.4] 0.753 [−0.2]
BMD L1−L4 [z-score] 0.805 [−1.7] 0.618 [−3.9] 0.692 [−3.5] 0.865 [−1.4] 0.577 [0.7] 0.711 [−2.0]
BMAD L2−L4 [z-score] 0.307 [−0.4] 0.164 [−4.4] 0.184 [−3.7] 0.308 [−0.4] 0.169 0.226 [−2.2]
IGF-I (ng/ml) [SDS] 99 [−1.1] 73 [−1.5] 86 [−1.6] 141 [−1.8] 73 [−1.4] 94 [−1.5]
IGF-II (ng/ml) [SDS] 352 [−1.0] 305 [−1.8] 305 [−1.7] 308 [−1.5] 296 [−1.1] 313.2 [−1.4]
IGFBP-1 (ng/ml) SDS] α  11 31 5 19 [−1.7] 164 [0.1] 46
IGFBP-2 (ng/ml) [SDS] 184 [0.1] 196 [0.3] 255 [0.9] 278 [1.5] 360 [1.1] 255 [0.8]
IGFBP-3 (mg/l) [SDS] 1.54 [−1.2] 0.93 [−2.9] 0.94 [−3.3] 1.19 [−3.2] 1.05 [−2.9] 1.13 [−2.7]
IGFBP-4 (ng/ml) [SDS] 196 [0.3] 117 [−1.1] 139 [−0.7] 139 [−0.8] 113 [−1.2] 141 [−0.7]
IGFBP-6 (ng/ml) [SDS] 185 [0.8] 176 [−0.3] 159 [−0.3] 147 [0.1] 112 [0.3] 156 [0.1]
ALS (mg/l) [SDS] 9.9 [−2.6] 10.5 [−1.9] 6.0 [−3.6] 9.0 [−3.0] 6.9 [−2.0] 8.5 [−2.6]
α Normal range for non-fasting subjects: 24−57 ng IGFBP-1 per ml.  After overnight fasting, there is an average fivefold
 rise in normal individuals. IGFBP-1 SDS values are not available for adults older than 24 years.
Table 3 Clinical features and biochemical characteristics of the non-carriers
II-3 II-5 II-6 III-6 III-7 Mean
IGFALS gene +/+ +/+ +/+ +/+ +/+
Gender F F M M M
Age (year) 34.3 32.7 37.6 5.6 5.6 23.2
Height (cm) [SDS] 151.3 [−1.7] 160.6 [0.0] 156.6 [−3.0] 114.5 [−0.1] 107.0 [−1.8] 138.0 [−1.3]
Head circumference (cm) [SDS] 53.0 [−1.4] 54.0 [−0.8] 56.0 [−1.0] 52.0 [0.2] 50.5 [−0.7] 53.1 [−0.7]
BMI (kg/m2) 24.4 25.4 27.1 14.6 13.8 21.1
Sitting height: Height [SDS] 0.53 [0.4] 0.55 [1.5] 0.55 [2.5] 0.54 [−0.2] 0.54 [−0.3] 0.54 [0.8]
Total BMD (g/cm2) [z-score] 1.037 [−0.5] 0.905 [−2.0] 1.013 0.668 [−0.1] − 0.906 [−0.9]
BMD femoral neck [z-score] 0.700 [−1.2] 0.683 [−1.4] 0.787 [−0.6] 0.659 [1.6] − 0.707 [−0.4]
BMD L1−L4 [z-score] 0.903 [−1.3] 0.778 [−2.4] 0.754 [−3.0] 0.434 [−1.3] − 0.717 [−2.0]
BMAD L2−L4 [z-score] 0.277 [−1.3] 0.239 [−2.4] 0.202 [−3.1] 0.141 − 0.215 [−2.3]
IGF-I (ng/ml) [SDS] 199 [0.8] 164 [0.0] 81 [−1.9] 144 [1.1] 77 [−0.5] 133 [−0.1]
IGF-II (ng/ml) [SDS] 436 [0.1] 543 [1.2] 441 [0.1] 546 [1.5] 302 [−0.9] 454 [0.4]
IGFBP-1 (ng/ml) [SDS] α <5 20 78 125 [−1.0] 81 [−2.0] 62
IGFBP-2 (ng/ml) [SDS] 237 [0.7] 156 [−0.2] 336 [1.5] 242 [−0.5] 426 [1.5] 279 [0.6]
IGFBP-3 (mg/l) [SDS] 1.94 [−0.6] 2.0 [−0.6] 1.6 [−1.2] 2.52 [0.9] 1.66 [−0.7] 1.9 [−0.4]
IGFBP-4 (ng/ml) [SDS] 79 [−2.0] 91 [−1.8] 133 [−0.8] 126 [−0.9] 105 [−1.3] 107 [−1.4]
IGFBP-6 (ng/ml) [SDS] 125 [−0.3] 159 [0.5] 187 [0.4] 130 [1.2] 75.2 [−0.7] 135.2 [0.2]
ALS (mg/l) [SDS] 14.5 [−1.5] − − 16.1 [1.7] − 15.3 [0.1]
To convert IGF-I to nanomoles per Liter (nmol/l), multiply by 0.131; to convert IGF-II to nmol/l, multiply by 0.134; to convert 
ALS to nmol/l, multiply by 15.8; to convert IGFBP-1 to nmol/l, multiply by 0.033; to convert IGFBP-2 to nmol/l, multiply by 
0.032; to convert IGFBP-3 to nmol/l, multiply by 33.3; to convert IGFBP-4 to nmol/l, multiply by 0.038; to convert IGFBP-6 
to nmol/l, multiply by 0.034.
α Normal range for non-fasting subjects: 24−57 ng IGFBP-1 per ml.  After overnight fasting, there is an average fivefold 
rise in normal individuals. IGFBP-1 SDS values are not available for adults older than 24 years.
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Figure 3
S200 gel filtration column chromatography. (A) Representative column profile for normal 
adult serum. (B) Serum of patient III-1 (solid line) and patient III-2 (dotted line), both exhibiting 
a homozygous mutation in the ALS gene. (C) Serum of the father II-2 (solid line) and uncle (II-4) 








We report three brothers of Kurdish origin, born from a consanguineous family, with a 
novel homozygous frameshift mutation in the ALS gene, presenting with short stature 
and microcephaly. In two cases a low BMD was observed, in one of them twice resulting 
in a fracture; but further studies of BMD in their relatives suggest that other genetic 
factors may be involved. Biochemically, serum ALS was undetectable; IGFBP-3 extremely 
low; IGFs, IGFBP-2, and IGFBP-1 decreased; and the ternary 150 kDa complex was virtually 
absent. Most of the circulating IGFs were either sequestered by IGFBPs forming binary 
complexes or remained unbound. The western blotting experiments indicate that there is 
no truncated form of ALS present. Even if this were the case, a truncated ALS would not be 
able to form the stable 3D doughnut-shaped structure, which is essential for its function.
The growth pattern of all previously reported cases of ALS deficiency (10, 15, 16, 18) is 
characterized by moderate or mild short stature during childhood and adolescence and a 
normal or slightly decreased adult stature. Our ALS-deficient patients are much shorter in 
comparison with the reference population, but this may be due to other genetic factors in 
this highly consanguineous family. The difference between their mean (near) adult height 
SDS (−4.1 SDS) and that of the five heterozygous carriers (−2.3 SDS) is 1.7 SD, comparable with 
earlier reports. Data on head circumference have not been presented in earlier reports; 
thus it remains to be established whether microcephaly represents a clinical feature of 
homozygous ALS deficiency.
The growth pattern in humans with ALS deficiency is comparable with the mild growth 
failure observed in Als gene knock-out (ALS-KO) mice, and is in contrast with the severe 
growth failure as observed in patients with a total IGF-I deficiency (2). This is in line with the 
hypothesis that the contribution of locally produced IGF-I to longitudinal growth is more 
important than that of IGF-I derived from the circulation (10, 17). As speculated previously, 
local production of IGF-I may be even higher than normal due to increased GH secretion, 
and might thereby compensate, at least in part, for any deficiency of circulating IGF-I 
(10). Another possible explanation of the near-normal growth, in spite of reduced levels 
of circulating IGF-I, may include an increase in the IGF-I flux toward the peripheral tissue 
compartments at the expense of the circulating IGF-I pool that cannot be maintained 
at normal levels without ALS (17, 29). It is uncertain whether ALS deficiency affects fetal 
growth.
At present, it is uncertain if an ALS defect is associated with pubertal delay. Three 
patients described previously seem to have experienced late onset of puberty (17, 18), but 
in the other cases puberty was normal. In our index patient III-1, pubertal onset was late, 
in III-2 unknown, and in III-4 normal. The low BMD in two of our patients and in the first 
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published case (19), in combination with the low BMD in ALS-KO mice (30-32) and previous 
studies showing that circulating IGF-I levels are related to sufficient bone growth and 
acquisition of peak bone mass (33, 34), suggested that ALS deficiency might be associated 
with a low BMD. However, further observations in the patients’ relatives did not support 
this.
Biochemically, in all cases reported so far, undetectable or very low levels of circulating 
ALS, extremely low IGFBP-3, and low IGF-I and IGF-II have been reported. The lack of 150 
kDa complex formation is expected to shorten the half-life of IGF-I in the circulation (31), 
and possibly also that of IGFBP-3 (10). The low IGFBP-1 and IGFBP-2 plasma levels observed 
in two earlier papers (16, 18) and in our three patients suggest that this is part of the 
syndrome. A consequence of the low plasma IGFBP-1 (an inhibitor of IGF-I effects) may be 
that growth is less compromised than would be expected from the low circulating IGF-I 
levels alone.
In the cases tested, we found an increased GH response to provocative stimuli, 
confirming earlier observations (10, 16, 18). The increased GH secretion can be explained 
by the reduction in free IGF-I as observed in previous studies (10, 35, 36), but is in contrast 
to the normal free IGF-I and GH levels in ALS-KO mice (19, 31). An IGF generation test was 
performed in three previous cases (10, 16, 18), and showed virtually no response of IGF-I, 
similar to the two cases tested. Our patients had a mild insulin resistance, confirming 
earlier reports (16, 18).
Heterozygosity for an ALS defect may have some effect on stature and head 
circumference compared with non-carriers, but these differences did not reach statistical 
significance. Within the heterozygous and wild-type individuals, height and head 
circumference varied considerably, which may be due to other genes that negatively affect 
growth in this highly consanguineous family. As in most previous reports, parents of 
affected patients were relatively short (10, 18); a meta-analysis of all cases may shed more 
light on this issue. Biochemically, carriers had low plasma ALS and IGFBP-3, and IGF-I in the 
low normal range, as reported previously (10).
In conclusion, these three cases with a novel frameshift mutation of ALS resulting in 
undetectable circulating ALS levels show that besides short stature and possible delayed 
onset of puberty, microcephaly may also be part of the syndrome. Biochemically, the 
absence of circulating ALS leads to extremely low levels of IGFBP-3, very low levels of IGF-I 
and IGF-II, low plasma IGFBP-1 and IGFBP-2, and mild insulin resistance. Heterozygosity for 
an ALS defect may have a small effect on height and head circumference.
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DNA sequence chromatogram of genomic ALS DNA. The upper panel represents the wild-type ALS 
sequence, the middle panel represents the sequence of heterozygous carriers of the mutation 
and the lower panel represents the sequence of the three brothers with the homozygous ALS 
mutation. The arrow indicates the duplication of a T nucleotide.




SSupplemental Figure 2Western blot analysis of ALS with an antibody against human amino-terminal ALS1-34 in serum 
samples of the family members and controls. Indicated above the blot is the family number. 
Below the blot is indicated if the serum sample is from a homozygous (−/−), heterozygous (+/−), 
or non-carrier (+/+) of the mutation.
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Abstract
Context: Small for gestational age (SGA)-born children comprise a heterogeneous group in 
which only few genetic causes have been identified.
Objective: To determine copy number variations in 18 growth-related genes in 100 SGA 
children with persistent short stature. 
Methods: Copy number variations in 18 growth-related genes (SHOX, GH1, GHR, IGF1, IGF1R, 
IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, and SOCS3) were determined by an “in 
house” multiplex ligation-dependent probe amplification kit. The deletions were further 
characterized by single-nucleotide polymorphism array analysis.
Results: Two heterozygous de novo insulin-like growth factor 1 receptor (IGF1R) deletions 
were found: a deletion of the complete IGF1R gene (15q26.3, exons 1-21), including distally 
flanking sequences, and a deletion comprising exons 3-21, extending further into the 
telomeric region. In one case, serum IGF-I was low (−2.78 SD Score), probably because of a 
coexisting growth hormone (GH) deficiency. Both children increased their height during GH 
treatment (1 mg/m2 per day). Functional studies in skin fibroblast cultures demonstrated 
similar levels of IGF1R autophosphorylation and a reduced activation of protein kinase B/
Akt upon a challenge with IGF-I in comparison with controls.  
Conclusions: IGF1R haploinsufficiency was present in 2 of 100 short SGA children. GH 
therapy resulted in moderate catch-up growth in our patients. A review of the literature 
shows that small birth size, short stature, small head size, relatively high IGF-I levels, 
developmental delay, and micrognathia are the main predictors for an IGF1R deletion. 




Children born with a low birth weight and/or birth length corrected for gestational age 
(small for gestational age, SGA) comprise a heterogeneous group with a broad spectrum of 
clinical characteristics. Reduced size at birth may result from fetal, maternal, placental, and/
or genetic factors. Although many children born SGA achieve sufficient growth to normalize 
their stature by 2 yr of age, approximately 15% maintain a height below −2 SD score and 
continue to be short throughout adolescence and adulthood (1). Short SGA children have a 
reduced lean body mass, fat mass, skinfolds, and body mass index (BMI) (2-4), as well as a 
lower caloric, fat, and carbohydrate intake (5). SGA children with a persistent short stature 
and/or a small head size have a higher risk of subnormal intellectual and psychological 
performance (6-9). 
Genetic causes have only been found in a small proportion of short SGA children, 
including point mutations and deletions in the IGF1 (10-12) and insulin-like growth factor 
1 receptor (IGF1R) genes (13-26). The availability of the complete sequence of the human 
genome and the introduction of high-throughput DNA-scanning techniques provide novel 
tools to investigate the genetic basis of short stature. In this study, we used multiplex 
ligation-dependent probe amplification (MLPA) to investigate rapidly whether copy 
number variations in growth-related genes (SHOX, GH1, GHR, IGF1, IGF1R, IGF2, IGFBP1-6, 
NSD1, GRB10, STAT5B, ALS, SOCS2, and SOCS3) were present in a group of 100 children born 
SGA with persistent short stature. The extent of the two deletions that were found was 
determined with single-nucleotide polymorphism (SNP) array analysis. Functional studies 
on dermal fibroblasts were performed to investigate the IGF1R signal transduction pathway 
in the two patients and age- and sex-matched healthy controls.
Subjects and Methods
Study population
The first hundred short SGA children participating in four prospective cohort trials 
evaluating the effect of GH treatment (3, 27) were included in the study. SGA was defined 
as a birth length and/or weight ≤−2 SD score for their gestational age (28), and only children 
were included who remained short in postnatal life [at age 3: height ≤−2.00 SD score: short 
SGA (29)]. All children were Caucasian and had an uncomplicated postnatal period. Severe 
chronic illness or endocrine disorders, chromosomal or genetic abnormalities, positive 
endomysial or transglutaminase antibodies, skeletal abnormalities and psychosocial 
dwarfism were reasons to exclude children from the study. The study protocol was approved 
by the Medical Ethics Committee of the Erasmus Medical Center (Rotterdam), and written 
informed consent was obtained.  
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Clinical and biochemical measurements
Birth and growth data before the start of GH treatment were retrieved from records 
of hospitals, community health services, and general practitioners. Children were 
systematically measured at the start of and during the GH trials (3, 27). Height and 
head circumference were expressed as SD scores (29). Body mass index was calculated 
(weight in kg/height in meters2) and expressed as SD scores for age and sex (30). Body 
proportion was assessed by the sitting height/height ratio and expressed in SD scores 
(31). GH production was assessed by arginine and clonidine GH provocation tests, and GH 
was measured by AutoDelphia (Perkin-Elmer) and standardized according to World Health 
Organization 80/505 guidelines. Serum IGF-I and IGFBP-3 levels were measured in the SGA 
subjects as described previously (32, 33), and values were transformed to SD scores by 
adjusting for sex and age (33). Bone age was determined according to Greulich and Pyle 
(34). Dysmorphological examination was performed by an experienced clinical geneticist 
(L.C.P.G.).
Genetic analysis
Genomic DNA was extracted from peripheral blood samples (35). DNA from control 
samples was isolated from leukocytes using Puregene nucleic acid purification chemistries 
for the Autopure LS Instrument (Gentra Systems, Minneapolis, MN).
The “in house” probe kit was designed according to the criteria described in White 
et al. (36). The kit contained 34 probes (supplementary Table 1) in 18 different growth-
related genes (SHOX, GH1, GHR, IGF1, IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, 
and SOCS3). Reactions were performed as described by Walenkamp et al. (25). MLPA of 
all 21 IGF1R exons was performed using the MRC Holland P217 MLPA kit according to the 
manufacturer’s instructions (MRC Holland, Amsterdam, The Netherlands).
All MLPA kits that were used were validated with DNA from patients with a deletion 
in that particular gene, that have been diagnosed with other molecular techniques. As a 
positive control, a patient that was previously published (25) was used. A number of normal 
individuals, including their parents, and a blank (no DNA) were used as negative controls. 
The Affymetrix GeneChip Human Mapping 262K NspI array was used according to 
the instructions provided in the Affymetrix GeneChip Human Mapping 500K Manual 
(http://www.affymetrix.com). SNP copy number was assessed using CNAG (Copy Number 
Analyser for GeneChip) version 2.0 (37).
IGF1 gene sequencing of all four exons and flanking intron-exon boundaries was 
performed according to standard procedures (primers and conditions available upon 
request).




Skin biopsies were taken from patients A and B, and a culture of dermal fibroblasts was 
established (38). For Western blotting, fibroblasts were stimulated for 10 minutes with 
5, 10, and 20 ng/ml IGF-I (PeproTech, Inc., Rocky Hill, NJ). Blots were probed with an 
antiphosphoprotein kinase B (PKB)/Akt (Ser473), total PKB/Akt, total IGF1Rβ (Cell Signaling 
Technology, Beverly, MA), and an antiphospho-IGF1R (Biosource International, Camarillo, 
CA) antibody as described previously (39). 
Results
All 100 short SGA children were investigated with the “in house” MLPA growth kit, and two 
patients were identified with a deletion of the IGF1R gene. No copy number variants (CNVs) 
in the other growth-related genes were detected.
Patient A 
Clinical description
Patient A was a girl who was born spontaneously after 40 weeks of gestation as the third 
child of nonconsanguineous parents. Because maternal age was 36 yr, her mother chose 
for amniocentesis showing a 46,XX karyotype. The pregnancy was complicated by vaginal 
bleeding and limited fetal movements. Her birth weight was 2890 g (−1.28 SD score) and 
birth length 47 cm (−2.21 SD score). The height of her father was 184.7 cm (0.40 SD score) 
and of her mother 176.6 cm (1.34 SD score), resulting in a (secular trend-corrected) target 
height of 178.8 cm (1.25 SD score). She had bilateral hip dysplasia and clubfeet, for which 
she had hip casting from 4 to 12 months of age. Her bilateral hearing loss improved by 
tympanostomy tubes, which were implanted at 3 yr of age. Psychomotor development was 
delayed. At 2.3 yr of age, her height was 78.9 cm (−3.46 SD score), weight 10.3 kg (−2.13 SD 
score weight for height), and head circumference 47.2 cm (−0.82 SD score). Arginine and 
clonidine stimulation tests were performed at age 2 with a maximal GH response of 19.1 
mU/liter and 14.1 mU/liter, respectively. She had a delayed dentition, starting at age 2. At 
age 3 her bone age was 2 yr. Her IGF-I level was 46 ng/ml (−1.61 SD score) and IGFBP-3 
level 1.17 mg/liter (−1.63 SD score). Cardiovascular, respiratory, and abdominal examinations 
were all normal. On magnetic resonance imaging of the hypothalamic and pituitary region, 
no abnormalities were seen.   
From age 4 onward, GH treatment was initiated at a dose of 1 mg/m2 per day (Fig. 1). At 
start of GH treatment, her height was 90.6 cm (−3.42 SD score), BMI 14.3 kg/m2 (−1.02 SD 
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score), sitting height/height ratio 0.60 (0.00 SD score), and head circumference 48.6 cm 
(−0.95 SD score). Her serum total IGF-I level was 34 ng/ml (−2.78 SD score), IGFBP-3 level 
1.35 mg/liter (−1.33 SD score), and her bone age was 1 yr behind. After 1 yr of GH treatment, 
height had increased by 1.02 SD and head circumference by 0.58 SD. Her serum total IGF-I 
level was 197 ng/ml (1.51 SD score), and IGFBP-3 level was 2.62 mg/liter (0.92 SD score). After 
4 yr of GH treatment, she had an increase in height of +1.65 SD score and an increase in 
IGF-I level of +5.75 SD. Currently, at age 8.3, her height is 123.3 cm (−1.68 SD score). Cardiac 
ultrasound showed an undulating shape of the left ventricular wall which could not be 
further specified.
Dysmorphological examination showed hypertelorism, hypocanthal folds, medial 
flaring of the eyebrows, broad nasal bridge, and thick hair (Fig. 2). She had a triangular 
face, large mouth, short and pigmented upper lip, and low-placed, posterior rotated ears. 
Her abdomen was protruded. She had bilateral clinodactyly, short fingers, and proximally 
placed, broad thumbs. She had a bilateral sandal gap and broad forefeet with pes planus. 
There was hyperlaxity of the joints, especially of the elbows and knees (Beighton score 
7/9). Dimples were present at the right flank and in the lumbar region. These dysmorphic 
features were absent in her parents. She goes to a regular primary school. Testing of her 
verbal and performance intelligence quotient showed an average intellectual level, with 
a score of 93 and 121 points, respectively. These scores indicate a disharmonic intellectual 
profile although being in the normal range. Her two brothers were born after 40 weeks 
gestation, had a normal birth size, and grew normally (data not shown). 
Genetic analysis
Patient A had a deletion of all three probes in the IGF1R gene on the MLPA growth kit. 
Confirmation of this result with the MRC Holland P217 MLPA kit showed a heterozygous 
deletion of all probes in the IGF1R gene (exon 1-21), including the two telomeric control probes 
which were located at 2.0 and 2.8 Mb downstream of the IGF1R gene. Her parents and both 
brothers did not carry this deletion. SNP array analysis showed a terminal deletion from 
location rs12912857, the first deleted SNP probe located at 95.883.282 bp until rs7169385, 
the last deleted SNP probe located at 100.192.115 bp (Ensembl release 49), comprising a 
4.5 Mb region on chromosome 15 (Fig. 3). No other pathogenic CNV was observed with 
SNP array analysis. Additional sequence analysis of the coding region of the IGF1 gene, to 
exclude a mutation as a cause of the low IGF-I level revealed no mutation.
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Figure 1  Growth charts of the two children with a IGF1R deletion.
Patient B 
Clinical description
Patient B was a boy born spontaneously after 40 weeks of gestation as the first child of 
nonconsanguineous parents. A decrease in fetal growth was observed during the last 
trimester by ultrasound. His birth weight was 2600 g (−1.91 SD score) and birth length 47 
cm (−2.21 SD score). The height of his father and mother was 187.6 cm (0.84 SD score) and 
165.2 cm (−0.50 SD score), respectively. His secular trend-corrected target height was 187.4 
cm (0.49 SD score). Bone age was 2 yr delayed at the chronological age of 4 yr. At age 2, 
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a rotation deformity of both tibial bones was observed, and tympanostomy tubes were 
implanted because of recurrent ear infections. At 3.0 yr of age, his height was 84.0 cm 
(−3.84 SD score), and his weight was 11.2 kg (−2.65 SD score). A clonidine stimulation test 
was performed at age 5 with a maximal GH response of 69.7 mU/liter. Cardiovascular, 
respiratory, and abdominal examinations were all normal.
From age 7 onward, he started GH treatment in a dose of 1 mg/m2 per day (Fig. 1). At start 
of GH treatment, his height was 109.4 cm (−3.57 SD score), BMI 16.5 kg/m2 (0.49 SD score), 
sitting height/height ratio of 0.55 (−1.86 SD score), and head circumference 51.3 cm (−0.53 
SD score). IGF-I was 208 ng/ml (1.25 SD score) and IGFBP-3 level 2.99 mg/liter (1.24 SD score). 
After 1 yr of GH treatment, his height had increased by 0.83 SD and head circumference by 
0.29 SD. His serum total IGF-I level was 356 ng/ml (2.28 SD score), and IGFBP-3 level was 
1.99 mg/liter (−0.40 SD score). After 4 yr of GH treatment, he had an increase in height 
of +1.69 SD and an increase in IGF-I of +0.39 SD. Currently, at age 17, his height is 168.9 cm 
(−1.89 SD score).
From age 11 onward, he used methylfenidate (10/5/5 mg) because of attention-deficit 
hyperactivity disorder. After primary school, he started a secondary school for children 
with hearing and speech difficulties. Currently, he receives training for becoming a baker. 
Cardiac evaluation showed no abnormalities.
Dysmorphological examination showed hypertelorism, upward slant, thin upper lip, 
bilateral extra nipple, proximal implanted thumbs, and broad feet (Fig. 2). These dysmorphic 
features were absent in his parents and brother. His brother has a height within the normal 
range.
Genetic analysis
MLPA analysis showed a deletion of two of three IGF1R probes (exons 8 and 18). The MRC 
Holland P217 MLPA kit showed a heterozygous deletion of exons 3-21 of the IGF1R gene 
comprising also both telomeric control probes located at 2.0 and 2.8 Mb downstream 
of the IGF1R gene. His parents and brother did not carry the deletion. SNP array analysis 
showed a terminal deletion of 3.1 Mb on chromosome 15, ranging from rs11857366, first 
deleted SNP probe at  97.081.324 bp until rs7169385, last deleted SNP probe at 100.192.115 
bp, containing 282 SNP probes (Fig. 3). No other pathogenic CNVs were observed in the SNP 
array analysis.




In previous reports it was shown that a patient with a heterozygous IGF1R mutation (E1050K) 
demonstrated a decreased activation of IGF1R intracellular signaling upon challenging with 
IGF-I (26), and in a patient with a heterozygous IGF1R deletion the activation of the IGF1R 
and PKB/Akt tended to be lower, but this did not reach significance (25).   
In our two patients Western blots from cultured skin fibroblasts demonstrated a slightly 
lower autophosphorylation of the IGF1R in patient B in comparison with controls (Fig. 4A), 
but on average autophosphorylation of the IGF1R in the two patients was similar to that in 
controls (Fig. 4B). There was a significantly reduced activation of PKB/Akt upon a challenge 
with 10 ng/ml IGF-I for 10 minutes compared with healthy controls. The levels of total PKB/
Akt and IGF1R protein expression were similar to controls, although total IGF1R protein 
expression appeared lower in patient B (Fig. 4A). Stimulation of the fibroblasts with a dose 
range of IGF-I for 10 minutes (Fig. 4, C and D) demonstrated reduced phosphorylation of PKB/
Akt in the patients compared with controls. Total PKB/Akt and IGF1R autophosporylation 
were similar in the patients and controls. Total IGF1R protein expression tended to be lower 
in the patients compared with controls.
Figure 2  Physical characteristics of Patient A, at age 9, and of Patient B at 18 yr of age.
Patient A Patient B
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Figure 4  Functional analysis. A, Dermal fibroblasts of the patients and four age- and sex-matched 
controls were stimulated with 10 ng/ml IGF-I for 10 minutes. Protein lysates were collected, and 
25 µg of protein was used for Western blotting with phosphospecific IGF1R and PKB/Akt (Ser473) 
antibodies and total IGF1R and PKB/Akt antibodies. B, Densitometric quantification of the Western 
blot shown in A. Data are expressed as a ratio of phosphospecific IGF1R or PKB/Akt and total 
IGF1R or PKB/Akt, respectively. The activation of PKB/Akt was significantly lower in the patients 
compared with the controls. Autophosporylation and total protein expression of the IGF1R tended 
to be lower in patient B, although this did not reach significance. C and D, Activation of PKB/Akt 
by phosphorylation on Ser473 as well as autophosphorylation of the IGF1R in fibroblasts of Patients 
A and B and four age- and sex-matched controls were determined by Western blotting after a 
challenge with a dose range of IGF-I. Protein lysates were collected after a 10-minutes stimulation. 
Total PKB/Akt was used to check for equal loading.
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Discussion
This study shows that IGF1R haploinsufficiency was detected in 2 of 100 short SGA children 
and that no other copy number variants were found in 18 other growth-associated genes. 
Because dominant de novo deletions are a well-recognized sign of pathogenicity, it is very 
likely that the observed deletions explain the short stature of both patients. In addition, 
according to the database of genomic variants (http://projects.tcag.ca/variation/) no 
deletion of the IGF1R gene region has been reported yet in the general population. This 
is further supported by previous clinical studies reporting subjects with IGF1R point 
mutations and deletions (13-15, 17-24, 26), including functional analysis of patients with 
a missense mutation and one with a complete deletion of the IGF1R gene (16, 25, 26). In 
vitro functional analysis of our patients showed almost similar IGF1R autophosporylation, 
a tendency toward reduced total IGF1R protein expression, and reduced intracellular PKB/
Akt activation compared with healthy controls. Our results are in line with the findings we 
reported earlier on another patient with IGF1R haploinsufficiency (25) and suggest that this 
condition is characterized by a lower number of IGF1 receptors on the cell surface, resulting 
in less signal transduction. In the family with a missense mutation in the intracellular 
kinase domain of the IGF1R, we observed a stronger decrease in activation of downstream 
signaling (26). Previously we have hypothesized (25) that the discrepancy between the 
results in IGF1R deletions and mutations in vitro may be explained by a dominant-negative 
effect of the mutation, which would decrease the number of fully functional receptors to 
25%, whereas haploinsufficiency would theoretically lead to a reduction of 50%. 
In our fibroblast model, the expression of the IGF1R tended to be lower in the patient’s 
cells but was not reduced with 50%. Downstream signaling as assessed by measuring 
phosphorylation of PKB/Akt was, however, reduced in the patient’s fibroblasts. These 
observations are in line with previously reported results obtained in fibroblasts of a patient 
with a terminal 15q deletion, which also demonstrated a nonsignificant reduction in IGF1R 
expression but a much stronger and significant reduction in activation of downstream 
signaling (25). However, the observation that the effect on growth is similar in patients 
with IGF1R mutations and deletions suggests a similar biological effect on growth. Thus, 
the consequences of IGF1R haploinsufficiency may be cell type-dependent, with possibly a 
relatively strong effect in growth plate chondrocytes, which are responsible for longitudinal 
growth, whereas the differences in the fibroblast model are less pronounced. 
Both children responded to GH treatment, increasing their height by 1.02 SD and 0.83 
SD, respectively, after 1 yr of GH treatment. This growth response was comparable with 
the mean 1-yr growth response in short SGA children (approximately 0.8 SD in prepubertal 
short SGA children on the same GH dosage) (40). 
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This positive growth response can be explained by a combination of the direct effect of GH 
on the epiphyseal chondrocytes which is independent of the biological actions of serum 
IGF (41), and of elevated serum IGF-I levels, which may partially overcome the diminished 
sensitivity.
When previous case reports of children with an IGF1R deletion or mutation were 
reviewed, only six other children had received GH treatment (Table 1). The children who 
received a GH dose of 1 mg/m2 per day increased their height with ~1.0 SD per year of GH 
treatment. Their serum IGF-I level increased with ~1.0 SD except for Patient A (discussed 
in the next paragraph). The other children received a higher GH dose but showed a similar 
variable response: a similar response in two of them, and no apparent response in two other 
patients (13, 16). Thus, six of eight children showed a beneficial effect of GH treatment.
An unexpected finding in Patient A was the low serum IGF-I level, in contrast to a high or 
normal serum IGF-I level usually observed in patients with an IGF1R mutation or deletion. 
Because no abnormalities in the IGF1 gene were found, we hypothesize that this may be 
explained by a partial GH deficiency. The marginal response of GH in the provocation test 
and the observation that IGF-I and IGFBP-3 strongly rose by +4.3 SD and +2.2 SD after 1 yr 
of GH treatment support our hypothesis. In the child with an IGF1R missense mutation 
who presented with severe failure to thrive, serum IGF-I was initially not elevated (+1.3 
SD score; van der Kamp, H.J., personal communication) (26), but after realimentation by a 
gastrostoma her IGF-I levels increased up to +2.9 SD score. 
The children we identified had a relatively mild phenotype compared with the other 
patients with a terminal IGF1R deletion who had lung hypoplasia, atrial and/or ventricular 
septal defects, hypoplastic left atrial or ventricular heart, dextrocardia, and diaphragmatic 
hernia (Table 2) (19-25). We believe that these clinical signs are primarily linked to other 
genes in the area, as in children with an IGF1R mutation a much smaller number of 
additional characteristics has been observed. Poot et al. indicated IGF1R flanking genes 
that might be responsible for several characteristics of the variation in the phenotypes of 
children with an IGF1R deletion (20). 
Both of our patients had hearing problems, showed mild developmental delay, and 
had proximal implanted thumbs. Hearing problems and developmental delay have been 
described in previous case reports of mutations in the IGF1 and IGF1R gene and might also 
be caused by their tissue-specific expression in the auditory and central nervous system 
(42, 43). 
To our knowledge, there are no diagnostic criteria for children with an IGF1R mutation 
or deletion. In Table 3 we have summarized clinical features of children with an IGF1R 
mutation or deletion according to their organ system. We identified major criteria that are 
predominantly related to growth restriction and minor criteria that are based on dysmorphic 
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features and signs of joint hypermobility. Based on the information summarized in Table 2, 
we propose the combinations of major and minor criteria which indicate a high likelihood 
of an IGF1R mutation or deletion. Interestingly, joint hypermobility is related to the fibrillin 
(FBN1) gene, which is located upstream of the IGF1R gene on 15q21. FBN1 gene mutations 
are responsible for Marfan’s syndrome, which is associated with tall stature. Because both 
clinical syndromes display joint hypermobility, we speculate that the IGF1R and FBN1 genes 
together might play a role in variations in height and hypermobility in short SGA patients.
The remaining 98 short SGA children had no CNVs in the 18 growth-associated genes 
we selected, but we did not exclude mutations in these genes. Future studies are needed 
to investigate whether deletions or mutations in other genes, or combinations of several 
gene defects, are associated with the short SGA phenotype.  
In summary, this study has shown that IGF1R haploinsufficiency was present in 2 of 100 
short SGA children. This study illustrates that the combination of a small birth size, short 
stature, small head size, relatively high IGF-I level, developmental delay, and micrognathia 
is suggestive for children with an IGF1R deletion. Because GH therapy leads to a moderate 
catch-up growth of ~1.0 SD in the first year, we recommend that the SGA children with a 
persistent short stature are tested for an IGF1R deletion, particularly if some of the major or 
minor criteria are present. The MLPA has shown to be a valuable tool in rapidly identifying 
these relatively large deletions in short SGA children.
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Table 3  Suggested clinical indicators for a heterozygous IGF1R mutation or terminal chromosome 15q deletion based on 
published cases
Anatomical system Major Minor
1. Skeletal Height ≤ −2.00ª
Birth length ≤  −2.00
Birth weight ≤ −2.00
Head circumference ≤  −2.00
IGF-I level SDS > 1.00
Triangular face/micrognathia
Proximal placed thumb




3. Cardiac Right sided aorta, bicuspid aortic valve, aortic coarctation
VSD
Aberrant left ventricular wall
4. Gastro-intestinal Diaphragmatic hernia
Gastroesophagal reflux






6. Skin Oculocutaneous albinism
ª SD score. VSD, Ventricular septal defect.
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IGF1R 2 U GATGTGTGAGAAGACCACCATCAACA 92 HEX
  D ATGAGTACAACTACCGCTGCTGGACCACAA   
 8 U CTACATGGGCTGAAGCCCTGGACTCAG 94 HEX
  D TACGCCGTTTACGTCAAGGCTGTGACCCTCA   
 18 U CAGTCCTAGCACCTCCAAGCCTGAGCA 90 HEX
  D AGATGATTCAGATGGCCGGAGAGATTG   
IGF1 3 U GAGTGCTGCTTCCGGAGCTGTGATCT 88 HEX
  D AAGGAGGCTGGAGATGTATTGCGCAC   
 4 U GTACATTTGAAGAACGCAAGTAGAGGGAGT 98 HEX
  D GCAGGAAACAAGAACTACAGGATGTAGGAAGA   
GH1 4 U CAACAGCCTGGTGTACGGCGCCTCTGACAGCAACGTCTATGA 116 FAM
  D CCTCCTAAAGGACCTAGAGGAAGGCATCCAAA   
GHR 4 U GCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACC 112 FAM
  D TAGGACCCATACAGCTGTTCTATACCAGAAG   
 10 U GGTACTTTGGTGGCCACATAAGCCATTATTCACTAGTATGA 110 HEX
  D CTAGTTGTGTCTGGCAGTTTATATTTAACTCTC   
SHOX 3 U GGATTTATGAATGCAAAGAGAAGCGCGAGGACG 106 HEX
  D TGAAGTCGGAGGACGAGGACGGGCAGACCAAGCTGAA   
 8 U CCCTGAGTTTCTCTGGTGACGCCCTCATTCTCCTAA 108 HEX
  D CGTTCAATAATCTCAATGTTGAGTTGCAGCAACAGA   
IGFBP1 1 U CAAACTTATTTTGAACACTCAGCTCCTAGCGTGCG 102 HEX
  D GCGCTGCCAATCATTAACCTCCTGGTGCAAG   
 4 U GTGAGACATCCATGGATGGAGAGGCGGGACTCTGCT 104 HEX
  D GGTGCGTCTACCCTTGGAATGGGAAGAGGATC   
IGFBP2 2 U CACTCAGAAGGAGGCCTGGTGGAGAACCACGT 100 FAM
  D GGACAGCACCATGAACATGTTGGGCG   
 4 U CAAGATGTCTCTGAACGGGCAGCGTGGGGAGTGCT 108 FAM
  D GGTGTGTGAACCCCAACACCGGGAAGCTGAT   
IGFBP3 2 U GCTAAAGACAGCCAGCGCTACAAAGTTGACTACG 100 HEX
  D AGTCTCAGAGCACAGATACCCAGAACTTCT   
 5 U CTGGAGCTCACAGCCTTCTGTGGTGTCATT 96 HEX
  D TCTGAAACAAGGGCGTGGATCCCTCAACCA   
IGFBP4 3 U GACCTCTACATCATCCCCATCCC 84 HEX
  D CAACTGCGACCGCAACGGCAACTTC   
hfst 5.indd   118 20-05-13   12:43
119
5chapterS
 4 U CAGAGTCAGAGGAGAAGAGACATGTACCTTGACCATCGTCC 114 HEX
  D TTCCTCTCAAGCTAGCCAGAGGGTGGGAGCCTAAGGA   
IGFBP5 2 U GATCTTCCGGCCCAAACACACCCGCATCTCCGAGCTGAAGGCTGAAG 120 HEX
  D CAGTGAAGAAGGACCGCAGAAAGAAGCTGACCCAGTC   
 3 U GTGCTGTGTACCTGCCCAATTGT 86 HEX
  D GACCGCAAAGGATTCTACAAGAGAAAG   
IGFBP6 2 U CCACAGGATGTGAACCGCAGAGA 92 FAM
  D CCAACAGAGGAATCCAGGCACCTCTAC   
 3 U CAAACACTCTACGTGCCCAATTGTG 90 FAM
  D ACCATCGAGGCTTCTACCGGAAG   
ALS 2 U GAACCTCTCTGGGAACTGTCTCCGG 88 FAM
  D AACCTTCCGGAGCAGGTGTTC   
STAT5B 2 U GATACAAGCTCAGCAGCTCCAAGGAGAAGCCCT 102 FAM
  D TCATCAGATGCAAGCGTTATATGGCCA   
 14 U GAGAATTTACCAGGACGGAATTACACTTTCTG 104 FAM
  D GCAATGGTTTGACGGTGTGATGGAAGTGTT   
SOCS3 2 U CTTCAGCATCTCTGTCGGAAGACCGTCAACG 98 FAM
  D GCCACCTGGACTCCTATGAGAAAGT   
GRB10 3 U GATGTGGACCTGGAAGCCCTGGTGAACGAT 96 FAM
  D ATGAATGCATCCCTGGAGAGCCTG   
 10 U CAGAGGACGAGCAAACCAGGACGTGCT 94 FAM
  D GGATGACAGCGTTCAGACTCCTCAA   
NSD1 3 U GAGATCTCATCTGGGCAAAATTCAAGAGACGCCCATGGTGGCCCT 116 HEX
  D GCAGGATTTGTTCTGATCCGTTGATTAACACACAT   
 13 U CACTGTTATGCAGAACAAGGGCTTCCGGTGCTCCCTCCACATCTGTA 118 HEX
 D TAACCTGTCATGCTGCTAATCCAGCCAATGTTTCT   
 20 U CTCGGTTCATGAATCATTGCTGCCAGCCCAACTGTGAAACACAGAAG 120 FAM
  D TGGTCTGTGAATGGAGATACCCGTGTAGGCC   
IGF2 2 U GAATCCCAATGGGGAAGTCGAT 86 FAM
(11p15)  D GCTGGTGCTTCTCACCTTCTTG   
 4 U CATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTT 114 FAM
  D CCATCCCGAAAATCTCTCGGTTCCACGTC   
SOCS2 1 U GCCGCGGCCTCAACTAAAAGTGGCCATTGACCTTTCAA 110 FAM
  D GCTTTCGAGCAGTGATGCAATAGAATAGAA   
* The Upstream hybridizing sequence (U) was extended with a labeled primer 5’-GGGTTCCCTAAGGGTTGGA-3’; the downstream hybridizing 
sequence was extended with an unlabeled primer 5’-GTGCCAGCAAGATCCAATCTAGA-3’.
Supplemental Data
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Abstract
Background/Aims: In short children, a low IGF-I and normal GH secretion may be associated 
with various monogenic causes, but their prevalence is unknown. We aimed at testing GH1, 
GHR, STAT5B, IGF1, and IGFALS in children with GH insensitivity.
Subjects and Methods: Patients were divided into three groups: group 1 (height SDS <–2.5, 
IGF-I <–2 SDS, n = 9), group 2 (height SDS –2.5 to –1.9, IGF-I <–2 SDS, n = 6) and group 3 
(height SDS <–1.9, IGF-I –2 to 0 SDS, n = 21). An IGF-I generation test was performed in 
11 patients. Genomic DNA was used for direct sequencing, multiplex ligation-dependent 
probe amplification and whole-genome SNP array analysis.
Results: Three patients in group 1 had two novel heterozygous STAT5B mutations, in two 
combined with novel IGFALS variants. In groups 2 and 3 the association between genetic 
variants and short stature was uncertain. The IGF-I generation test was not predictive for 
the growth response to GH treatment.     
Conclusion: In severely short children with IGF-I deficiency, genetic assessment is advised. 
Heterozygous STAT5B mutations, with or without heterozygous IGFALS defects, may 
be associated with GH insensitivity. In children with less severe short stature or IGF-I 
deficiency, functional variants are rare.





In approximately 80% of children who are referred to a pediatric clinic because of short 
stature, no definite cause can be established, even after a thorough diagnostic workup 
including extensive biochemical screening and radiologic investigations [1–4]. Such children 
are usually classified as idiopathic short stature (ISS) [1]. Within the ISS group, especially 
those children with a low circulating IGF-I level, in the face of a normal or even elevated GH 
secretion (also labeled ‘primary IGF-I deficiency’), pose a diagnostic challenge.
At present, the known monogenic causes of short stature which are associated with 
a low serum IGF-I level and normal or elevated GH secretion include defects of GH1 
(bioinactive GH) [5], GHSR (ghrelin receptor) [6], GHR (GH receptor) [7], STAT5B [8], IGF1 [9] 
and IGFALS [10; for reviews, see 11, 12]. With increasing numbers of reports on these gene 
defects it has become clear that the phenotype is more variable than suggested by the 
first cases. For example, the clinical features of homozygous GHR mutations can vary 
substantially depending on the location of the mutation. Furthermore, heterozygosity for 
the same gene defect may be associated with a mild negative effect on growth (approx. 1 
SD), as observed for mutations in IGF1 [9, 13, 14] and IGFALS [15–17]. On the other hand, some 
cases of heterozygosity for a GHR mutation are associated with pronounced growth failure 
[12, 18].
So far, only monogenic causes of primary IGF-I deficiency have been reported. However, 
it is conceivable that primary IGF-I deficiency can also be associated with the cumulative 
effect of digenic or oligogenic defects, in a similar fashion as recently shown for 
hypogonadism [19]. This view is supported by the results from genome-wide association 
studies that have shown that height is determined by more than 180 genes [20].
Based on the clinical and biochemical phenotype of children with monogenetic disorders 
of the GH-IGF-I axis, we and others have proposed algorithms for the diagnostic approach 
of children with short stature [11, 12, 21]. As a first step, IGF-I generation tests theoretically 
should allow one to discriminate between a normal GH sensitivity (GH1 and GHSR defects) 
and GH insensitivity (GHR, STAT5B, IGF1, IGFALS defects) [11, 21]. However, the diagnostic 
accuracy of the various regimens for an IGF-I generation test is uncertain [reviewed in 22]. 
The second step would be genetic testing of the most likely candidate gene(s). Finally, as 
a third step, we have suggested a whole-genome single nucleotide polymorphism (SNP) 
array analysis [11].
In this paper we present the results of a genetic analysis for GH1, GHR, STAT5B, IGF1, 
and IGFALS, followed by whole-genome SNP array analysis, in short children with various 
degrees of IGF-I deficiency and a normal or increased GH secretion pattern.
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DNA from patients with short stature was sent to us for genetic analysis. For this study we 
included patients with short stature (height standard deviation score (SDS) <–1.9, according 
to Dutch references [23]) and no abnormalities with respect to medical history, physical 
examination, radiologic, and biochemical investigations, that could point to a diagnosis. 
GH secretion was either normal (6.7–26.6 μg/l) or elevated (arbitrarily defined as ≥ 26.7 
μg/l), as assessed by a standard GH provocation test (clonidine or arginine test) (except for 
2 cases where it was not tested), and body proportions (sitting height/height ratio) were 
normal (between –2.5 and +2.5 SDS for age) [24].
Subjects were divided into three groups, based on height SDS and serum level of IGF-I 
(assessed at least twice). Group 1 consisted of severely short children (height SDS <–2.5) 
with a low serum level of IGF-I (<–2 SDS). According to the recently proposed algorithm [11], 
these children would be suitable candidates for genetic testing. Children in group 2 were 
less short (height SDS between –2.5 and –1.9), but IGF-I deficient (serum IGF-I <–2 SDS). 
Group 3 consisted of children with a wide range of short stature (height SDS <–1.9) and a 
serum IGF-I in the lower normal range (i.e. between –2 and 0 SDS).
Auxological data and clinical characteristics were collected from case records. Birth 
weight, length and head circumference were expressed as SDS according to Swedish 
reference data [25]. In children of whom no birth length or head circumference were 
available, length and head circumference SDS in the first 3 months of life were used as 
proxy estimates. Height at presentation as well as parental heights were expressed as SDS 
according to Dutch nation-wide reference charts [23]. Conditional target height (cTH) SDS 
was calculated as 0.72 × mean parental height SDS [26], and the distance between height 
SDS and cTH SDS was recorded. The growth response to GH treatment is expressed as the 
change in height SDS [23] during the first year. Body mass index (BMI) was calculated as 
height (m)/weight (kg)2 and expressed as SDS for the Dutch 1980 references, which were 
collected before the start of the obesity epidemic [27]. The serum IGF-I data presented in 
the tables were obtained at clinical presentation.
Biochemical Tests
Serum levels of IGF-I were measured either in Leiden University Medical Center or University 
Medical Center Utrecht (UMCU) on the Immulite 2500 or Immulite 1000 (Siemens, Munich, 
Germany), respectively. Both methods were correlated to the original in-house IGF-I RIA for 
which age references had been determined [28]. Serum IGFBP-3 was determined in Utrecht 
as described previously [28] and in Leiden on the Immulite 2500. Results were expressed 
as SDS for age and gender, after correction for inter-assay differences, based on previously 




described age references [28]. GH was measured in local laboratories, but a nation-wide 
quality control system assured that the results of different assays were comparable [29]. 
Results are expressed as μg/l (1 μg/l = 3 mU/l according to the most recent standard (IS 
98/574)).
For subjects suspected for ALS deficiency, serum ALS levels were determined using the 
ELISA kit of Mediagnost (Reutlingen, Germany). Intra-assay variations were 6.6 and 6.8% at 
mean levels of 911 and 1,338 mU/ml, respectively. Inter-assay variations were 9, 8 and 8% at 
mean levels of 931, 1,061, and 1,926 mU/ml, respectively. Since ALS levels in the circulation 
depend on age and gender (although less than serum levels of IGF-I and IGFBP-3), values 
were transformed to SDS using reference values. In order to establish normative ranges for 
ALS in the circulation, non-fasting blood samples were collected from 159 children (81 girls, 
78 boys) ranging in age from 10 months to 18 years. These samples were derived either from 
healthy children from several primary schools in the Netherlands, selected populations of 
patients (e.g. with minor ear, nose or throat conditions) or their healthy siblings visiting 
the UMCU. In addition, serum or EDTA plasma samples of adolescents and adults (176 
females, 181 males) ranging from 18 to 78 years were obtained from the Red Cross Blood 
Bank Utrecht (Utrecht, the Netherlands), and from healthy volunteers working in the 
endocrine department of UMCU. None of these subjects were suffering from malnutrition 
or showed signs of acute disease or endocrine abnormalities. All samples were obtained 
after informed consent and stored at –20°C until analysis.
The different molecular-size classes of endogenous IGF-IGFBP complexes in plasma 
were determined by neutral gel filtration through a 1.6 × 60 cm HiLoad Superdex-200 
column, as described previously [15]. In order to investigate if the abnormal profiles could be 
normalized by spiking the samples with excess rhIGFBP-3, we used glycosylated hIGFBP-3, 
isolated from pooled normal human plasma using the purification procedure as modified 
by Martin and Baxter [30].
IGF-I Generation Test
The GH dose-escalation IGF-I generation test was performed as previously described [21]. 
In brief, GH was administered once a day subcutaneously for 1 week with a dosage of 0.7 
mg/m2/day. In case of an insufficient response (defined as a change of <1 SDS), the dose 
was doubled (1.4 mg/m2/day), and if the response was still too low, a third series of GH 
injections (2.8 mg/m2/day) was administered. Serum IGF-I was measured before the first 
injection and after the seventh one. Washout periods between subsequent doses of GH 
lasted at least 4 weeks.
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Genetic Tests
Genomic DNA was isolated from peripheral blood samples using the Autopure LS 
Instrument (Gentra Systems). Direct sequencing was carried out according to standard 
procedures (primer sequences are available upon request).
Variants were classified as polymorphisms on the basis of their presence in dbSNP (build 
132) or as polymorphisms in gene-specific mutation databases (HGMD). Missense mutations 
were classified as pathogenic or unclassified variant (UV) based on their presence in gene-
specific mutation databases and in silico prediction programs (Polyphen, SIFT). Intronic 
and neutral amino acid substitution variants were analyzed with various in silico splice 
predict software programs (Human Splicing Finder, SpliceSiteFinder-like, MaxEntScan, 
and NNSPLICE) to determine the potential effect on splicing. Different Multiplex Ligation-
dependent Probe Amplification (MLPA) kits (MRC Holland, The Netherlands) were used to 
detect deletions and duplications in various genes: P262 for GHR, IGF1 and STAT5b, P216 
for LHX4, POU1F1, HESX1, PROP1, GHRHR, LHX3 and GH1, P18D1 for SHOX, and P217 for IGF1R, 
IGFBP3 and IGFALS, according to the manufacturer’s instructions. The Affymetrix GeneChip 
Human Mapping 262K NspI array was used according to the instruction provided in the 
Affymetrix GeneChip Human Mapping 500K Manual (http://www.affymetrix.com) to 
detect copy number variants (CNVs). SNP copy number was assessed in the patient using 
CNAG (Copy Number Analyzer for GeneChip®) Version 2.0 [31].
Functional Studies
Antibodies
The following antibodies were used: anti-phospho-STAT5 (Tyr694) from Cell Signaling 
Technology (Beverly, Mass., USA), anti-STAT5b (G2) from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, Calif., USA), anti-FLAG M2 antibody from Sigma (St. Louis, Mo., USA), and anti-
mouse IgG and anti-rabbit IgG from Amersham-Pharmacia Biotech (Uppsala, Sweden).
Generation of Recombinant Mutant N-FLAG-STAT5b Plasmids
N-terminally FLAG-tagged wild-type STAT5b (F-STAT5b) was described previously [32]. 
FLAG-STAT5b-V498M (F-V498M) was generated by site-specific mutagenesis (QuickChange 
II Site-Directed Mutagenesis Kit; Stratagene, La Jolla, Calif., USA), using F-STAT5b as 
template. The primers used were forward 5’-gggtgccatttgccatgcctgacaaagtg-3’ and 
reverse 5’-cactttgtcaggcatggcaaatggcaccc-3’. The nucleotide substitutions (in bold) are 
underlined. The resulting F-V498M variant was confirmed by DNA sequencing.
Cell Culture and Transfection Experiments
HEK293 cells stably transfected with the full-length human GHR cDNA, HEK293(hGHR) 




[33], were maintained as recommended. For reconstitution studies, HEK293(hGHR) cells 
were seeded at 2 × 105/well, grown to ~60% confluence in 6-well tissue culture plates, and 
transiently transfected with 1 μg of vector, pcDNA3.1, or 1 μg of vector carrying F-STAT5b, 
or F-V498M, using TransIT-LT1 (Mirus, Madison, Wisc., USA). After 24 h of transfection, cells 
were starved for 9 h prior to a 20-min treatment with 100 ng/ml rhGH (generous gift 
from Serono), as described previously [32]. Transfection experiments were performed in 
duplicates, at least three independent times.
Luciferase Reporter Assay
Luciferase (pGHRE-LUC)-transfected HEK293(hGHR) cells were analyzed for reporter 
activity using the luciferase assay system (Promega Corp., Madison, Wisc., USA). A total 
input of DNA was 2 μg/well: 1 μg of pGHRE-LUC plus 1 μg of pcDNA3.1, or relevant F-STAT5b 
variant (F-STAT5b, or F-V498M). After treatment with GH for 24 h, collected cell lysates 
(total amount is as indicated) were analyzed for reporter activity using a luminometer 
(BioTek Instruments Inc., Winooski, Vt., USA). The results (from at least two independent 
experiments, performed in duplicate) are reported as relative fold induction ± SD, compared 
to activities detected in 20 μg of total protein of untreated, pcDNA3.1 transfected cell 
lysates, which was given an arbitrary unit of 1.
Results
Auxology and Biochemistry
Clinical and biochemical characteristics of the subjects in groups 1–3 are shown in tables 
1–3, respectively. Three out of 9 children in group 3 were born small for gestational age 
(SGA). The average GH peak after provocation was clearly elevated (112 mU/l), and in 7 out 
of 9 cases the GH peak was ≥26.7 μg/l. In group 2, none of the 6 children was born SGA, and 
only 1 had a GH peak ≥26.7 μg/l. In group 3, 10 out of 21 children were born SGA, and 10 out 
of 19 had a GH peak ≥26.7 μg/l. Two participants (DD and JK) did not undergo a provocation 
test because both their serum IGF-I levels were within the normal range and GH treatment 
was approved because of SGA. Most patients were treated with biosynthetic GH and all 
except 2 cases in group 3 (NV, Δ height SDS 0.1; DD, Δ height SDS 0.3) showed a normal 
growth response to GH during the first year of treatment (Δ height SDS 0.4–1.1).
IGF-I Generation Test
In 11 of the 36 subjects, GH sensitivity was studied using an IGF-I generation test (table 4). A 
normal response was defined as an increase of the serum IGF-I level with >1 SDS on a dosage 
of 0.7 mg/m2/day (equivalent to 25 μg/kg/day at a body surface area of 1 m2). This was 
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observed for 3 subjects, i.e. JH, KB (group 2) and (borderline response) NV (group 3). A low 
response (a serum IGF-I increase <1 SDS) to the lowest dose of GH, but a sufficient response 
to the intermediate dosage (1.4 mg/m2/day) of GH, suggesting partial GH resistance, was 
observed for 5 patients (group 1: ER and CH; group 2: JB and JT; group 3: MV). One patient 
(IR, group 1) only showed an IGF-I response to the highest GH dose, suggesting a severe GH 
insensitivity. Finally, 2 patients (brothers RZ and IZ) were virtually insensitive to GH, and 
were not treated with GH.
The short-term serum IGF-I responses to GH in the IGF-I generation test did not 
correlate well with the growth response to long-term GH treatment (tables 1–4), although 
the variety of doses makes a comparison difficult. On average, the growth response of the 
3 children with a normal IGF-I generation test was 0.5 SDS (range 0.1–0.9) in the first year, 
and of the 5 children with partial insensitivity it was 0.8 SDS (range 0.5–1.0). One of the two 
poor responders in terms of growth response (NV) had a borderline normal IGF-I response. 
The patient with severe GH insensitivity (IR) was treated with both GH and GnRH analogue 
from 13.8 till 15.7 years of age, and GH was continued until 17.0 years. Her height SDS at start 
of GH treatment was -4.6 SDS and increased to –3.4 SDS at 17 years.
Genetic Findings
Group 1
Five out of 9 patients exhibited one or more variants in direct sequencing of genes known 
to be involved in the regulation of growth or in the whole-genome SNP array analysis 
(table 5). These findings are described in detail below.
The 2 brothers (RZ and IZ) both showed abdominal obesity, a high-pitched voice, 
mid-face hypoplasia, and frontal bossing, and the biochemical picture of complete GH 
insensitivity (tables 1, 4). They shared a heterozygous unclassified variant (UV) in STAT5B 
(p.Glu315Ala) which was not inherited from their mother (unfortunately, no DNA was 
available from their father). RZ was 0.9 SD shorter than his brother, and has two additional 
genetic variants. His shorter stature may be caused by the UV in IGFALS (p.Arg548Trp) 
rather than by the interstitial deletion (maximally 272.5 kb) in Xq25 containing one gene 
(WDR40C). This is supported by both the lower 150 kDa ternary complex peak (fig. 1b) and 
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Table 5  Genetic findings in group 1






arr Xq25 (SNP_A-2190162→SNP_A-2154195)×0 mat,






IZª het UV c.944A>Cp.Glu315Ala




arr 2q24.3q31.1 (SNP_A-1903408→SNP_A-1965788)×3 mat,
2q31.1 (SNP_A-2147815→SNP_A-2193545)×3 mat,
containing 6 and 2 genes, respectivelyb
het = Heterozygous; UV = unclassified variant; mat = maternal; POL = polymorphism.
ª Brothers. b The most proximal duplication contains 6 protein coding genes: NOSTRIN, SPC25, G6PC2, ABCB11, DHRS9 and LRP2. 
The most distal duplication contains two protein coding genes: DYNC1I2 and SLC25A12.
Addition of purified hIGFBP-3 (2.0 μg) per ml serum of RZ restored 150 kDa complex 
formation efficiently, i.e. it became comparable to the pattern found when the same 
amount of IGFBP-3 was added to 1 ml serum from IZ (fig. 1c) or a normal control (fig. 1a). This 
result would suggest that patient’s ALS should be capable of effective 150 kDa complex 
formation at a higher level of IGFBP-3. Possibly, RZ’s variant IGFALS has a reduced affinity 
for IGF-IGFBP-3 complexes, which only becomes manifest at his relatively low endogenous 
level of serum IGFBP-3.
A boy with clinical features suggestive for a STAT5B defect (CH), including severe 
constitutional eczema from infancy, borderline elevated serum prolactin, low serum 
immunoglobulins, and a very low IgG antibody response to hemophilus B vaccination at 6 
months of age, showed heterozygous UVs in STAT5B (p.Val498Met, maternally transmitted) 
and IGFALS (p.Pro378Leu, paternally transmitted). The STAT5B missense mutation is located 
in exon 13 and affects a highly conserved nucleotide and amino acid. In reconstitution 
studies, homozygous expression of the mutant STAT5B was lower than the wild-type gene 
(fig. 2). However, immunologically equivalent amounts of the mutant STAT5b protein could 
still be phosphorylated by the GH-GHR signaling pathway (fig. 2a) and was able to induce 
transcriptional activities comparable to that of wild-type STAT5b (fig. 2b).
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Figure 1  S200 gel filtration column chromatography. a Representative column profile for normal 
adult serum. b Serum RZ. c Serum IZ. Solid line: without addition; dotted line: addition of purified 
hIGFBP-3 (2.0 μg/ml serum). 
The IGFALS variant appears to lead to a partial ALS deficiency, since serum ALS was 
–1.8 SDS and column chromatography showed a pattern consistent with a heterozygous 
IGFALS defect (fig. 3). This variant has not been found in previous studies, nor in controls. 
PolyPhen 2 [34] predicts that the IGFALS variant could be pathogenic (HumDiv 0.999 score; 
HumVar 0.985 score). However, addition of purified hIGFBP-3 (2.0 μg/ml) to patient’s serum 
led to increased 150 kDa complex formation (data not shown), and became similar to that 
observed in normal serum (fig. 1a). It remains to be determined whether the heterozygous 
STAT5B p.Val498Met mutation by itself, or synergistically with the heterozygous IGFALS 
mutation, is the cause of patient’s severe short stature and his low serum IGF-I level.




Figure 2  Reconstitution studies of the heterozygous STAT5B p.V498M mutation identified in CH. 
Reconstitution studies were performed in HEK293(hGHR). To compare immunologically equivalent 
amounts of FLAG-tagged STAT5b protein, loading of cell lysates from cells transfected with 
F-V498M was twice that of cells transfected with wild-type F-STAT5b or with vector, pcDNA3.1. 
a Western immunoblot analyses of GH-induced STAT5b tyrosine phosphorylation (pY-STAT5). 
Primary antibodies are indicated on the left side of panels. b GH-induced luciferase reporter 
activities.
Figure 3  S200 gel filtration column chromatography. Column profile for serum of CH (dotted line) 
compared with normal adult serum (solid line). 
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AL had two different interstitial duplications in the long arm of chromosome 2, which 
have not been described in the normal population. No association with height is known 
for any of these genes. However, her mother, who was also short (table 1) also carried both 
duplications, suggesting a functional role of one or both of these duplications. AL responded 
very well to a regular dose of GH (table 1).
It is uncertain to which extent the heterozygous UV in IGFALS (p.Pro287Leu) and the 
polymorphism in the GHR contributed to the severely short stature and low serum IGF-I level 
of BV. This IGFALS variant has been considered to represent a SNP with low abundance (MAF 
= 0.0053), in silico analysis predicted it to be benign, and serum IGFBP-3 level was within 
the normal range, all suggestive for a neutral variant. However, this UV has been found 
previously in patients with ISS [35], and in vitro expression of the mutant p.Pro287Leu ALS 
protein resulted in increased trans-Golgi co-localization, suggesting impaired trafficking 
[36]. BV’s brother who has comparable short stature (height SDS –5.5) carries the same GHR 
and IGFALS variants, in addition to two IGFALS polymorphisms (c.1566G>A, p.Thr522Thr and 
c.1386C>T, p.Tyr462Tyr).
Group 2
In 2 out of 6 patients, DNA variants could be detected (table 6), described in detail below.
In JB, the low serum levels of IGF-I and IGFBP-3 would suggest ALS deficiency. Indeed, the 
concentration of ALS in serum was low (–2.4 SDS) and 150 kDa ternary complex formation 
reduced, as assessed by column chromatography, being consistent with partial IGFALS 
deficiency (fig. 4a). As in cases RZ and CH, the profile normalized after adding excess purified 
hIGFBP-3 (2.0 μg/ml) (data not shown). Also on GH treatment the column profile normalized 
(fig. 4a) as well as serum ALS (0.8 SDS), and the growth response was excellent (table 2). 
However, direct sequencing of IGFALS only showed a c.1386C>T, p.Tyr462Tyr polymorphism 
transmitted from his normal statured father, that has been encountered in 18.0% of ISS 
subjects and 14.8% of normal children [35]. Serum levels of IGF-I, IGFBP-3 and ALS in carriers 
for this SNP do not differ from those in non-carriers, both in ISS and normal children [H.M. 
Domené, pers. commun.]. We then performed column chromatography in both parents (fig. 
4b) and measured serum ALS. Serum of the relatively short mother (height –1.5 SDS) showed 
a reduced 150 kDa ternary complex, although serum ALS was normal (0 SDS). The father 
(with a height of 0.5 SDS) had a normal profile and a high serum ALS (+2.6 SDS). Although 
we have no good explanation for these findings, they are suggestive for the presence of 
an ALS abnormality that cannot be discovered by sequencing of the coding domains of the 
gene. Both for the patient and his mother, the addition of hIGFBP-3 to their serum led to a 
substantial increase in 150 kDa complex formation, to the same extent as encountered for 
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Figure 4   S200 gel filtration column chromatography. a Column profile of JB before GH treatment 
(solid line) and after 4 years of GH treatment (dotted line). b Column profile of mother (solid line) 
and father (dotted line).
normal serum (fig. 1a), suggesting only a partial decrease of IGFALS affinity for IGF-IGFBP-3 
binary complexes.
KB had several characteristics of a bioinactive GH molecule, such as short stature, a 
very low serum IGF-I level that increased sufficiently after a low dose of GH in an IGF-I 
generation test, and a very high GH peak after provocation. However, curiously the GH1 
variant found in intron 1 originated from KB’s mother, who had a normal height (+0.4 SDS). 




His short father (height SDS –2.6) had a normal serum IGF-I and IGFBP-3. KB’s growth rate 
increased moderately on GH treatment (1 mg/m2, started at 7.2 years) and serum IGF-I 
normalized as well (+0.6 SDS after 1 year), supporting the possibility that his endogenous 
GH is not biologically active.
Group 3
In 8 out of 21 patients, DNA variants were detected (table 6), but in all cases the pathogenic 
relevance remains uncertain, as outlined below.
Out of the 4 copy number variations (CNVs) found with SNP array analysis, the 1.4-
Mb duplication detected in DD, containing part of ROBO2, a non-coding RNA (ncRNA) 
and a microRNA (miRNA), may suggest an association with short stature. DD was born 
SGA, remained extremely short and microcephalic, and has short parents (table 3). His 
mother does not carry the variant, but his younger brother with a similar growth curve 
(most recent height –4.3 SDS) carries the same duplication. Unfortunately, no DNA from 
his father is available. The duplication has not been described as a genomic variation in 
the available databases, however overlapping duplications have been found in two other 
families investigated in our laboratory. The index patients of these families had short 
stature, but further analysis of the family showed that the duplication was inherited from 
a parent with normal stature.
MM had normal serum levels of IGF-I and IGFBP-3, but a very high serum GH peak level 
after provocation, suggesting either a defect of the IGF-I receptor (IGF1R), a post-receptor 
defect, or an IGF1 defect. No abnormalities could be found in the IGF1R nor IGF1, but a small 
interstitial deletion was detected in chromosome 1q, containing 4 genes (table 6). His 
mother with a normal height (–0.8 SDS) carried the same deletion. The CNVs detected 
in MM and the other 2 cases (JK and NV) have not been associated previously with short 
stature, and, as far as known, no clear candidate genes are present in the deleted or 
duplicated regions.
Two patients showed UVs in IGFALS (BrKa and JO), but in both cases it is unlikely that the 
clinical and biochemical features can be explained due to these mutations. In BrKa the UV 
in the 5’ UTR of IGFALS was inherited from her normal statured mother (height SDS –0.4). 
During GH treatment there was an excellent growth response (table 3), an elevated level 
of serum ALS (+2.7 SDS), and normal 150 kDa ternary complex formation. In JO, two variants 
were found in IGFALS, although serum ALS was 0.2 SDS and most of 125I-IGF-I migrated in 
the 150 kDa ternary complex peak, after column chromatography. Moreover, as explained 
in the case of BV, it is uncertain whether the p.Pro287Leu variant leads to pathogenic 
effects. The p.Tyr462Tyr is considered to represent a polymorphism.
RK (table 3) had biochemical characteristics of partial ALS deficiency (a lower serum 
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IGFBP-3 level than serum IGF-I, a column chromatography pattern typical for partial ALS 
deficiency, and a serum ALS value of –1.1 SDS), but mutation screening and MLPA did not 
show any IGFALS variant.
LR inherited an UV of the GHR from her mother with a height of –1.7 SDS, which makes 
it unlikely that this variant by itself had caused severe GH insensitivity in this patient. The 
GHR variant in MV represents a synonymous polymorphism.
Polymorphisms
Within the whole cohort of ISS subjects investigated, the frequency of the known 
polymorphism in GHR (a deletion of exon 3, d3) was 50% full length, 34% heterozygous for 
d3, and 16% homozygous d3/d3. Two known polymorphisms of IGF1 were found in 3 cases 
(exon 2: c.64–23A>C in 1 case, exon 3: c.221–164G>A in the other 2 cases).
Discussion
In our group 1 (9 patients with severe short stature (height SDS <–2.5) and decreased serum 
IGF-I), 5 were found to carry a gene variant. In 3 of them (RZ, IZ and CH), heterozygous 
mutations of STAT5B appeared to be involved in the observed GH insensitivity. In 2 other 
patients the associations between the respective genetic variants in IGFALS and short 
stature remains uncertain. Thus, according to the previously proposed clinical algorithm 
[11], the yield in terms of established diagnoses was 3/9, i.e. 33%. By contrast, the association 
between the genetic variants observed in groups 2 and 3 with the clinical and biochemical 
features remained uncertain.
With respect to the two novel heterozygous STAT5B variants, for which in silico analysis 
suggested pathogenicity, we first speculated that these mutations could exert dominant 
negative effects. However, so far we have not been able to confirm this. Alternatively, 
mutations may exist in non-coding regions of the STAT5B gene (e.g. the promoter) in 
the other allele, resulting in a compound heterozygous defect, or in unidentified genes 
involved in its regulation of expression. Another interesting novel observation is that 
several patients show a combination of variants in two genes that are known to be 
involved in the regulation of growth, for example, the STAT5B and IGFALS variants in CH 
and RZ. We hypothesize that, similar to the finding of a high percentage of abnormalities 
of oligogenic origin in hypogonadotropic hypogonadism [19], GH insensitivity may be of 
digenic, oligogenic or polygenic origin.
Although we found three GHR variants, the only one for which the association with 
GH resistance cannot be excluded is the c.1319G>T, p.Cys440Phe mutation. However, 




the maternal transmission (maternal height –1.7 SDS) makes its pathogenicity doubtful, 
which is in line with previous publications on this variant (in older nomenclature termed 
p.Cys422Phe), showing no difference in signaling in vitro, when compared with controls 
[reviewed in 37].
It is also unlikely that the variant in GH1 exerts a pathogenic effect in KB, since the GH1 
variant was inherited from the normal statured mother, and the response to long-term GH 
treatment was only moderate. We have not been able to test for GHSR variants, but the 
prevalence of abnormalities in this gene appears to be low [6, 38–40].
The biological significance of the heterozygous variants in IGFALS observed in 6 patients 
within the whole cohort of ISS subjects remains uncertain. In previous studies, we showed 
that heterozygosity for dysfunctional IGFALS mutations may lead to approximately a 1 SD 
height loss [15–17]. In contrast to his brother IZ, RZ had an additional p.Arg548Trp IGFALS 
variant besides the STAT5B variant which both brothers carried. The differences between 
the 2 brothers with respect to height SDS (i.e. 0.9 SD), serum ALS levels, and the relative 
size of the 150 kDa peak after column chromatography, is consistent with an additional 
effect of the heterozygous IGFALS variant in RZ. Possibly, this variant decreases the affinity 
of IGFALS, since in the presence of a high concentration of IGFBP-3, 150 kDa complex 
formation increased substantially. The p.Arg548Trp IGFALS variant is described as a SNP 
in several databases, and has been encountered previously in 2 ISS children as well as in 
2 normal control children [H. R. Domené, pers. commun.]. However, in silico analysis by 
PolyPhen predicts a damaging effect, and preliminary in vitro studies on the expression of 
the p.Arg548Trp ALS mutant protein indicate an increased trans-Golgi co-localization and 
a reduction in ALS secretion [36]. The 2 ISS children carrying this heterozygous variant had 
serum levels of IGF-I, IGFBP-3 and ALS all below –2.0 SDS. On the other hand, 2 normally 
statured children carrying this same heterozygous variant showed circulating levels of 
IGF-I, IGFBP-3 and ALS within the respective normal ranges [H. R. Domené, pers. commun.]. 
The p.Pro378Leu IGFALS variant in combination with the STAT5B variant in CH may have 
contributed to his severe short stature and GH insensitivity. The role of the p.Pro287Leu 
IGFALS variant that we found in 2 other patients is less clear. In BV it is unlikely that this 
is the cause of the severe short stature, whereas in JO the column profile did not point to 
ALS deficiency.
An interesting observation was a low or low-normal serum ALS level and reduced 150 
kDa ternary complex formation in 2 children (JB and RK) with a phenotype and biochemical 
features suggestive for a heterozygous IGFALS defect. Nonetheless, IGFALS sequencing 
only showed a common (neutral) synonymous SNP and the WT sequence of nucleotides, 
respectively. This suggests that there may be abnormalities of ALS secretion that are not 
caused by exonic variants. In 1 of them (JB), serum ALS and the 150 kDa ternary complex 
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formation normalized on GH treatment, as well as in vitro after addition of exogenous 
hIGFBP-3. With respect to the genetic finding in patient BrKa, there is no reported cis-
element in the 5’-UTR promoter region of the IGFALS gene affected by the variant (c.56–
30A>T) [41, 42].
Our data show that the GH dose-escalating IGF-I generation test has some diagnostic 
value by allowing discrimination between severe GH insensitivity, as in the cases with 
STAT5B variants, and reduced bioactivity of endogenous GH. However, the predictive value 
of this test for the efficacy of GH treatment is low, since almost all patients who were 
treated with GH showed an adequate growth response, independent of the results of 
the IGF-I generation test. It must be emphasized, however, that some of them received 
supraphysiologic doses of GH. Further studies on alternative regimens of the test including 
a larger number of patients are needed before definitive conclusions about its value in the 
diagnostic workup of patients with IGF-I deficiency can be reached.
Besides the variants in known genes involved in growth disorders, we found novel CNVs 
in 6 short children. It is possible that in some of these patients the CNVs are associated 
with the phenotype, but in none of these CNVs clear candidate genes were involved. This 
finding is concurrent with a recent report on an increased burden of lower-frequency 
deletions in children with short stature [43]. With the accumulation of CNV data on many 
more patients into the databases, novel gene defects may be discovered that play a role in 
IGF-I generation and growth.
In conclusion, the diagnostic yield of genetic testing in children with severe short 
stature (height <–2.5) and low serum IGF-I is approximately 30%, which appears sufficient 
to advise genetic assessment of the genes that are currently known to be associated 
with GH insensitivity. We have presented evidence that heterozygous STAT5B mutations 
may be associated with GH insensitivity. In at least two cases we found evidence for a 
digenic origin of short stature. In children with less severe short stature and/or modestly 
decreased serum IGF-I levels, the likelihood of finding variants in these genes is much 
lower, suggesting that other, as yet unknown, genes play a role.
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Abstract
Height is a highly heritable and classic polygenic trait. Recent Genome-Wide Association 
studies (GWAS) have revealed that at least 180 genetic variants influence adult height. 
However, these variants explain only about 10% of the phenotypic variation in height. 
Genetic analysis of short individuals can lead to the discovery of novel rare gene defects 
with a large effect on growth. 
In an effort to identify novel genes associated with short stature, genome-wide 
analysis for copy number variants (CNVs), using Single Nucleotide Polymorphism arrays, 
in 162 patients (149 families) with short stature was performed. Segregation analysis was 
performed if possible, and genes in CNVs were compared with information from GWAS, 
gene expression in rodents’ growth plates, and published information.  
CNVs were detected in 40 families. In six families a known cause of short stature was 
found (SHOX deletion or duplication, IGF1R deletion), in two combined with a de novo 
potentially pathogenic CNV. Thirty-three families had one or more potentially pathogenic 
CNVs (n = 40). In 24 of these families segregation analysis could be performed, identifying 
3 de novo CNVs and 9 CNVs segregating with short stature. Four were located near loci 
associated with height in GWAS (ADAMTS17, TULP4, PRKG2/BMP3 and PAPPA). 
 Besides six CNVs known to be causative for short stature, 40 CNVs with possible 
pathogenicity were identified. Segregation studies and bioinformatics analysis suggested 
various potential candidate genes.





Height is a highly heritable and classic polygenic trait. In order to discover genes involved 
in growth regulation, there are basically two approaches. The first approach is to carry 
out genome-wide association studies (GWAS) for common variants in large populations of 
individuals. This has led to the discovery of at least 180 loci associated with adult height. 
However, the contribution of each locus is small, each locus contains various genes, 
and cumulative loci only explain about 10% of the phenotypic variation 1. Alternatively, 
when using all Single Nucleotide Polymorphisms (SNPs) identified in a GWAS approach 
as predictors simultaneously, up to 40% of the variance in height can be explained 2. The 
second approach is to perform genetic studies in patients with extremely short or tall 
height, and search for causative variants 3. With this approach one can either test for gene 
defects that were previously described or that appear plausible based on observations in 
knockout mice (candidate gene approach), or perform a genome-wide analysis for copy 
number variants (CNVs) or whole exome sequencing (WES) for mutations. The candidate 
gene approach has led to the detection of a substantial number of genes that are involved 
in monogenic defects associated with short or tall stature, such as IGF1, STAT5B, IGFALS, and 
IGF1R 4-10, but obviously does not result in finding novel genes involved in growth regulation.
In two previous papers from our group 11,12 we have described the results of a candidate 
gene approach in children with short stature, either associated with a low birth size (small 
for gestational age, SGA) 13 or with a normal birth size (idiopathic short stature, ISS) 14. In the 
present paper we describe the results of a genome-wide analysis for CNVs using SNP arrays 
in short children, in an effort to identify novel gene variants associated with short stature. 
Subjects and Methods
Patients
We studied 191 patients from 173 unrelated families with short stature of unknown 
origin, either born with a normal birth size or born small for gestational age (SGA). DNA 
was sent to our laboratory for analysis because of short stature between 2008 and 2011. 
Twenty-nine were excluded from the present analysis: eight because of a height standard 
deviation score (SDS) > −2.0, fifteen because of insufficient or low quality DNA or no 
parental consent, and six cases belonging to one family were separately described with 
a heterozygous IGF1 mutation and an additional 435.7 Kb deletion (arr 3q26.1(162,681,814 
−163,117,547)×1) 6. This resulted in an analyzable group of 162 patients from 149 families. 
Height standard deviation score (SDS) was calculated for Dutch population references 15, 
except for one patient (I.6/II.2) for whom the reference for children of Turkish ethnicity was 
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used 16. With consent of the Medical Ethical Committee of the Leiden University Medical 
Center, clinical data were collected and anonymized for all patients.
SNP arrays
In 103 cases the Affymetrix GeneChip Human Mapping 262K NspI or 238K StyI arrays 
(Affymetrix, Santa Clara, CA, USA) was used, containing 262,262 and 238,304 25−mer 
oligonucleotides, respectively, with an average spacing of approximately 12 kb per array. An 
amount of 250 ng DNA was processed according to the manufacturer’s protocol. Detection 
of SNP copy number was performed using copy number analyzer for GeneChip (CNAG) 
version 2.0 17. 
In 54 cases the Illumina HumanHap300 BeadChip (Illumina Inc., San Diego, CA, USA) was 
used, containing 317,000 TagSNPs, with an average spacing of approximately 9 kb, and in 
5 cases the Illumina HumanCNV370 BeadChip (Illumina Inc., Eindhoven, The Netherlands), 
containing 317,000 TagSNPs and 52,000 non-polymorphic markers for specifically targeting 
nearly 14,000 known CNVs. This array has an average spacing of approximately 7.7 kb. A 
total of 750 ng DNA was processed according to the manufacturer’s protocol. SNP copy 
number (log R ratio) and B-allele frequency were assessed using Beadstudio Data Analysis 
Software Version 3.2 (Illumina Inc., Eindhoven, The Netherlands).
Evaluation of CNVs
Deletions of at least five adjacent SNPs and a minimum region of 150 kb and duplications of 
at least seven adjacent SNPs and a minimum region of 200 kb were evaluated 18, except for 
3 families in which a prominent, but smaller duplication than 200 kb (although consisting of 
≥ 10 adjacent SNP probes) was observed. The CNVs were classified into four groups: I, known 
pathogenic CNVs (known microdeletion or microduplication syndromes); II, potentially 
pathogenic CNVs, not described in the Database of Genomic Variants (DGV; The Centre for 
Applied Genomics, The Hospital for Sick Children, Toronto, Canada, http://projects.tcag.
ca/variation/); III, CNVs not described in the DGV, but not containing any protein-coding 
genes; and IV, known polymorphic CNVs described in the DGV or observed in our in-house 
reference set, whereby at least three individuals must have been reported with the same 
rearrangement. Type IV CNVs were not further evaluated. All type II CNVs were assessed 
with Ensembl (Wellcome Trust Genome Campus, Hinxton, Cambridge, UK, http://www.
ensembl.org: Ensembl release 63 – June 2011) and the DECIPHER database (Wellcome Trust 
Genome Campus, Hinxton, Cambridge, UK) for gene and microRNA (miRNA) content and 
similar cases, respectively. If DNA from the parents was available, segregation analysis was 
performed by SNP array.
The type I CNVs were confirmed with multiplex ligation-dependent probe amplification 




(MLPA), using Salsa MLPA P018 probemix for SHOX and P217 for IGF1R analysis (MRC Holland, 
Amsterdam, The Netherlands). Amplification products were identified and quantified by 
capillary electrophoresis on an ABI 3130 genetic analyzer (Applied Biosystems, Nieuwerkerk 
aan de IJssel, The Netherlands). Fragment analysis was performed using GeneMarker 
(SoftGenetics, State College, USA). Thresholds for deletions and duplications were set at 
0.75 and 1.25 respectively 19. 
Bioinformatics approach
We checked for all CNVs whether they were located in one of the chromosomal regions 
associated with height in GWAS 1. For genes in deleted or duplicated regions in cases with 
de novo CNVs, we used three additional approaches. First, the rodent homologues were 
checked for three criteria: 1) higher expression in 1 week old mouse growth plate than in 1 
week old mouse lung, kidney, and heart; 2) spatial regulation: significant difference between 
zones in the 1 week old rat growth plate; and 3) temporal regulation: significant difference 
between 3 and 12 weeks of age in the rat growth plate using previously established mRNA 
expression profiles 20,21. Second, associations were investigated for mouse growth plate-
related phenotypes. Third, associations with human growth plate-related phenotypes 
were investigated. For details, see Lui et al. 21.
 
173 unrelated families 
(191 patients) 
149 unrelated families 
(162 patients) 
 
24 unrelated families 
(29 patients) excluded 
4 type I CNVs  
in 4 families (4 patients) 
40 type II CNVs  
in 33 families (36 patients) 
1 type III CNV in 
1 family (1 patient) Type IV or no CNVs 
Segregation analysis of  
31 CNVs possible in  
24 families (27 patients) 
 
No segregation analysis 
of 9 CNVs possible in  
9 families (9 patients) 
 
2 CNVs de novo in  
2 families (2 patients) 
1 family (1 patient) with  
1 de novo CNV and 1 CNV  
not segregating with short stature 
 
In 109 families  
(115 patients) 
In 4 patients 
related to a patient 
with a type II CNV 
2 type I combined with  
2 de novo type II CNVs in 
2 families (2 patients) 
 
9 CNVs segregating  
with short stature in  
6 families (8 patients) 
18 CNVs not segregating  
with short stature in  
15 families (16 patients) 
 
Figure 1  Organization Chart  Organization chart illustrating the identified CNVs. The 149 unrelated families 
(162 patients) divided in  the different subcategories are depicted in bold. A total of 49 CNVs were found  
in 40 families (43 patients).
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An organization chart illustrating the identified CNVs is shown in figure 1. In the 162 
patients belonging to 149 unrelated families, a total of 49 CNVs were found in 40 families 
(43 patients). 
In six families (4.0%, 6 patients) a type I CNV was observed and in two of them an 
additional de novo type II CNV. Table 1 shows the clinical and genetic findings of these 
6 patients, including 2 microdeletions (I.1 and I.2) and 2 microduplications (I.3 and I.4) 
containing SHOX, and two terminal 15q deletions containing IGF1R (I.5/II.1/mi.3 and I.6/II.2). 
All these CNVs were confirmed with MLPA.
One or more type II CNVs (n = 40) were found in 33 unrelated families (22.1%, 36 patients). 
Five of these potentially pathogenic CNVs contained besides protein-coding genes also 
miRNAs (Table 2). In 24 families (27 patients) segregation analysis could be performed, 
which led to a total of 5 de novo CNVs (Table 3) and 9 CNVs segregating with a height 
below −1.5 SDS of a carrier family member (Table 4). For 19 CNVs the lack of segregation 
with short stature makes a causative role of the CNV unlikely (Supplementary Table 1). In 9 
patients (9 CNVs) no information on segregation could be obtained (Supplementary Table 
2). In two non-related patients (cases II.24 and II.25) a similar CNV (a deletion containing 
DCAF12L2, alias WDR40C) in the X-chromosome was identified, but both children inherited 
the deletion from a normal parent. 
In one family (0.7%, 1 patient) a type III CNV was found encompassing a 192.3 Kb deletion 
of chromosome 13 (arr 13q31.1(86,733,645−86,925,974)×1). The girl (case III.1) was born SGA, 
had poor food intake and severe postnatal growth failure (length −8.2 SDS at 2.5 years). 
Screening for IGF1 and the IGF1R for mutations or deletions was negative. The function of 
this region is unknown. 
No potential pathogenic CNVs (only type IV or no CNVs) were found in 109 families (73.2 
%, 119 patients).
Bioinformatics approach
Five CNVs encountered in our study are close to the loci associated with height in GWAS 1. 
Four of these CNVs were de novo or segregating with short stature, including loci close to 
ADAMTS17 (case II.5), PRKG2/BMP3 (cases II.11 and II.13), PAPPA (cases II.11 and II.13) and TULP4 
(case II.7). However, none of the deletions included genes tightly linked (r2 < 0.5) to a GWAS 
SNP implicated in human height variations. The fifth CNV is close to the MKL2 locus (case 
II.37/mi.4) but did not segregate with short stature (Supplementary Table 1). 
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We reasoned that some of the identified CNVs might cause short stature because 
they contain genes that are expressed and function in the growth plate. We therefore 
used existing expression microarray data to identify genes that show greater expression 
in mouse growth plate than in soft tissues, temporal regulation in rat growth plate, or 
spatial regulation in rat growth plate. Within de novo CNVs, this approach implicated 5 
genes (Aldh1a3, Fam3c, Furin, Lrrk1, and Chsy1), and within segregating CNVs, this implicated 
7 genes (Col14A1, Dscc1, Enpp2, Ezr, Prelid2, Taf2, and Trim32) (Table 5). This information, in 
combination with other bioinformatic data, was used to formulate the arguments pro and 
contra an association of these genes with short stature (summarized in Tables 3 and 4). 
Potential candidate genes in de novo CNVs associated with short stature (Table 3) include 
FURIN, DOCK8 and/or KANK1, NLRP3, FAM3C, SLC13A1, ADAMTS17, ALDH1A3, LRRK1 and CHSY1. 
Potential candidate genes in CNVs segregating with short stature (Table 4) include FHIT, 
PTPRG, TULP4, EZR,  ENPP2, TAF2, COL14A1, DSCC1, LPPR1, ZNF675, C4orf22 (or PRKG2/BMP3), 
PRELID2, and ASTN2 and TRIM32 (or PAPPA). 
For the CNVs for which insufficient information was available about segregation with 
short stature, the in silico analysis provided support for four potential candidate genes 
(TBL1X, ROBO2, CHD8 and TOX4), as well as a candidate region (distal part of common 22q11 
deletion syndrome) (Supplementary Table 2).
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Whole genome SNP array analysis in 162 patients with short stature from 149 unrelated 
families (Fig. 1) led to the detection of type I CNVs known to cause short stature (involving 
SHOX or IGF1R) in six families (in two of them combined with type II CNVs), and 40 
potentially pathogenic CNVs (type II) in 33 families. Out of the total of 42 type II CNVs, five 
were de novo and nine others were associated with short stature in their families. In one 
severely short child a deletion without protein-coding genes was found, and in 5 CNVs 6 
microRNAs were encountered. 
A recent study on a genome-wide association analysis of copy-number variation and 
stature showed that children with short stature had a greater global burden of lower-
frequency and rare deletions and a greater average CNV length than controls 22. There 
were no significant associations with tall stature. These observations suggest that CNVs 
might contribute to genetic variation in stature in the general population. These authors 
also identified three preliminary candidate regions as having significant associations 
with stature; a duplication at 11q11 and deletions at 14q11.2 and 17q21.31. In our analysis 
these regions all display common CNVs, which have been often observed in our in-house 
database and in the DGV (type IV CNVs).  
The two patients carrying a heterozygous deletion containing the SHOX gene had 
disproportionate short stature, but no Madelung deformity. Case I.1 (sitting height/height 
(SH/H) ratio +3.7 SDS) inherited the deletion from her mother, who also had disproportionate 
short stature (height −1.8 SDS, SH/H ratio +4.2 SDS). Case I.2 (SH/H ratio +3.8 SDS) carries 
besides a de novo SHOX haploinsufficiency also a heterozygous unclassified variant (UV) in 
the IGFALS gene (c.1555C>T, p.Arg519Trp) inherited from her father (height −1.1 SDS). IGFALS 
sequencing was performed because of a low circulating IGF-I and IGFBP-3 despite elevated 
GH secretion. While the referring physician had not suspected Leri-Weill syndrome, in 
retrospect the increased sitting height/height ratio would have been sufficient reason to 
directly test for SHOX defects. The two patients in whom a duplication of the SHOX gene 
including surrounding genes was observed (de novo and inherited via a normal statured 
parent, respectively), had a sitting height/height ratio of approximately +1.9 SDS. We and 
others have recently reported that a phenotype similar to Leri-Weill syndrome (including 
short stature) can be associated with SHOX duplication 11,23,24.  
In two patients a heterozygous deletion on chromosome 15 containing the IGF1R gene 
was identified, a well-established cause of short stature 11,25,26. In both patients an additional 
de novo CNV was present (Table 3). In case I.5/II.1/mi.3 this was a duplication in 15q26.1q26.2 
(located upstream of the deleted area). Although this patient’s growth failure is similar to 
that of other patients with IGF1R defects 26, duplication of FURIN may play an additional 
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role. In case I.6/II.2, considerably shorter than usual for IGF1R deletions 26, the terminal 15q 
deletion was combined with a terminal 9p24.3p24.2 duplication, suggesting the presence 
of an unbalanced reciprocal translocation.  We suspect that one of the parents is a carrier 
of a balanced 9;15 translocation, but unfortunately parental chromosomes were not 
available for testing. The presence of two patients in the DECIPHER database with a similar 
9q duplication and short stature suggests that there may be an association between the 
genes DOCK8 and KANK1, and stature. 
Bioinformatics analysis of the three other cases with de novo type II CNVs led to several 
candidate genes (Table 3). In case II.3 a duplication of NLRP3 may be associated with short 
stature. The CNV in case II.4 (who has besides short stature also mental retardation, 
behavioral problems, strabismus, and various dysmorphic features) suggests that FAM3C 
and SLC13A1 deletions may be associated with short stature, particularly because of the 
expression data of Fam3c in the murine growth plate and the dwarfism and skeletal 
deformities in Texel sheep and mice with loss of function of Slc13a1 27,28. 
Case II.5, with a terminal de novo 15q deletion located 1.5 Mb downstream of IGF1R and 
244 Kb downstream of the ADAMTS17 locus on the reverse strand, had a normal birth size, 
but showed proportionate progressive growth failure (SH/H ratio +1.58 SDS) with a normal 
head circumference. Clinical characteristics included slight frontal bossing of the skull, a 
high pitched voice and slight abdominal adiposity and delayed bone age. GH secretion 
and circulating IGF-I were normal, but IGFBP-3 was low (−2 SDS). Several arguments are 
in favor of a role of ADAMTS17 in growth regulation (for summary, see Table 3), including: 
1) significant association with height in population GWAS 1; 2) a short child with a similar 
terminal deletion in the DECIPHER database; 3) significant association with size in a 
GWAS in the domestic dog 29; 4) human mutations in ADAMTS17 causing the acromelic 
chondrodysplasia Weill-Marchesani-like syndrome (OMIM #277600 and #608328) 30-33; 
and 5) association of members of the ADAMTSL/ADAMTS family with the modulation of 
fibrillin-1 function 31,33. Unfortunately, expression of the rodent homologue of ADAMTS17 
could not be investigated, because the gene was not represented on the microarrays used. 
Besides ADAMTS17, this deletion contains three other genes, ALDH1A3, LRRK1 and CHSY1, that 
might be implicated in short stature. 
Nine CNVs in 6 families (5 families with one index patient each, and one family consisting 
of a mother and her 2 sons) segregated with a height of less than −1.5 SDS of a carrier 
family member (Table 4). The 3p duplication that case II.6 (height −2.0 SDS) inherited from 
his father (−1.8 SDS) contains FHIT and the first part of PTPRG. Both genes are considered 
tumor suppressors 34,35. The 6q duplication that case II.7 inherited from his mother is located 
nearby (97 Kb downstream) a locus (TULP4) associated with height 1. One of the duplicated 
genes (ENPP2) in case II.8 encodes for a lysophospholipase D, producing lysophosphatidic 




acid (LPA) inducing cell proliferation 36. The mouse homologs of TAF2, COL14A1 and DSCC1 
are differentially expressed in the growth plate. In case II.9, the 9q deletion containing part 
of LPPR1 (also known as PRG3) did not fully segregate with short stature in the family, but 
the observation that Prg1 knockout mice are smaller compared to wild type littermates 37 
suggests a role for this gene in height regulation. The 19p deletion that case II.10 inherited 
from his father includes ZNF675, associated with osteoclast differentiation 38. Out of the 
four CNVs in cases II.11, 12 and 13 (the short members of one family),  C4orf22, ASTN2 and 
TRIM32 are located close to loci (374 KB upstream PRKG2/BMP3 and 289 Kb downstream 
PAPPA, respectively) associated with height 1, suggesting that the 4q and/or 9q deletion 
are associated with stature.    
Four out of nine patients in whom no segregation analysis could be performed 
(Supplementary Table 2) carry a CNV suggestive for an association with short stature. One 
of the genes in the duplication of case II.14 is TBL1X (alias TBL1), encoding for transducin 
beta-like protein 1 (TBL1). TBL1 and its highly related family member TBLR1 are required 
for Wnt-beta-catenin-mediated transcription 39. Case II.17, described previously 12, carries 
a duplication of 3p12.3 containing part of ROBO2, as well as his younger brother (height 
−4.3), but his mother (height −3.6 SDS) does not carry the variant, while no DNA is available 
from the father. The encoded protein is a receptor for SLIT2 and probably SLIT1, which 
are thought to function in axon guidance and cell migration 40. Case II.21 was born SGA, 
and at 1.2 years her length was −3.7 SDS and head circumference −3.1 SDS. Further clinical 
characteristics include clinodactily, a protruded tongue and delayed bone age. The mother 
does not carry this duplication, and DNA from her father is not available. A search in the 
DECIPHER database revealed 2 patients with (partially) overlapping duplications, one of 
whom was short (patient #258583) and one was not (#258497). Out of the 6 genes outside 
the overlapping region with patient #258497 CHD8 and TOX4 appear potential candidate 
genes 41,42. Case II.22/mi.5 has a 22q deletion containing only the distal part of the common 
22q11 deletion syndrome (Velocardiofacial/DiGeorge syndrome). His mother does not carry 
the duplication, and DNA from the father is not available. In 8 patients in the DECIPHER 
database with overlapping deletions short stature was observed. The common deleted 
region contains PI4KA, SERPIND1, SNAP29, CRKL, AIFM3, LZTR1, THAP7, and P2RX6. 
Although non-coding DNA can play an important regulatory role 43,44, no supportive 
evidence could be obtained on a possible role of novel type III CNVs.  Similarly, none of the 
6 miRNAs (Table 2) identified in the type II CNVs could be directly linked to short stature, 
due to lack of segregation with short stature (data not shown), although miRNA 484, 649, 
and 1972 have been predicted to bind to various isoforms of SHOX, and contribute to the 
regulation of SHOX expression 45.  
In conclusion, whole genome SNP array analysis in this exploratory study on 162 patients 
hfst 7.indd   169 20-05-13   12:15
Chapter 7  |  Copy number variants in patients with short stature
170
with short stature belonging to 149 unrelated families identified 6 CNVs in 6 families 
(4%) for which the association with short stature is virtually certain, and 40 CNVs in 33 
families (22.1%) with possible pathogenicity. Several of the deleted or duplicated genes 
may be considered as potential candidate genes for growth disorders, including four genes 
associated with height in the genome-wide association studies (ADAMTS17, PRKG2/BMP3, 
PAPPA, TULP4). Future studies are needed to support the role of these and other genes in 
longitudinal growth regulation.
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Abstract
C-type natriuretic peptide (CNP)/natriuretic peptide receptor 2 (NPR2) signalling is essential 
for long bone growth. In response to CNP, NPR2 synthesizes cyclic GMP, which stimulates 
proliferation, growth and differentiation of chondrocytes. Homozygous and compound 
heterozygous inactivating NPR2 mutations cause acromesomelic dysplasia, Maroteaux 
type, a severe form of short-limbed dwarfism. Here we describe a novel heterozygous 
NPR2 mutation (c.1963C>T, p.Arg655Cys) in an extremely tall (221 cm) male proband. 
CNP stimulated cyclic GMP production by the mutant NPR2 was markedly increased in 
skin fibroblasts of the proband as well as in transfected HEK 293 cells. Furthermore, the 
stimulatory effects of ATP on CNP-dependent guanylate cyclase activity were markedly 
enhanced, suggesting that this novel mutation enhances both the responsiveness of NPR2 
to CNP and its allosteric modulation/stabilization by ATP. Coimmunoprecipitation showed 
that wildtype and mutant NPR2 can form stable heterodimers, suggesting a dominant 
positive effect. In accordance with augmented endogenous receptor activity, plasma 
concentration of NTproCNP (a marker of CNP production in tissues) was reduced in the 
proband. In summary, we report the first activating mutation within the kinase homology 
domain of NPR2, emphasizing the important role of this domain in the regulation of 
guanylate cyclase activity and bone growth by CNP.





Natriuretic peptide receptor 2 (NPR2), also known as NPR-B or guanylate cyclase B, and 
encoded by the gene NPR2, is one of five human transmembrane receptors that catalyse 
the formation of cyclic GMP (cGMP) from GTP. These receptors consist of an extracellular 
ligand binding domain (ECD), a short membrane-spanning region and intracellularly 
a kinase homology domain (KHD), a helical hinge region and the C-terminal cGMP-
synthesizing guanylate cyclase (GC) domain. NPR2 is expressed by different types of cells 
(e.g. chondrocytes, cardiomyocytes, neurons, fibroblasts and vascular smooth muscle 
cells), in different tissues (e.g. in bone, brain, heart, vasculature, lung, ovary) 1. Its ligand 
is C-type natriuretic peptide (CNP), a paracrine hormone of the natriuretic peptide family. 
In the absence of CNP, NPR2 exists as a homodimer or homotetramer, and ligand binding 
does not lead to further aggregation 1, 2. Multiple extra- and intracellular domains mediate 
this oligomerization. The intracellular oligomerization interface region has been mapped 
to the amphipathic sequence that bisects the KHD and GC domains 1. Based on structural 
studies of the homologous protein NPR1 (also known as NPR-A or guanlyate cylcase A, the 
receptor for atrial natriuretic peptide (ANP), which exhibits 78% sequence identity to NPR2 
3) it is postulated that CNP-induced rotation of the ECD is transmitted across the membrane 
and reorients the two intracellular domains into the active conformation, thereby enabling 
cGMP synthesis. 
 Studies in genetic mouse models revealed that CNP-NPR2-cGMP signalling is essential 
for stimulation of endochondral ossification required for long bone growth, for oocyte 
maturation and for sensory axon bifurcation in the spinal cord 4-6. In humans, homozygous 
and compound heterozygous inactivating NPR2 mutations cause acromesomelic dysplasia, 
Maroteaux type (AMDM) 7, and heterozygous inactivating mutations have been associated 
with short stature 8. Enhanced production of CNP caused by chromosomal translocations 
results in tall stature, a Marfanoid phenotype and skeletal abnormalities 9,10. Concordantly, 
an activating NPR2 mutation located in the GC domain also causes skeletal overgrowth 11. 
Here we describe a novel heterozygous activating NPR2 mutation located within the 
KHD, in a proband with extremely tall stature but with only mild skeletal deformities. 
We show an increased cGMP response of the mutant NPR2 to CNP in the proband’s 
skin fibroblasts and in transfected HEK 293 cells, and suppressed markers of tissue CNP 
production in the proband’s serum, in accordance with increased NPR2 activity in vivo. 
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Materials and methods
GH and prolactin secretion studies 
The healthy volunteers of the present study participated in previous studies on pituitary 
hormone secretory dynamics; testing conditions were previously described 12, 13. Blood 
samples (2.0 ml) were withdrawn at 10-min intervals for 24 h, and stored at -20°C for 
hormone measurements. Plasma GH concentrations were measured with a sensitive time-
resolved fluoroimmunoassay (Wallac, Turku, Finland). The assay is specific for 22-kDa GH 
and was previously described in detail 14. Plasma prolactin concentrations were measured 
with a sensitive time-resolved fluoroimmunoassay (Wallac Oy, Turku, Finland), details were 
previously described 13. Hormone concentration time series were analyzed via a recently 
developed automated deconvolution method, empirically validated using hypothalamo-
pituitary sampling and simulated pulsatile time series 15, 16. 
DNA analysis
Genomic DNA was isolated from peripheral blood samples using the AUTOPURE LS 
Instrument (Gentra Systems). Cytogenetic microarray analysis was performed using the 
Affymetrix CytoScan HD Array according to the manufacturer’s procedures. Copy number 
was assessed in the proband using ChAS software (Chromosome Analysis Suite) (Affymetrix, 
California, USA). Whole exome sequencing was performed on DNA  fragmented into 200-
400 bp fragments using Covaris Adaptive Focused Acoustics (AFA) shearing according to 
the manufacturer’s instructions (Covaris, Inc., Woburn, MA). The exome was captured by 
Nimblegen SeqCap EZ V2 kit (Roche Nimblegen, Inc., Madison, WI) in combination with 
Illumina paired end library preparation and 2x 100 bp sequencing with at least 70x mean 
coverage. Downstream analyses included demultiplexing (CASAVA software, Illumina), 
sequence quality control, capture quality control, SNP calling and indel (insertions and 
deletions) calling using different software applications as described by Santen et al 17. The 
NPR2 mutation was confirmed by Sanger sequencing using standard procedures (primer 
sequences available on request).     
Site-directed mutagenesis and intracellular cGMP responses of transfected HEK 293 cells 
The expression plasmid encoding a FLAG-tagged NPR2 Arg655Cys mutant protein was 
generated by PCR-mediated mutagenesis using FLAG-tagged NPR2 in pFLAG-CMV1 18. Two 
oligonucleotides were synthesized; Arg655Cys-forward: 5’- cc aac tgt gtg gtg gat agt tgc ttt 
gtg ctc aaa ata aca g -3’ and Arg655Cys-reverse: 5’- ct gtt att ttg agc aca aag caa cta tcc acc 
aca cag ttg g -3’ (the underlined nucleotides represent the site of Arg655Cys mutation), to 
change residue arginine655 to cysteine. Mutagenesis was performed using a Quick-Change 
site-directed mutagenesis kit (Agilent Technologies). The mutation and the absence 




of unwanted mutations were verified by sequencing. HEK 293 cells were transiently 
transfected with the FLAG- or Myc-tagged wildtype or mutant NPR2 expression constructs 
using FuGene (Roche). Transfected cells were serum-starved for 4 h prior to CNP exposure 
(48 h after transfection). Cells were pretreated with 0.1 mM of the phosphodiesterase 
inhibitor 3-isobutyl-1-methylxanthine (IBMX) for 15 min, and then exposed to various 
concentrations of CNP (Bachem, Heidelberg, Germany) for another 10 min. Intracellular 
cGMP contents were determined by radioimmunoassay 19, 20.
Guanylate cyclase assays 
GC activity of crude membranes prepared from transfected HEK 293 cells was essentially 
assessed as described before 19. Activity assays were carried out in 50 mM HEPES buffer, 
pH 7.4, containing 50 mM NaCl, 5% glycerol, 0.05% BSA, 1 mM IBMX, 2 mM GTP, 30 mM 
creatine phosphate, 1.5 U/ml creatine phosphokinase, and different concentrations of ATP 
(as indicated in the results section) 19. To stimulate GC activity, membranes (20 mg protein) 
were incubated with 0.01 to 1000 nM CNP (ligand dependent activity), or with 1% (v/v) 
Triton X-100 (detergent stimulated, maximal activity) during 10 min 19. cGMP formation 
was measured by radioimmunoassay 19, 20. The basal and CNP-stimulated cGMP responses 
were calculated as percentage of the maximal, Triton-stimulated activity. NPR2 expression 
levels in the cytosol versus membrane fractions were assessed by Western blotting using 
an antibody against the FLAG epitope (Cell Signaling).
Isolation and culture of human skin fibroblasts and cGMP determinations
Skin biopsies were taken from the proband and a control donor, and a culture of dermal 
fibroblasts was established as previously described 21. Experiments were performed with 
cells with a passage number ranging between 5 and 7 in mitogen-free, serum-reduced 
DMEM (0.5% fetal calf serum during 3 h prior to experimentation). Cells were pretreated 
with 0.1 mM IBMX for 15 min, and then exposed to CNP (0.1-1000 nM) for another 10 min. 
Intracellular cGMP contents were determined by RIA 19, 20. 
Coimmunoprecipitation and Western blot analyses 
For co-expression of FLAG-tagged wildtype NPR2 and Myc-tagged mutant NPR2, the FLAG 
(DYKDDDDK) and Myc (EQKLISEEDL) epitopes were positioned directly after the cleavage 
site of the NPR2 signal peptide by PCR-mediated mutagenesis. HEK 293 cells were prepared 
in 10 cm dishes and (co)transfected with 10 µg plasmid as described above. After 48 h cells 
were lysed at 4°C for 30 min in 250 µl of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% Triton X-100, pH 7.5), with protease and phosphatase inhibitors 
(Roche). After centrifugation (2000 g, 10 min, 4°C), the supernatant was incubated with 25 
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µl pre-equilibrated anti-FLAG M2 affinity gel beads (Sigma) at 4°C for 2 h. The beads were 
washed three times, resuspended in 100 µl of electrophoresis sample buffer (200 mM 
Tris·HCl, pH 6.8, 6% (w/v) SDS, 15% glycerol, 10% ß-mercaptoethanol, 0.01% bromophenol 
blue) and boiled for 10 min. For Western blot analyses, protein samples were resolved 
by 10% SDS-PAGE. Electrophoresis and immunoblotting were performed as previously 
described 20. Antibodies were anti-FLAG (Cell Signaling) or anti-Myc (Bioscience). 
Modeling of the NPR2 mutant Arg655Cys
The full-length model of NPR2 was built from homology models of the individual domains 
on the basis of structure templates for the NPR2 ECD (protein data bank (PDB) entries 1DP4, 
1T34, crystal structure of free and ligand-bound NPR1), the KHD (2EVA, 3P86, 2PHK) and 
the GC domain (3ET6). Since no structural templates are available for the linker regions, 
secondary structure prediction was applied using the amino acid sequence. A de novo 
modeling approach was applied to connect the individually modeled domains, ECD, 
KHD and GC. As the structure of the linker domains is purely speculative, the full-length 
model serves only representative purposes and was not used to predict or propose any 
activation mechanism. The most suited templates for modeling of the individual domains 
were identified by Basic Local Alignment Search Tool (BLAST) searches using the amino 
acid sequence of the individual domains (KHD and GC) and the PDB (http://www.rcsb.
org). For modeling of the KHD, the best match of the BLAST search (PDB entry 3P86, 
crystal structure of the Crt1 kinase, a member of the raf-like kinase family, 22) was used to 
obtain a 3D model. In addition, to minimize model bias, structures of kinases with lower 
E-values and amino acid sequence identity (i.e. PDB entries 2EVA: Kinase TAK1, a member 
of the MAPKKK family 23, and 2PHK: Phosphorylase kinase-gt 24) were also used to build 
models for the KHD of NPR2. The model for the GC domain of NPR2 was obtained using 
the crystal structure of a soluble eukaryotic guanylyl cyclase, which was shown to exist 
as homodimer and is specific for cGMP (PDB entry 3ET6). The models were obtained 
either from automatic modeling using the SWISS-MODEL server 25 providing a sequence 
alignment and the structure template or by manually exchanging residues of the structure 
template using a multiple sequence alignment of target and template sequences using 
the software Quanta2008 (MSI Accelrys). Deletion and insertions between target and 
template molecule were modeled by manual model building. Sequence alignments were 
made using the software CLUSTALW. 
CNP, ANP and BNP Assays
Plasma ANP, BNP, CNP and NTproCNP, following extraction over C18 SepPac cartridges 
(Waters Corp., Milford, MA), were measured by RIA as previously described 26, 27. Recoveries 




for CNP22 and NTproCNP over SepPac cartridges were 98% and 108% respectively. 
Crossreactivity of human BNP (at 100 pmol/L) in the CNP assay is approximately 4%. CNP 
concentrations were not corrected for BNP crossreactivity. Crossreactivity of CNP and 
human BNP in the NTproCNP assay was <0.05% for both. 
Data Analysis
Statistical comparisons were done using Student’s t test (p < 0.05). Data are given as mean 
± S.E.
Results 
Case - clinical description and investigations
Growth and skeletal phenotype. The proband was born at term with a weight of 4 kg (+ 
1 standard deviation score (SDS)) and a length of 62 cm (+ 6 SDS). He continued to be 
tall in infancy, childhood and adolescence. Psychomotor development was normal but 
puberty started late, at the age of approximately 15 yr. At age 16 yr his height was 216 cm; 
on X-ray his epiphyses were ‘wide open’ but the exact bone age was not documented. 
He underwent epiphysiodesis of the distal femur and proximal tibia and fibula. His adult 
height is 221 cm (+ 5.2 SDS), sitting height is 107.8 cm (+3.7 SDS), sitting height/height ratio 
0.49 (-1.3 SDS), arm span 232 cm, weight 155 kg, and head circumference 60 cm (+1.2 SDS) 
(Figure 1A). He has suffered several fractures, mainly due to sports accidents, and one 
metatarsal fracture after a long hike. Physical examination showed long fingers and mild 
thoracic kyphosis (Figures 1B and C). He did not have particularly long halluces (Figure 1D) or 
a Marfanoid habitus, which were described in the previously reported cases with increased 
CNP production or an activating NPR2 mutation 9-11. A skeletal survey demonstrated mild 
scoliosis and secondary degenerative changes of the skeleton, coxa valga with slightly 
flat femoral heads and mild right hip dysplasia (Figures 1E-I). Bone mineral density was 
normal (Z-score lumbar spine +1.9, hips +1.6 and +1.4, as determined by dexa scan (Hologic 
Discovery A)).
Cardiovascular system. Chronic venous insufficiency of the lower extremities was 
present since the age of 36 yr. Blood pressure was 130/80 mmHg, with a regular pulse. 
Echocardiography showed normal cardiac size (corrected for BMI) and contractile functions, 
with the exception of paroxysmal atrial fibrillation.
Endocrinology. Non-insulin dependent diabetes mellitus (NIDDM) was diagnosed at age 
53 yr and is well controlled with metformin. Testicular volumes were normal, with a cystic 
abnormality of 4 mm in the left testis and a solitary microcalcification in the right testis 
on ultrasound. 
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Figure 1  Clinical features of the proband
(A-D) Photographs of the proband, showing no Marfanoid habitus. (A) Proband with two of the 
authors (SEH, 173 cm, AMP, 192 cm). (B) Lateral photograph showing increased thoracic kyphosis 
and lumbar lordosis. (C) Proband’s hand, holding a ping-pong ball for reference, showing long 
fingers. (D) Proband’s feet, halluces are not particularly long. (EF) Posterioanterior and lateral 
radiographs of the thoracic spine. (GH) Posterioanterior and lateral radiographs of the lumbar 
spine, showing mild scoliosis. (I) Pelvic radiograph showing coxa valga, slightly flat femoral heads, 
mild right hip dysplasia and degenerative changes. The proband gave permission for publication 
of these photographs.
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He has bilateral gynaecomastia and serum prolactin was elevated on two occasions. At age 
55 yr the 24 h growth hormone (GH) and prolactin secretion rates were quantified showing 
low-normal GH secretion compared to control subjects (nine healthy males aged 47-61 yr, 
BMI 21-31 kg/m2) (Supplemental figure 1A). Both basal and pulsatile prolactin secretion, 
however, were markedly increased with a total secretion of 679 µg/l distribution volume 
per 24 h compared to 183 µg/l distribution volume per 24 h (range 99-325) in the controls 
(Supplemental figure 1B and Table 1 of supplemental data). The only medication used at 
the time of sampling was lactulose (to treat constipation), which is not known to alter 
prolactin secretion. Although a recent prolactin level, at age 61 yr, was within the normal 
range (Table 1), this does not necessarily indicate that prolactin secretion has normalised 
since the serum levels were not constantly elevated during the 24 h profile either.  Levels of 
other relevant hormones were in the normal range (Table 1).
Neurology. Axonal sensorimotor polyneuropathy was diagnosed at age 41 yr and was later 
attributed to NIDDM.
Identification of NPR2 mutation and microdeletion on chromosome 15q
Because the tall stature was not due to GH overproduction and the proband did 
not show features of any known syndrome, a SNP array analysis was performed. 
This showed a heterozygous microdeletion in chromosome 15 (karyotype: array 
15q25.2q25.3(85,084,470-85,724,984)x1 (Human Genome 19)), containing 8 genes (ZSCAN2, 
WDR73, NMB, SEC11A, ZNF592, ALPK3, SLC28A1 and PDE8A), encoding the following proteins: 
zinc finger and SCAN domain-containing protein 2, WD repeat-containing protein 73, 
neuromedin-B, signal peptidase complex catalytic subunit SEC11A, zinc finger protein 592, 
alpha-kinase 3, sodium/nucleoside cotransporter 1 and cAMP-specific  phosphodiesterase 
8A, respectively). Sequencing of this region on the remaining allele showed no mutations. 
Since this microdeletion cannot explain the tall stature, we subsequently performed whole 
exome sequencing and identified a heterozygous c.1963C>T mutation in the NPR2 gene, 
predicted to exchange arginine at position 655 to cysteine within the KHD of NPR2. The 
mutation and microdeletion were not found in the proband’s sister or son, who are not as 
tall as the proband (Figure 2). Unfortunately, we were unable to investigate other family 
members.
Site-directed mutagenesis shows that the substitution Arg655Cys enhances the guanylate 
cyclase activity of NPR2 
We tested the function of the mutant NPR2Arg655Cys by transfecting HEK 293 cells and 
measuring cGMP production under baseline conditions and after stimulation with CNP. 
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Table 1  Blood biochemistry tests 
Parameter Age 55 yr Age 61 yr Unit Normal range
Urea 10.7 mmol/l 2.5-7.5
Creatinin 58 70 µmol/l 64-104
SGOT 35 38 U/l 0-35
SGPT 32 52 U/l 0-45 
Calcium 2.25 2.46 mmol/l 2.15-2.55
Phosphate 0.83 0.88 mmol/l 0.9-1.5
Alkaline phosphatase 79 87 U/l 0-115
P1NP 36 ng/ml <59 
Beta crosslaps 0.17 ng/ml <0.704 
HbA1c 6.3 % 4.3-6.3
HbA1c 45 mmol/mmol Hb 20-42
Cholesterol 5.19 4.86 mmol/l 3.9-7.3
Triglycerides 1.88 1.03 mmol/l 0.8-2.3 
TSH 2.96 1.99 mU/l 0.3-4.8
FT4 14.3 15.5 pmol/l 10-24
IGF-I 15.3 (+0.5 SDS) 28.5 (+3.1 SDS) nmol/l 7-83
IGFBP-3 1.6 3.8 mg/l 1.5-6
Prolactin 17.1 8.1 µg/l 4-15
Cortisol (8:00) 0.422 µmol/l 0.1-0.6
Androstenedione 4.1 1.7 nmol/l 2-10
DHEA-S 3.09 1.7 µmol/l 2-15
FSH 4.1 6.9 U/l 2-10
LH 3.2 4.6 U/l 2-9
Testosterone 9.1 13 nmol/l 8-31
Estradiol 71 pmol/l 70-200
Estrone 227 pmol/l 100-200
AMH 1.6 µg/l 5.1-9.1
Inhibin B 112 ng/l 150-400
ANP 32.8 pmol/l 4-27
BNP 7.8 pmol/l 3-12
CNP 0.9 pmol/l 0.5-1.2
NTproCNP 8.1 pmol/l 12-25
cGMP 5.8 nmol/l 2.5-7.7




Figure 2  Family pedigree  
The proband, III-3, is indicated with an arrow. The NPR2 mutation and microdeletion on 
chromosome 15 were absent in his sister and son, other family members have not been 
investigated. Heights of family members (in cm), as reported by the proband, are indicated below 
the symbols. Heart valve pathology is indicated with hatching. Av = average height.
Transfection with cDNA encoding the FLAG-tagged mutant NPR2 produced equivalent 
amounts of membrane protein, compared with FLAG-tagged wildtype NPR2, suggesting 
that the mutation does not alter protein synthesis and membrane localization (see Western 
blots depicted in Figures 3A and B). However, basal cGMP contents of cells expressing 
mutant NPR2 were ~2.1 ± 0.3-fold higher in comparison with cells expressing wildtype 
NPR2 (n = 3). Intracellular cGMP levels were increased by CNP in a concentration-dependent 
manner, and these responses were much greater in cells expressing the mutant protein 
as compared to cells expressing wildtype NPR2 (Figure 3A). Intriguingly, co-expression of 
wildtype and mutant NPR2 resulted in cGMP responses to CNP which were almost as high 
as those observed with mutant NPR2 alone (Figure 3A). 
Additionally, the effect of this amino acid substitution on NPR2 activity was evaluated in 
guanylate cyclase assays performed with crude membranes from transfected HEK 293 cells 
expressing either the wildtype or the mutated receptor, or both (Figure 3B). The membranes 
were incubated with CNP, and cGMP formation was measured by RIA 19. Assays were 
performed in the presence of 2 mM ATP to mimic cytoplasmic ATP levels, which are in the 
range of 1-10 mM 28. Again we confirmed, by immunoblotting, that mutant and wildtype 
FLAG-tagged NPR2, and their combination, were expressed in similar amounts (see inset 
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of Figure 3B). In addition, to account for small differences in the expression level of the 
two variants, we normalized the CNP-stimulated activity data to the respective maximal, 
Triton-stimulated NPR2 activity 19. Wildtype NPR2 responded to CNP with a concentration-
dependent increase in cGMP production (Figure 3B). In comparison, CNP-stimulated cGMP 
production by membranes containing mutant NPR2 or both mutant and wildtype NPR2 
was markedly enhanced (Figure 3B). 
Wildtype NPR2 can form heterodimers with mutant NPR2
Although the NPR2 contains a single cyclase catalytic site per polypeptide chain, a dimeric 
receptor assembly is essential for the activation of the catalytic domain 1. The introduction 
of the Arg655Cys mutation in individual subunits could therefore lead to the formation 
of hyperfunctional dimers. The observation that co-expression of wildtype and mutant 
NPR2 resulted in cGMP responses to CNP close to those observed with mutant NPR2 alone 
suggested this “dominant positive” effect. Indeed, co-immunoprecipitation of FLAG-
tagged wildtype NPR2 and Myc-tagged mutant NPR2 confirmed a tight interaction of both 
proteins (Figure 3C). 
Arg655Cys substitution results in increased activity of native NPR2 in skin fibroblasts
To study the mutant NPR2 in primary cells we used cultured fibroblasts harvested and 
expanded from a skin biopsy from the proband’s forearm. Intracellular cGMP levels were 
compared to levels in control skin fibroblasts obtained from a healthy 48 yr-old male 
donor with a height of 192 cm. Basal cGMP contents were similar in proband and control 
fibroblasts but the responses to CNP were markedly increased in the former (Figure 4A). 
In contrast, the cGMP responses to ANP, which are mediated by NPR1, were not different 
between proband and control fibroblasts (Figure 4B). This confirms increased CNP-
stimulated activity of the mutant NPR2 not only when transfected into HEK 293 cells but 
also when naturally expressed in fibroblasts.




Figure 3  Increased cGMP responses to CNP of HEK 293 cells expressing mutant NPR2  
(A) HEK 293 cells expressing FLAG-tagged wildtype (WT) or mutant (mut) NPR2, or both, were 
incubated with CNP (10 pM – 1 mM, 10 min). Whole cell cGMP contents were quantified by RIA 
(n=3 per condition). (B) Crude membranes prepared from HEK 293 cells expressing FLAG-tagged 
wildtype (WT) NPR2, mutant NPR2 (mut), or both, were incubated with vehicle, CNP or detergent 
(1% Triton X-100). cGMP production was measured by RIA in [fmol cGMP·(µg protein)−1·min−1]. 
All values were calculated as X-fold of the maximal Triton-induced activity (n=4 per condition). 
Insets in A,B: Western blots demonstrating similar expression levels of WT and mutated NPR2 
in transfected HEK 293 cells (all 50 µg protein per lane). (C) Heterodimer formation of wildtype 
and mutant NPR2. Extracts from cells transfected with FLAG-NPR2 and pCMV5 (Mock), cells 
with FLAG-NPR2 and Myc-tagged mutant-NPR2, or cells with pCMV5 and Myc-tagged mutant 
NPR2 were immunoprecipitated (IP) with anti (α)-FLAG M2 affinity gel beads (Sigma). Aliquots 
of cell lysates (before IP: input) as well as the IP proteins were analyzed by Western blot and 
subsequent FLAG- and Myc-specific immunodetection. Results show that Myc-tagged mutant 
NRP2 is precipitated with FLAG-tagged wildtype NPR2, indicating interaction between these two 
isoforms. Similar data were obtained in two independent experiments. 
A B
C
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Homology modeling studies
As mentioned above, in contrast to previously published mutations directly affecting the 
GC domain, the novel mutation that we describe here is localized within the KHD of NPR2. 
Although the KHD binds ATP 29, kinase activity has never been demonstrated 30. Modeling 
indeed revealed that although all elements required for ATP binding are present 31, the lack 
of kinase activity is likely linked to the loss of the conserved aspartate in the activation loop 
which is replaced by a serine (Ser644) in NPR. This abstracts the proton from the phospho-
group acceptor required for the g-phosphate transfer from ATP 32. However, experiments 
by Duda et al. have shown that ATP binding to the KHD is coupled to a conformational 
rearrangement which possibly results in allosteric modulation of the GC domain 31.
To obtain insights into the molecular mechanism by which the Arg655Cys substitution 
influences NPR2 activation, we performed homology modeling to derive 3D models of 
the different protein domains (Figure 5). First a model of the mutation-carrying KHD was 
prepared (Figure 5A). Several different structure templates of protein kinases from the 
protein structure data bank RCSB were used to minimize structural bias of the KHD model 
towards a particular kinase template. In all models prepared, residue Arg655 is located at 
the solvent-accessible surface of the KHD (Figure 5B and C). The residue shares no direct 
contact with the ATP binding pocket or the dynamic linker connecting the upper and lower 
lobe of the kinase (Figure 5B and C). Thus, our modeling study suggests that the mutation 
does not directly influence ATP binding. Furthermore, an influence of the mutation 
Arg→Cys on protein folding seems unlikely due to the solvent-exposed position of Arg655. 
Figure 4  Increased effects of CNP on cGMP levels of proband ś skin fibroblasts 
Proband and control fibroblasts were incubated with vehicle, CNP or ANP (both 0.1 nM – 1 mM) for 
10 min, and intracellular cGMP contents were determined by RIA (n=8). (A) In comparison to the 
control fibroblasts, the CNP-induced cGMP-responses of the proband’s fibroblasts were markedly 
increased. (B) The responses to ANP remained unaltered.




Figure 5  Homology modeling 
(A) A theoretical model of NPR2 consisting of the ECD connected to the KHD and GC domains via 
a single transmembrane domain. The structurally characterized domains were modeled on the 
basis of structure templates obtained from the PDB databank, the linker regions were built on 
the basis of secondary structure predictions. Thus the full-length model only serves illustrative 
purposes. The area within the rectangle is shown in more detail in figures B and C. (B) A 3D model 
of the KHD of wildtype NPR2. The dimer assembly was obtained by docking the monomeric 
model structure of KHD onto the kinase structure of Crt1 (PDB entry 3P86). The side chain of 
arginine at position 655 (indicated as sticks) is located close to the dimer interface thereby 
possibly restraining the conformational rearrangement of the dimer assembly due to steric and 
electrostatic forces. (C)  Replacement of the bulky, positively charged arginine side chain by a small 
and neutral cysteine could potentially relieve these restraints. Alternatively, the close proximity 
of two Cys655 residues in a homodimeric NPR2 mutant assembly might allow the formation of an 
intermolecular disulfide bridge leading to a semiactivated receptor. 
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Arg655Cys substitution enhances the ATP-dependent activation of NPR2
To test whether the mutation of Arg655 to cysteine influences the modulatory effect of 
ATP on cyclase activity, we performed CNP concentration-response assays in the absence 
and presence of three different concentrations of ATP (10, 100 and 1000 nM). NPR2 activity 
was evaluated in guanylate cyclase assays performed with crude membranes prepared 
from transfected HEK 293 cells. Again we confirmed that mutant and wildtype FLAG-
tagged NPR2 receptors were expressed in similar amounts (see Figure 6, upper part) 
and we normalized the CNP-stimulated activity to the maximal, Triton-stimulated NPR2 
activity 19. In the absence of ATP, the cGMP-responses of wildtype NPR2 to CNP were small: 
1.1-fold (in response to 1 nM CNP), 2-fold (10 nM CNP) and 6-fold (100 nM CNP) increases of 
baseline activity. Basal and CNP-stimulated activities of mutant NPR2 were only slightly 
enhanced. More precisely, baseline activity of mutant NPR2 was 2-fold higher as compared 
to wildtype NPR2. In response to CNP baseline cGMP production raised 3-fold (1 nM CNP), 
4.6-fold (10 nM CNP) and 6-fold (100 nM CNP) (n=4 per condition). In the absence of CNP, 
ATP (10-1000 nM) barely influenced cyclase activities of the wildtype and mutant receptors 
(Figure 6). However, increasing concentrations of ATP enhanced the ligand-dependent 
activation of wildtype and mutant NPR2. Notably, ATP increased the potency of CNP much 
more for the mutant as compared to the wildtype receptor (Figure 6).
Decreased level of NT-proCNP in proband’s plasma
To assess whether increased NPR2 activity in vivo leads to reduced production of its ligand 
we measured the proband ś plasma levels of the CNP prohormone (NTproCNP) and the 
processed peptide (CNP) by respective radioimmunoassays. When renal function is normal, 
plasma NTproCNP level is a better reflection of CNP production in tissues than plasma CNP 
33, 34. While the concentration of NTproCNP was diminished (8.1 pmol/l, which is 3.3 SD below 
the mean for a subject of his age and sex; normal range in healthy donors of the same age: 
12-25.0 pmol/l 34), the plasma CNP concentration was normal (0.9 pmol/l; reference range 
0.5-1.2 pmol/l). Plasma cGMP concentration in the same sample was within normal limits 
(5.8 nmol/l, normal range 2.5-7.7 nmol/l). Plasma ANP was mildly elevated (32.8 pmol/l, 
normal 4-27) and brain natriuretic peptide (BNP) level was 7.8 pmol/l (normal 3-12 pmol/l).




Figure 6  Enhanced modulatory effect of ATP on CNP-dependent guanylyl cyclase activity of 
mutant NPR2  
GC activity was determined in crude membranes prepared from HEK 293 cells (expressing 
wildtype or mutant NPR2) in the absence or presence  of ATP (10-1000 nM) and the indicated 
concentrations of CNP (n=4). Inset: Western blots demonstrating similar membrane location and 
expression of WT and mutated NPR2 in transfected HEK 293 cells (all 50 µg protein per lane).
Discussion
We identified a novel heterozygous NPR2 mutation in a proband with extremely tall 
stature. In vitro assays with transfected HEK 293 cells showed that the NPR2 variant 
Arg655Cys can form stable heterodimers with the wildtype receptor and responds to CNP 
with markedly enhanced cGMP production. Ex vivo studies with the proband’s fibroblasts 
confirmed that the endogenously expressed NPR2 variant mediates markedly enhanced 
CNP/cGMP signalling. Because this pathway is critically involved in bone development by 
stimulating growth plate chondrocyte differentiation and proliferation 4 and an activating 
NPR2 mutation was previously found to result in tall stature 11, we conclude that the 
Arg655Cys mutation is responsible for the observed skeletal overgrowth in the proband. 
 Reduced production of CNP, as reflected by low NTproCNP level in the proband’s plasma, 
is consistent with increased NPR2 activity in vivo. Low NTproCNP levels were also reported 
in two of the three Japanese patients with an activating mutation in the GC domain of 
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NPR2 11 and are opposite to the marked increase in plasma CNP levels in subjects with 
loss of function mutations in NPR2 8, 34. Together, these findings suggest the presence of 
a negative feedback mechanism whereby increased receptor activity leads to decreased 
CNP production and vice versa. NPR2-mediated cGMP production in response to CNP was 
markedly increased in the proband’s skin fibroblasts, suggesting that the responsiveness 
of the mutant NPR2 expressed in the bone and many other tissues of the proband is also 
enhanced. Nevertheless, plasma cGMP concentrations were normal. However, in our 
experience even very high plasma levels of active CNP, achieved by intravenous infusion 
of synthetic peptide, have little if any effect on plasma cGMP levels in healthy controls 
35. Compared with cGMP increments evoked by equimolar concentrations of ANP and 
BNP, those induced by CNP were less than 10%. Other studies showed that plasma cGMP 
is mainly derived from vascular endothelial cells, which express high levels of NPR1 (the 
ANP receptor) but very low levels of NPR2 36. Hence, it is not surprising that plasma cGMP 
concentrations were normal in the proband. 
The tall stature (height +5.2 SDS) is more severe in this case compared to the reported 
cases in the Japanese family with an activating mutation within the GC domain of NPR2 
(height +2.7 to +3.8 SDS) 11, especially considering the fact that the proband would have 
been even taller without epiphysiodesis (his arm span of 232 cm suggests that without 
intervention adult height would have been approximately 230 cm). Of note, excessive 
length was already evident at birth. Other features, however, like a Marfanoid phenotype 
and skeletal deformities were much less pronounced than in the Japanese patients and in 
patients with CNP overproduction 9-11. What causes this difference in phenotype is currently 
unclear; it might be related to the location of the mutation within the NPR2 (KHD versus GC 
domain) or perhaps to the different genetic background. Importantly, the findings in the 
proband imply that an activating NPR2 mutation should be considered as a possible cause 
of isolated tall stature without dysmorphic features or skeletal deformities and could be 
screened for by measuring NTproCNP, provided renal function is normal. 
How does the heterozygous Arg655Cys substitution within the conserved region of the 
KHD enhance NPR2 activity? As mentioned above, the function of this domain is not well 
understood. Although being inactive with respect to phosphorylating substrates 30, it binds 
ATP and modulates the enzymatic activity of the distal GC domain 37. Furthermore, several 
studies showed that in the absence of ligand the KHD represses the activity of the GC 
domain 2, 30. NPR activation possibly follows a ligand-induced rearrangement mechanism 
38 and ATP binding to the KHD seems to allosterically modulate the ligand-stimulated 
catalytic activity of the GC domain 29, 37.
As illustrated in Figures 5B and C, homology modeling of the KHD suggests that Arg655 
is solvent-exposed and does not affect ATP binding. For these modeling studies we used 




different kinase structure templates, some of which form dimeric assemblies in the crystal. 
Sequence comparisons indicated that the KHD of NPR2 showed the highest homology (33% 
identity, 51% similarity on amino acid sequence level) to the serine/threonine kinase Ctr1 
(constitutive triple response 1 kinase), which is a member of the raf-like kinases 22. In the 
crystal structure Ctr1 has a dimeric assembly with a rather large interface between the two 
kinase subunits. An identical dimer architecture is also seen in crystal structures of the Raf-
kinases C-Raf and B-Raf indicating that the dimer arrangement is of functional relevance. 
The monomeric model of the NPR2 KHD could be docked onto this dimer arrangement 
forming a similar large interface (see Figure 5). In our dimer model of the KHD of NPR2, 
Arg655 is located close to the dimer interface with the Cα atoms of Arg655 in either subunit 
distanced by about 6 Å only. Thus, the exchange of this arginine by a cysteine could bring 
the two thiol groups of a homodimeric mutant NPR2 in close proximity allowing formation 
of an intermolecular disulfide bond, thereby possibly leading to a semiactivated state of 
NPR2. Although disulfide bond formation inside the cytoplasm is rare, a recent study using a 
fluorescence resonance energy transfer (FRET)-based thiol-containing sensor showed that 
despite the reducing environment a significant amount of the sensor contained disulfide 
bonds 39. Alternatively, the close proximity of Arg655 to the dimer interface could point 
to a mechanism relying on a relief from steric/electrostatic repulsion. Substitution of the 
bulky and positively charged arginine by a small and neutral cysteine might favor or ease 
the conformational rearrangement induced by extracellular CNP binding and facilitate the 
allosteric activation by intracellular ATP. This hypothesis is supported by our observation 
that the stimulatory effect of ATP on CNP-dependent guanylate cyclase activity of the 
mutant NPR2 was markedly enhanced.
Besides stimulating skeletal growth, CNP/NPR2 signalling is involved in the modulation 
of cardiovascular, neuronal and reproductive functions 40. It is therefore important 
to mention that the proband has several medical problems outside the skeleton. In 
particular he has gynaecomastia and 24 h prolactin secretion was increased, which could 
not be attributed to medication. Increased prolactin secretion might be related to the 
activating NPR2 mutation, as CNP injected into the third ventricle of castrated male rats 
and ovariectomised female rats increased plasma prolactin 41. CNP does not seem to act 
directly on lactotrophs but may act at the hypothalamic level,  where both CNP and NPR2 
are expressed 42. In fact, CNP and NTproCNP are present in human cerebrospinal fluid at 
levels that greatly exceed those in plasma 43. 
In addition, the proband has a polyneuropathy which was attributed to diabetes 
mellitus but was diagnosed more than 10 years before diabetes mellitus was apparent. It 
is interesting to speculate on a role of the NPR2 mutation because NPR2 was shown to be 
essential for sensory axon bifurcation in the spinal cord of mice 6 and CNP knockout mice 
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display a decreased response to pain 44. In addition, the foot ulcers in the proband were 
regarded to be secondary to the diabetes and venous insufficiency, but again it is tempting 
to speculate on a direct effect of altered NPR2 function, since NPR2 has been suggested to 
play a role in wound healing 45.
Lastly, CNP, via NPR2, was reported to counteract experimental hypertensive cardiac 
remodeling and to inhibit valve interstitial cell differentiation 46, 47. Tricuspid and mitral 
valve pathologies were reported in a 14 yr old girl with CNP overexpression 9. However, 
the proband did not exhibit changes in cardiac size or function, with exception of atrial 
fibrillation.
It is unclear whether the heterozygous microdeletion on chromosome 15 found in the 
proband has any clinical consequences. Two of the proteins affected by this deletion have 
been studied in genetic mouse models. The Pde8a knockout mouse did not show an obvious 
change in body size or bone length (personal communication of Prof. Beavo), neither did the 
alpha-kinase 2 knockout mouse 48. In humans, a homozygous mutation in ZNF592 causes 
CAMOS (cerebellar ataxia with mental retardation, optic atrophy and skin abnormalities) 
and proportionate short stature 49. Overall, these data suggest that haploinsufficiency 
of the genes affected by the heterozygous microdeletion on chromosome 15 does not 
contribute to the tall stature of the proband. 
In conclusion, we report a novel activating NPR2 mutation located in the KHD, which 
results in extremely tall stature without a Marfanoid phenotype or severe skeletal 
abnormalities. This activating mutation indicates that the KHD, whose function is still 
poorly understood, is crucially involved in regulating guanylate cyclase activity of NPR2. 
Whether the hyperprolactinemia, diabetes mellitus and polyneuropathy of the proband 
are also related to the NPR2 mutation or to the microdeletion on chromosome 15, awaits 
further investigation.
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Supplemental Figure + Table
A
B
Supplemental figure 1  Profiles (24 h) of growth hormone and prolactin secretion.
(A) Pulsatile GH secretion of the proband. Compared to healthy controls of similar age GH secretion 
is low, consistent with his increased BMI. For details of the secretion see supplemental table 1.
(B) Prolactin secretion was clearly elevated (see supplemental table 1).




Supplemental Figure + Table
S
Table 1  Deconvolution analysis of 24 h serum hormone profiles in controls and proband
GH secretion in controls Patient PRL secretion in controls Patient
Pulse frequency (no/24 h) 13 (10-21) 14 20 (16-24) 19
Half-life (min) 14.3 (8-25) 17.7 32 (20-42) 23.8
Pulse mode day (min) 14.2 (4.6-30) 13.9 12.1 (6.4-24) 3.79
Pulse mode night (min) 16.7 (6.9-30) 16.5 5.3 (3-14.6) 5.14
Basal secretion (units/liter) 4.2 (1.5 -42) 3.8 83 (44-201) 491
Pulsatile secretion (units/liter) 72 (27-277) 40.3 83 (30-125) 188
Total secretion (units/liter) 73 (32-319) 44.1 183 (99-325) 679
Pulse regularity (unitless) 1.40 (1.13-1.70) 1.28 1.99 (1.41-2.80) 2
Data are median and range. GH is expressed in mU/liter and prolactin as µg/liter. 
Secretion rates are in unit/liter distribution volume per 24 h.
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General discussion
The aim of this thesis was to investigate the genetic causes of growth disorders, following 
either the candidate gene or the whole genome approach and subsequently establish 
genotype-phenotype correlations, in order to acquire more insight in the regulation of 
longitudinal growth. In this chapter the results of our findings are discussed, as well as 
future perspectives. 
A. Candidate gene approach
Since the introduction and optimization of the polymerase chain reaction (PCR) and 
sequencing techniques, a rollercoaster ride started in the genetics field, such as the start 
of the 13-year Human Genome Project in 1990 to determine the sequences of the 3 billion 
chemical base pairs that make up human DNA and to identify all the approximately 20,000-
25,000 genes in human DNA. All this new information and the novel techniques, together 
with the already established knowledge, led to detection of genetic defects causing a 
certain phenotype or disease. Thus introducing the candidate gene approach. Meaning 
that by thoroughly investigating the clinical and biochemical phenotype of the patient 
and compare this to the medical literature, one or more candidate genes can be selected. 
Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis 
to identify mutations and copy number variations (CNVs; deletions and duplications) of 
these genes can be performed to investigate the presence of a genetic defect. 
The candidate gene approach proved to be successful in the diagnosis of several patients 
with short stature. In chapter 2 & 3, and 4 two families are described in whom the genetic 
defect (in IGF1 and IGFALS, respectively) was identified following the candidate gene 
approach. The first family with a heterozygous mutation in the IGF1 gene associated with 
severe short stature is described in chapter 2. The two children had severe short stature 
(height SD score -4.1 and -4.6), microcephaly and low circulating IGF-I levels. The flowchart 
created by our Leiden Growth Genetics Working Group (1) suggested in the oldest index 
case a homozygous IGF1 missense mutation as a possible cause, and suggested mutation 
analysis of IGF1. However, in the youngest index case the flowchart did not suggest 
mutation analysis of IGF1, due to the normal birth weight and length. Just before these 
patients came to our attention, a patient exhibiting intrauterine and postnatal growth 
failure, microcephaly, mild intellectual impairment, but normal hearing caused by a 
homozygous IGF1 mutation was described (2). This led us to sequence IGF1, but surprisingly 
we identified a heterozygous mutation. Until that point there was some evidence that 
heterozygosity for an IGF1 defect was associated with a modest decrease of height, but 
it had never been associated with extreme short stature. Studies on the structural and 




functional characteristics of the putative truncated IGF-I protein (synthetically derived 
mutant IGF-I protein), described in chapter 3, revealed that the severe short stature was 
not caused by a dominant negative effect of the truncated protein. Based on the clinical, 
structural and functional data we speculated that the growth failure was caused by a 
combination of partial IGF-I deficiency, placental IGF-I insufficiency, and other (not yet 
identified) genetic factors. We also speculated that such growth disorder can be treated 
successfully with growth hormone (GH), which indeed was confirmed in the following years 
(Noordam, personal communication). This study indicates that heterozygous mutations in 
IGF1 can also result in short stature. This expanded the phenotype spectrum caused by an 
IGF1 defect and amongst other findings led to adjustment of the flowchart (3). 
The benefit of the identification of a genetic defect in a (large) family is that the effect 
of the mutation against the same genetic background can be investigated, as well as 
the possible effect of carrying a heterozygous mutation. An example of this is described 
in chapter 4. Investigation of the various family members carrying a homozygous or 
heterozygous mutation in the IGFALS gene compared to their family members that did not 
carry the mutation led to the hypothesis that there might be a gene-dosage effect, resulting 
in some negative effect on height and head circumference in heterozygous carriers. The 
international acid-labile subunit consortium investigated the impact of heterozygosity for 
IGFALS gene mutations on short stature in as many affected patients and families with 
mutations in IGFALS as possible, including the family we described, and concluded that 
heterozygosity indeed resulted in approximately 1.0 SDS height loss in comparison with 
family members that did not carry the mutation (4). Thus, this is in line with our hypothesis 
of a gene-dosage effect.
B. Combined candidate gene and whole genome approach
Although the candidate gene approach was successful in the two families described above, 
this was not always the case. The candidate gene approach can be very labor intensive, 
particularly if the phenotype is not typical for a certain gene defect. Furthermore, with this 
approach no novel genes involved in growth can be identified. We hypothesized that the 
phenotype caused by various genetic defects can be more heterogeneous than expected. 
If this is the case the candidate gene approach is not always the best approach to use. 
Therefore, we performed a diagnostic procedure in which the candidate gene approach 
was combined with a whole genome approach. The results are presented in chapters 5 
and 6. In chapter 5 we investigated 100 children born small for gestational age (SGA) with 
persistent short stature for intragenic (small) CNVs in 18 growth-related genes with MLPA. 
In chapter 6 the experiment was extended by investigating short children with apparent 
GH insensitivity through combining the candidate gene approach, sequence analysis and 
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MLPA of 5 candidate genes, with whole genome single-nucleotide polymorphism (SNP) 
array analysis to identify (larger) CNVs with a size >150 kb, to identify novel genes involved 
in the regulation of longitudinal growth. 
MLPA analysis of 18 growth-related genes in 100 SGA children with persistent short 
stature resulted in 2 patients with a de novo heterozygous 15q terminal deletion. The 
terminal deletion contained the complete IGF1R gene in patient A and exons 3-21 of the IGF1R 
in patient B. In patient A, serum IGF-I was low (-2.78 SDS), probably because of a coexisting 
GH deficiency. Functional studies in skin fibroblast cultures demonstrated similar levels 
of IGF1R autophosphorylation compared with controls, a tendency toward reduced total 
IGF1R protein expression, and reduced intracellular activation of protein kinase B/Akt upon 
a challenge with IGF-I. These results are in line with data observed in an earlier report on 
a patient with IGF1R haploinsufficiency (5) and suggest that this condition is characterized 
by a lower number of IGF-I receptors on the cell surface, resulting in decreased signal 
transduction. Haploinsufficiency would theoretically lead to a reduction of 50% of fully 
functional IGF-I receptors. However, in our fibroblast model this was not the case, although 
expression of the IGF1R tended to be lower. Still, downstream signaling was reduced. 
Probably the fibroblast model used to investigate the IGF1R haploinsufficiency is not the 
optimal model. It may be better to use other tissue, ideally growth plate chondrocytes, 
which are responsible for longitudinal growth. This tissue, however, is not available for 
study. We hypothesize that the consequence of  haploinsufficiency may be cell type 
dependent, with possibly a relatively strong effect in growth plate chondrocytes, whereas 
the effect in the fibroblast model is less pronounced. In this study only MLPA was used to 
detect CNVs. Since sequence analysis of the 18 growth-related genes was not performed, 
mutations in these genes could not be excluded. 
The combined search strategy in short children with apparent GH insensitivity (primary 
IGF-I deficiency), described in chapter 6, led to the detection of three patients with two 
novel heterozygous STAT5B mutations, in two of them combined with novel heterozygous 
IGFALS variants. The heterozygous mutations of STAT5B appeared to be involved in the 
observed GH insensitivity; the associations between the genetic variants in IGFALS and 
short stature remains uncertain. It is however conceivable that primary IGF-I deficiency 
resulting in short stature can also be associated with the cumulative effect of digenic or 
oligogenic defects, as height is determined by more than 180 genes (6) and possibly even 
up to 700 genes (Visser, personal communication). In this study we show that in severely 
short children with a low circulating IGF-I, for which the updated flowchart recommended 
genetic testing (3), the yield in terms of established diagnoses was 33%. This indicates that 
the clinical algorithm proposed in the flow chart may serve as a helpful tool for choosing 
the genetic tests to be performed in children with apparent GH insensitivity. In children 




with less severe short stature and/or modestly decreased serum IGF-I levels, the likelihood 
of finding variants in these genes is much lower, suggesting that other, as yet unknown, 
genes play a role.
C. Whole genome approach
In chapter 7 we describe a large study to identify novel gene variants associated with the 
regulation of longitudinal growth, by performing whole genome SNP array analysis in 
149 unrelated families (162 patients) with short stature of unknown origin (height more 
than 2 standard deviations (SD) below the corresponding mean height for the individual’s 
age, sex and ethnicity). This method of patient selection is called an extreme-trait design; 
a carefully selected population at one end of the extremes of a phenotype. The idea is 
that variants that contribute to the trait will be enriched in frequency in such population, 
therefore even small sample sizes may suggest many candidate variants. For confirming 
potentially pathogenic variants, co-segregation data obtained via family members of the 
extreme individuals are invaluable. The potentially pathogenic variants that remain after 
co-segregation analysis can then be genotyped, for example by MLPA or sequence analysis, 
for confirmation in a much larger group of samples (7). 
In this study we identified 6 copy number variations (CNVs) in 6 families for which the 
association with short stature is virtually certain (4.0%), and 40 CNVs in 33 families (22.1%) 
with possible pathogenicity, several of whom may be considered as potential candidate 
genes for growth disorders. Genome-wide association study (GWAS) and bioinformatics 
analysis identified various potential candidate genes in de novo and co-segregating CNVs. 
However, future studies will be needed to support the potential role of these genes in 
longitudinal growth regulation. 
D. Combined whole genome approach and functional studies
Finally, in chapter 8 we describe the use of whole exome sequencing (WES) and subsequent 
functional studies in the identification and characterization of a novel activating NPR2 
gene mutation which results in extremely tall stature of 221 cm in a healthy male. GH 
hormone overproduction had been excluded as the cause of tall stature and the patient 
did not show features of any known syndrome. SNP array analysis showed a deletion in 
chromosome 15q25.2q25.3, containing 8 protein-coding genes (ZSCAN2, WDR73, NMB, 
SEC11A, ZNF592, ALPK3, SLC28A1 and PDE8A). Sequencing showed no mutations in these 
genes on the remaining allele. Since this deletion could not explain the tall stature, we 
subsequently performed WES which identified a heterozygous missense mutation in NPR2 
in a conserved region of the gene. The NPR2 mutation and 15q25.2q25.3 deletion were not 
found in the patient’s sister or son. Transfection studies of the mutant NPR2 protein in 
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HEK293 cells resulted in increased basal and stimulated NPR2 activity and co-expression 
of wild-type and mutant NPR2 resulted in increased activity, almost as high as those with 
mutant NPR2 alone, suggesting a dominant positive effect. Co-immunoprecipitation 
studies confirmed heterodimer forming of wild-type and mutant NPR2. Studies using 
skin fibroblasts of the patient showed increased NPR2 activity after stimulation with CNP, 
compared to control skin fibroblasts.
This study is a good example of the use of WES in the identification of a possibly pathogenic 
genetic defect. The challenge is how to prove the involvement of the genetic defect in the 
observed phenotype of the patient. First, an in silico analysis is performed to get more 
information about the protein in humans, but also in animals, and a possible linkage to 
the phenotype. Second, to really prove if the protein is involved in the manifestation of 
the phenotype, functional studies are necessary. Examples of functional studies are 
studies using the mutant protein, such as transfection studies with the mutant gene in 
an expression plasmid, or even synthesize the mutant protein and use this as a stimulant 
compared to the wild type protein. Expression studies can be carried out in different cell 
systems, such as HEK293 (Human Embryonic Kidney 293) which is a cell line originally 
derived from cultured human embryonic kidney cells. These cells are very easy to culture 
and transfect, therefore they have been widely used in research for many years, mainly for 
analysing protein expression after gene transfection. For investigating synthesized mutant 
protein expression compared to wild type protein expression, different cell systems can be 
used. For example, a stably transfected cell line containing characteristics that are relevant 
for the research question, or a patient derived cell line, for example skin fibroblasts which 
are easy to obtain and culture. In case of the stably transfected cell line a disadvantage 
is that the genetic environment does not mimic the patients’ situation; the results only 
give an indication of the effect in vitro and it cannot be ruled out that the  situation is 
different. In case of a patient derived cell line, not all cell types are easily obtainable and 
can be kept in culture. Skin fibroblasts can be easily obtained and cultured, but as described 
above and in chapter 5, this model may not always be representative for the results in other 
tissues due to tissue specific expression of genes. To investigate a genetic defect in the 
same genetic background of the patient, induced pluripotent stem cells (iPS cells) of the 
patient can be produced. iPS cells are a type of pluripotent stem cells artificially derived 
via reprogramming of a non-pluripotent cell (a somatic cell, for example blood, liver, lung, 
skin and stomach cells), by overexpression of specific genes (8-10). These patient iPS cells 
can then be differentiated to the desired cell type for investigating the genetic defect, 
thus the cells in the tissue important for the patient’s phenotype, in our case growth plate 
chondrocytes. After obtaining the differentiated cells, further experiments on these cells 




to prove the involvement of the genetic defect in the observed phenotype of the patient 
can be performed. 
Conclusion and future perspectives
In this thesis we describe the results of genetic studies in patients with growth disorders, 
in order to detect the causal genetic defect. The candidate gene approach proved to be 
successful for identifying genetic defects in the GH-IGF-I axis, although we have to keep in 
mind that the phenotype caused by various genetic defects may be more heterogeneous 
than assumed on the first observations. Therefore we combined the candidate gene 
approach with the whole genome approach. This led to the hypothesis that short stature 
can be associated with the cumulative effect of digenic or oligogenic defects, as proposed 
in other genetic studies (11;12). In the large whole genome approach study, the SNP array 
technique was successfully used for the detection of novel CNVs. However, the clinical 
significance of detected potentially pathogenic CNVs is not immediately clear. Future 
studies will be needed to support or discard the role of these genes in longitudinal growth 
regulation. The combined whole genome approach and functional studies is a nice example 
of the identification of a potentially pathogenic gene mutation using WES and subsequent 
characterization of the mutation using functional studies, to prove the involvement of the 
genetic defect in the observed phenotype of the patient. 
Since a few years next generation sequencing has been used to identify genetic defects. 
With this technique it is possible to detect mutations as well as deletions, duplications, 
inversions and translocations. Using this technique, similar problems will be encountered 
as using the whole genome SNP arrays, probably on an even larger scale. When novel 
variants are identified, the challenge is how to distinguish between non-causal and causal 
variants, and how to identify multiple variants contributing to a disease in a cumulative 
fashion, thus identifying causal digenic or oligogenic variants. We predict that studies 
using next generation sequencing will result in a higher and probably more convincing 
yield of genes associated with short stature.
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Summary
Growth in humans, primarily longitudinal growth, is a complex process which starts at 
conception and proceeds through various developmental stages, mainly controlled by 
genetic factors and to a lesser degree by environmental, psychosocial and nutritional 
factors. The GH-IGF-I axis is an important regulator of longitudinal growth, what is evident 
from the observation that genetic defects in this axis have been shown to be responsible 
for abnormal growth. These mutations, however, are rare and do not explain the ‘normal’ 
variation in height among people. This thesis focuses on the detection of genetic defects 
in the GH-IGF-I axis that may explain growth disorders. Initially the so-called ‘candidate 
gene approach’ was used, examining various genes in the GH-IGF-I axis. After that, a whole 
genome approach was used to identify novel genes involved in aberrant growth using 
whole genome microarray studies (SNP arrays) and next-generation sequencing. Also, for 
some genes genotype-phenotype correlations were established. With this we have tried to 
acquire more insight in the regulation of longitudinal growth. 
Chapter 1 presents a general introduction and the outline of this thesis.
In part A the candidate gene approach in the GH-IGF-I axis is described. In Chapters 2 and 
3 the first family with a heterozygous mutation in the IGF1 gene associated with severe 
short stature and subsequent studies on the structural and functional characteristics of the 
mutant IGF-I protein are described. The two children presented with severe short stature 
(height SD score -4.1 and -4.6), microcephaly and low circulating IGF-I levels. Genetic analysis 
revealed a heterozygous duplication of four nucleotides in exon 4, resulting in a frame shift 
and a premature stopcodon. Until that point there was some evidence that heterozygosity 
for an IGF1 defect was associated with a modest decrease of height, but it had never been 
associated with extreme short stature. We hypothesized that the putative truncated 
mutant IGF-I protein had a dominant negative effect on the wild type IGF-I protein, 
resulting in the extreme short stature observed in this family. The mutant IGF-I protein was 
synthetically derived to study the structural and functional characteristics of this putative 
truncated IGF-I protein. These studies revealed that the severe short stature was not caused 
by a dominant negative effect of the truncated protein, rejecting our hypothesis. Based 
on the clinical, structural and functional data we speculated that the growth failure was 
caused by a combination of partial IGF-I deficiency, placental IGF-I insufficiency, and other 
(not yet identified) genetic factors. In the following years, this growth disorder proved to be 
successfully treated with growth hormone. This study was the first to indicate that besides 
homozygous IGF1 mutations, heterozygous mutations can also result in short stature. 




Another candidate gene in the GH-IGF-I axis is IGFALS. Homozygous molecular defects of 
IGFALS can cause moderate short stature, pubertal delay and insulin insensitivity. Since 
the first report of a homozygous IGFALS mutation, a total of 16 unique homozygous or 
compound heterozygous mutations in 21 patients with ALS deficiency have been described. 
In Chapter 4 the family members of a large Kurdish family carrying a homozygous, a 
heterozygous or no mutation in the IGFALS gene are described. The three index cases 
(brothers) presented with short stature (height SD score -4.2, -3.6 and -4.4), microcephaly, 
low circulating IGF-I and IGFBP-3, and undetectable ALS levels. Two were known with a low 
bone mineral density and one of them had suffered from two fractures. Genetic analysis 
revealed a homozygous duplication of one nucleotide in exon 2, resulting in a frame shift 
and a premature stopcodon. The IGF-I, IGFBP-3, and ALS 150 kDa ternary complex was 
absent in the sera of the three patients, and ALS proteins were not detected with Western 
blot. IGFPB-1 and IGFPB-2 plasma levels were low and there was a mild insulin resistance. 
Five heterozygous carriers of the IGFALS mutation tended to have a lower height and head 
circumference than five non-carriers, and had low plasma ALS and IGFBP-3 levels. Bone 
mineral (apparent) density was low in two out of three homozygous carriers, and also in 
four out of nine relatives. A benefit of this study was that the effect of the mutation could 
be investigated against the same genetic background, as well as the possible effect of 
carrying a heterozygous mutation. This led to the hypothesis that there might be a gene-
dosage effect, resulting in a small negative effect on height and head circumference in 
heterozygous carriers. The international acid-labile subunit consortium investigated the 
impact of heterozygosity for IGFALS gene mutations on short stature in as many affected 
patients and families with mutations in IGFALS as possible, including the family we 
described, and concluded that heterozygosity indeed resulted in approximately 1.0 SDS 
height loss in comparison with wild type family members. An important lesson learned 
from these studies on ALS deficiency is that local IGF-I appears to be more important for 
growth than circulating IGF-I.
Part B describes the candidate gene approach in the GH-IGF-I axis in combination with a 
whole genome approach using single-nucleotide polymorphism (SNP) array analysis. The 
candidate gene approach was extended, because this strategy can be very labour intensive, 
no novel genes involved in growth can be identified, and we hypothesized that the 
phenotype caused by various genetic defects can be more heterogeneous than expected. 
In Chapter 5 we investigated 100 children born small for gestational age (SGA) with 
persistent short stature for intragenic (small) CNVs in 18 growth-related genes with MLPA. 
This resulted in 2 patients with a de novo heterozygous 15q terminal deletion containing 
the complete (patient A) and partial (patient B) IGF1R gene. In patient A, serum IGF-I was 
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low (-2.78 SDS), probably because of a coexisting GH deficiency. Functional studies using 
skin fibroblast demonstrated similar levels of IGF-I receptor (IGF1R) autophosphorylation 
compared with controls, a tendency toward reduced total IGF1R protein expression, and 
reduced intracellular activation of protein kinase B/Akt upon a challenge with IGF-I. 
Functional studies using skin fibroblasts to test the theory that haploinsufficiency leads 
to a 50% reduction of fully functional IGF1Rs revealed that this was not the case, although 
IGF1R expression tended to be lower. However, other functional studies showed that 
downstream signaling was reduced. We hypothesize that the consequences of IGF1R 
haploinsufficiency may be cell type dependent, with possibly a relatively strong effect in 
growth plate chondrocytes, whereas the effect in the fibroblast model is less pronounced. 
In this study only MLPA was used to detect CNVs. Since sequence analysis of the 18 growth-
related genes was not performed, mutations in these genes could not be excluded. In 
Chapter 6 we investigated short children with apparent GH insensitivity (low IGF-I and 
normal GH secretion) using the candidate gene approach (sequence analysis and MLPA of 
5 candidate genes in the GH-IGF-I axis) in combination with SNP array analysis to detect 
(larger) CNVs with a size >150 kb. Patients were divided into three groups based on height 
and IGF-I SDS, with a low height SDS and IGF-I level in group 1, moderate short stature 
associated with a low IGF-I in group 2 and short stature with serum IGF-I levels in the lower 
half of the normal range in group 3. This led to the detection of three patients in group 
1 with two novel heterozygous STAT5B mutations, in two of them combined with novel 
heterozygous IGFALS variants. In groups 2 and 3 the association between genetic variants 
and short stature was uncertain. The heterozygous STAT5B mutations appeared to be 
involved in the observed GH insensitivity, but the association between the genetic variants 
in IGFALS and short stature remains uncertain. It is however conceivable that primary IGF-I 
deficiency resulting in short stature can also be associated with the cumulative effect 
of digenic or oligogenic defects. Besides the variants in the candidate genes, novel CNVs 
in 6 children were identified. It is possible that in some of these patients the CNVs are 
associated with the phenotype, but no clear candidate genes were present. This finding 
is in line with a recent report on an association between the presence of low-frequency 
genomic deletions in children with short stature. In this study we show that in severely 
short children with a low circulating IGF-I, genetic testing is advised. The yield in terms of 
established diagnoses was 33%. In children with less severe short stature and/or modestly 
decreased serum IGF-I levels, the likelihood of finding variants in these genes is much 
lower, suggesting that other, as yet unknown, genes play a role.
In part C the whole genome approach solely is described, using SNP array analysis in 149 
unrelated families (162 patients) with short stature of unknown origin to identify novel 
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genes associated with short stature (Chapter 7). If possible, analysis of co-segregation 
of the CNV with the phenotype in families was performed, for confirming potentially 
pathogenic variants. In this study CNVs were detected in 40 families. In 6 families (4%) 
a known cause of short stature was found (SHOX deletion or duplication, IGF1R deletion), 
in two combined with a potentially pathogenic CNV. In 33 families (22.1%) one or more 
potentially pathogenic CNVs (n=40) were identified; in 9 families these CNVs occurred de 
novo or segregated with short stature. Several of the deleted or duplicated genes may be 
considered as potential candidate genes for growth disorders, including 4 genes previously 
associated with height in the genome-wide association studies (ADAMTS17, PRKG2/BMP3, 
PAPPA, TULP4). However, future studies will be needed to support the role of these and 
other genes in longitudinal growth regulation.
Part D describes the combined whole genome approach using whole exome sequencing 
(WES) and subsequent functional studies in the identification and characterization of a 
novel activating NPR2 gene mutation which results in extremely tall stature of 221 cm 
in a healthy male (Chapter 8). GH overproduction, known syndromes, and a deletion in 
chromosome 15q25.2q25.3 containing 8 protein-coding genes and mutations in these 
genes on the remaining allele had been excluded as the cause of tall stature. WES was 
performed and a heterozygous missense mutation in the NPR2 gene was detected. 
Resulting in an amino acid change at position 655 from Arginine to Cysteine, in the 
kinase homology domain of NPR2. The mutation was not present as a known variant in 
all available databases. The NPR2 mutation and 15q25.2q25.3 deletion were not found in 
the patient’s sister or son, who are not as tall as the proband. Transfection studies of the 
mutant NPR2 protein in HEK293 cells resulted in increased basal and CNP stimulated NPR2 
activity and co-expression of wild type and mutant NPR2 resulted in increased activity, 
almost as high as those with mutant NPR2 alone, suggesting a dominant positive effect. 
Co-immunoprecipitation studies confirmed heterodimer forming of wild type and mutant 
NPR2. Studies using skin fibroblasts of the patient showed increased NPR2 activity after 
stimulation with CNP, confirming that the mutant NPR2 enhances CNP-NPR2-cGMP 
signalling. This pathway is critically involved in bone development by stimulating growth 
plate chondrocyte differentiation and proliferation. Based on these results and a previously 
found activating NPR2 mutation resulting in tall stature, we conclude that the identified 
NPR2 mutation in our patient is responsible for the extremely tall stature.
In Chapter 9 the major findings of this thesis are summarized and critically reviewed and 
future perspectives are discussed. First it is discussed that the candidate gene approach 
proved to be successful in the diagnosis of several patients with short stature. However, the 
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candidate gene approach also has its disadvantages. It is very labour intensive, particularly 
if the phenotype is not typical for a certain gene defect, no novel genes involved in growth 
can be identified, and if the phenotype caused by a genetic defect is more heterogeneous 
than expected, it will not be recognized. Second, a new strategy is discussed combining 
the candidate gene and whole genome approach. This did not lead to the identification of 
novel genes, but did identify mutations in the GH-IGF-I axis and led to the hypothesis that 
short stature can also be associated with the cumulative effect of digenic or oligogenic 
defects. Third, whole genome SNP array analysis proved to be a good method to identify 
potential candidate genes for growth disorders, although future studies will be needed to 
support the potential role of these genes. Finally, using a new activating NPR2 mutation 
which results in extremely tall stature, it was illustrated that the use of WES combined 
with functional studies is successful in the identification and characterization of novel 
mutations in growth related genes.
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Samenvatting
De groei van de mens, waarmee primair de lengtegroei wordt bedoeld, is een complex 
proces dat begint bij de conceptie en verloopt via verschillende ontwikkelingsstadia. Groei 
is voornamelijk gereguleerd door genetische factoren en in mindere mate door omgevings-, 
psychosociale en voedingsfactoren. De GH-IGF-I as is een belangrijke regulator van 
lengtegroei, wat onder andere blijkt uit de observatie dat genetische afwijkingen in deze as 
verantwoordelijk zijn voor abnormale groei. Deze mutaties zijn echter zeldzaam en kunnen 
de ‘normale’ variatie in lengte tussen mensen niet verklaren. Dit proefschrift richt zich op 
de detectie van genetische defecten die een groeistoornis kunnen verklaren. Aanvankelijk 
is hiervoor de zogenaamde ‘kandidaatgen aanpak‘ gebruikt, waarbij diverse genen in de 
GH-IGF-I as zijn onderzocht. Daarna is met een genoom-brede aanpak gezocht naar nog 
onbekende genen die betrokken zijn bij afwijkende groei met behulp van genoom-brede 
microarray studies (SNP arrays) en ’next-generation sequencing‘. Ook zijn voor enkele 
genen genotype-fenotype correlaties vastgesteld. Wij hebben geprobeerd om hiermee 
meer inzicht te verkrijgen in de regulatie van longitudinale groei.
In Hoofdstuk 1 wordt een algemene introductie en de opbouw van dit proefschrift 
gepresenteerd.
In deel A wordt de kandidaatgen aanpak in de GH-IGF-I as beschreven. In de Hoofdstukken 
2 en 3 wordt de eerste familie beschreven met een heterozygote mutatie in het IGF1 
gen welke geassocieerd is met een zeer kleine lengte en de hierop volgende studies 
naar de structurele en functionele eigenschappen van het mutant IGF-I eiwit. De twee 
kinderen presenteerden met zeer kleine lengte (lengte SD score -4,1 en -4,6), microcefalie 
(een geringe hoofdomtrek) en lage circulerende IGF-I spiegels in het bloed. Genetische 
analyse toonde een heterozygote duplicatie van vier nucleotiden in exon 4, resulterend 
in een frame shift en een prematuur stopcodon. Tot dat moment waren er weliswaar 
aanwijzingen dat heterozygotie voor een IGF1 defect een kleine afname van de lengte zou 
kunnen veroorzaken, maar het was nog nooit in verband gebracht met extreem kleine 
lengte. We veronderstelden dat het verkorte mutant IGF-I eiwit een dominant negatief 
effect op het wild type IGF-I eiwit zou kunnen hebben, wat de extreme kleine lengte 
in deze familie zou kunnen veroorzaken. Het mutant IGF-I eiwit werd gesynthetiseerd 
om de structurele en functionele kenmerken van dit verkorte IGF-I eiwit te bestuderen. 
Deze studies toonden aan dat de zeer kleine lengte niet werd veroorzaakt door een 
dominant negatief effect van het verkorte eiwit, en daarmee werd onze hypothese dus 
verworpen. Gebaseerd op de klinische, structurele en functionele gegevens speculeren we 




dat de groeiafwijking is veroorzaakt door een combinatie van partiële IGF-I deficiëntie, 
placentaire IGF-I insufficiëntie en andere (nog niet geïdentificeerde) genetische factoren. 
In de hierop volgende jaren bleek dat de groeistoornis succesvol behandeld kon worden 
met groeihormoon. Deze studie was de eerste die liet zien dat naast homozygote IGF1 
mutaties, ook heterozygote IGF1 mutaties kunnen resulteren in een kleine lengte.
Een ander kandidaatgen in de GH-IGF-I as is IGFALS. Homozygote moleculaire defecten 
in IGFALS kunnen een matig kleine lengte, vertraging van de puberteit en insuline 
ongevoeligheid veroorzaken. Sinds het verschijnen van de eerste rapportage over een 
homozygote IGFALS mutatie, zijn er in totaal 16 unieke homozygote of compound 
heterozygote mutaties in 21 patiënten met ALS deficiëntie beschreven. In Hoofdstuk 4 
worden de familieleden van een grote Koerdische familie beschreven, die een homozygote, 
een heterozygote of geen mutatie in het IGFALS gen dragen. De drie index patiënten 
(broers) presenteerden met kleine lengte (lengte SD score -4,2, -3,6 en -4,4), microcefalie, 
lage bloedspiegels van IGF-I en IGFBP-3, en onmeetbaar lage ALS spiegels in het bloed. 
Twee van de jongens waren bekend met een lage botmineraaldichtheid en één van hen 
had twee botbreuken gehad. Genetische analyse toonde een homozygote duplicatie van 
één nucleotide in exon 2, resulterend in een frame shift en een prematuur stopcodon. 
Het 150 kDa grote ternaire complex van IGF-I, IGFBP-3 en ALS was afwezig in de sera 
van de drie patiënten en er werden geen ALS eiwitten gedetecteerd met Western blot. 
IGFPB-1 en IGFBP-2 plasmaspiegels waren laag en er was een milde insulineresistentie. 
Vijf heterozygote dragers van de IGFALS mutatie neigden naar een kleinere lengte en een 
geringere hoofdomvang dan vijf niet-dragers, en hadden lage ALS en IGFBP-3 waarden 
in het bloed. De botdichtheid was laag in twee van de drie homozygote dragers, en ook 
in vier van de negen familieleden. Een voordeel van deze studie was dat het effect van 
de mutatie onderzocht kon worden tegen dezelfde genetische achtergrond, evenals het 
mogelijke effect van het dragen van een heterozygote mutatie. Dit leidde tot de hypothese 
dat er mogelijk een gen-dosis effect is, resulterend in een klein negatief effect op lengte en 
hoofdomvang in heterozygote dragers. Hierna heeft ook het internationale ALS consortium 
onderzoek gedaan naar de impact van heterozygotie voor IGFALS mutaties op kleine lengte 
in zoveel mogelijk aangedane patiënten en families, met inbegrip van de familie die wij 
hebben beschreven. In deze publicatie kon worden bevestigd dat heterozygotie inderdaad 
resulteerde in een lengteverlies van ongeveer 1,0 SDS in vergelijking met familieleden 
zonder een afwijking van het IGFALS. Deze en andere studies naar patiënten met ALS 
deficiëntie hebben laten zien dat het lokaal geproduceerde IGF-I belangrijker is voor groei 
dan circulerend IGF-I.
hfst 10.indd   233 20-05-13   12:33
234
Deel B beschrijft de kandidaatgen aanpak in de GH-IGF-I as in combinatie met een 
genoom-brede aanpak. Hierbij hebben we gebruik gemaakt van de zogenaamde 
“single-nucleotide polymorphism (SNP) array analyse”. De belangrijkste reden om de 
kandidaatgen aanpak uit te breiden was dat deze strategie zeer arbeidsintensief kan zijn, 
en dat hiermee geen nieuwe genen betrokken bij groei kunnen worden geïdentificeerd. 
Daarnaast realiseerden wij ons dat het fenotype veroorzaakt door verschillende genetische 
defecten veel heterogener kan zijn dan verwacht. In Hoofdstuk 5 onderzochten we 100 
kinderen, die klein werden geboren voor de zwangerschapsduur (‘small for gestational 
age’, SGA) waarbij de achterstand in lengtegroei vervolgens niet werd gecompenseerd 
door ’inhaalgroei‘. Wij hebben hiervoor de zogenaamde MLPA techniek gebruikt (Multiplex 
Ligation-dependent Probe Amplification), waarmee intragene (kleine) ’copy number 
variants‘ (CNVs) in 18 groei-gerelateerde genen konden worden onderzocht. Dit resulteerde 
in 2 patiënten met een de novo heterozygote terminale 15q deletie, welke het volledige (bij 
patiënt A) en gedeeltelijke (bij patiënt B) IGF1R gen bevatte. Serum IGF-I was laag (-2,78 
SDS) bij patiënt A, waarschijnlijk als gevolg van een eveneens aanwezige GH deficiëntie. 
Functionele studies met huidfibroblasten lieten een vergelijkbare IGF-I receptor (IGF1R) 
autofosforylering zien als in huidfibroblasten van controles, een tendens tot verminderde 
IGF1R eiwitexpressie en een verminderde intracellulaire activering van proteïne kinase B/
Akt na stimulering met IGF-I. Met functionele studies met behulp van huidfibroblasten 
hebben wij daarna de hypothese getoetst dat haploinsufficiëntie van IGF1R tot een 
50% reductie van volledig functionele IGF-I receptoren leidt. Dit bleek niet het geval te 
zijn, hoewel de IGF1R expressie wel lager leek te zijn. Andere functionele studies lieten 
echter zien dat de intracellulaire signalering verminderd was. Onze hypothese is, dat de 
gevolgen van IGF1R haploinsufficiëntie afhankelijk kan zijn van het celtype, met mogelijk 
een relatief sterk effect in groeischijf chondrocyten, terwijl het effect in het fibroblast 
model minder uitgesproken is. In dit onderzoek werd alleen MLPA gebruikt om CNVs te 
detecteren. Aangezien er geen sequentieanalyse van de 18 groei-gerelateerde genen 
werd uitgevoerd kunnen mutaties in deze genen niet worden uitgesloten. In Hoofdstuk 6 
hebben we kinderen met een kleine lengte en aanwijzingen voor GH ongevoeligheid (een 
lage bloedspiegel van IGF-I bij een normale groeihormoon secretie) onderzocht met de 
kandidaatgen aanpak (sequentieanalyse en MLPA van 5 kandidaatgenen in de GH-IGF-I as) 
in combinatie met SNP (single nucleotide polymorphism) array analyse om (grotere) ’copy 
number variants’ (CNVs) op te sporen, met een afmeting van > 150 kb. Patiënten werden 
verdeeld in drie groepen op basis van lengte en IGF-I SDS. Kinderen met een lage lengte SDS 
en IGF-I waarde werden ondergebracht in groep 1; kinderen met een matig kleine lengte die 
wel een laag IGF-I hadden werden ondergebracht in groep 2; en kinderen met kleine lengte 
met serum IGF-I waarden in de onderste helft van het normale gebied kwamen in groep 3. 
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Hierbij werden drie patiënten in groep 1 gevonden met twee nieuwe heterozygote STAT5B 
mutaties, in twee daarvan gecombineerd met nieuwe heterozygote IGFALS varianten. In de 
groepen 2 en 3 was de associatie tussen genetische varianten en kleine lengte onzeker. Er 
waren voldoende aanwijzingen dat de heterozygote STAT5B mutaties betrokken zijn bij de 
waargenomen GH ongevoeligheid, maar de associatie tussen de genetische varianten in 
IGFALS en kleine lengte blijft onzeker. Het is echter denkbaar dat IGF-I deficiëntie resulterend 
in kleine lengte ook geassocieerd kan worden met het cumulatieve effect van een defect 
in twee (digeen) of meer genen (oligogeen). Naast de varianten in de kandidaatgenen zijn 
er nieuwe CNVs in 6 kinderen geïdentificeerd. Het is mogelijk dat in sommige van deze 
patiënten de CNVs geassocieerd kunnen worden met het fenotype, maar er waren geen 
duidelijke kandidaatgenen aanwezig. Deze bevinding is in lijn met een recent rapport over 
een associatie tussen de aanwezigheid van laag frequente genomische deleties in kinderen 
met een kleine lengte. In deze studie hebben we aangetoond dat het raadzaam is om bij 
kinderen met een zeer kleine lengte en een laag circulerend IGF-I genetisch onderzoek te 
verrichten. De opbrengst in termen van vastgestelde diagnoses was 33%. Bij kinderen met 
minder kleine lengte en/of matig verlaagde serum IGF-I waarden, is de waarschijnlijkheid 
van het vinden van varianten in deze genen veel lager, wat suggereert dat andere, nog 
onbekende, genen een rol spelen.
In deel C wordt de genoom-brede aanpak beschreven, gebruik makend van SNP array 
analyse in 149 niet-verwante families (162 patiënten) met een kleine lengte door onbekende 
oorzaak. Hiermee kunnen nieuwe genen worden gevonden die zijn geassocieerd met 
kleine lengte (Hoofdstuk 7). Indien mogelijk werd co-segregatie analyse van de CNV met 
het fenotype in de familie uitgevoerd, voor het bevestigen van potentieel pathogene 
varianten. In deze studie werden CNVs gedetecteerd in 40 families. In 6 families (4%) werd 
een bekende oorzaak van kleine lengte gevonden (SHOX deletie of duplicatie, IGF1R deletie), 
in twee daarvan gecombineerd met een potentieel pathogene CNV. In 33 families (22,1%) 
werden één of meer potentieel pathogene CNVs (n = 40) geïdentificeerd, en in 9 families 
ontstonden deze CNVs de novo of segregeerden ze met kleine lengte. Verschillende 
van de gedeleteerde of gedupliceerde genen kunnen worden beschouwd als potentiële 
kandidaatgenen voor groeistoornissen, met inbegrip van 4 genen die eerder in verband 
werden gebracht met lengte in genoom-brede associatie studies (ADAMTS17, PRKG2/BMP3, 
PAPPA, TULP4). Er zijn echter aanvullende studies nodig om de rol van deze en andere genen 
in de regulatie van longitudinale groei te ondersteunen.
Deel D beschrijft de gecombineerde genoom-brede aanpak door middel van exoom-brede 
sequencing (whole exome sequencing, WES) en de hierop volgende functionele studies. 
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Deze aanpak was succesvol voor de identificatie en karakterisering van een nieuwe 
activerende NPR2 mutatie, welke resulteert in een zeer grote lengte van 221 cm in een 
verder gezonde man (Hoofdstuk 8). Groeihormoon overproductie, bekende syndromen 
en een deletie in chromosoom 15q25.2q25.3 met 8 eiwit-coderende genen en mutaties in 
deze genen op het andere allel waren uitgesloten als de oorzaak van de grote lengte. De 
heterozygote missense mutatie in het NPR2 gen resulteert in een aminozuurverandering 
op positie 655 van Arginine naar Cysteine, in het kinase homologie domein van NPR2 en is 
niet aanwezig als bekende variant in alle beschikbare databases. De NPR2 mutatie en de 
15q25.2q25.3 deletie werden niet gevonden in de zus en de zoon van de patiënt, die niet 
zo lang waren als de patiënt. Transfectie studies van het mutant NPR2 eiwit in HEK293 
cellen resulteerde in verhoogde basale en CNP gestimuleerde NPR2 activiteit. Co-expressie 
van wild type en mutant NPR2 resulteerde in verhoogde activiteit, bijna even hoog als 
die met mutant NPR2 alleen. Co-immunoprecipitatie studies bevestigden heterodimeer 
vorming van wild type en mutant NPR2. Studies met huidfibroblasten van de patiënt 
toonden een toegenomen NPR2 activiteit na stimulatie met CNP, hetgeen bevestigt dat 
de NPR2 mutant de CNP-NPR2-cGMP signalering versterkt. Deze signaleringsroute is 
kritisch betrokken bij botontwikkeling door stimulering van chondrocyt differentiatie en 
proliferatie in de groeischijven van de lange pijpbeenderen. Op basis van deze resultaten 
en een eerder door Japanse onderzoekers gevonden activerende NPR2 mutatie welke 
resulteerde in grote lengte, concluderen we dat de geïdentificeerde NPR2 mutatie in onze 
patiënt verantwoordelijk is voor de extreem grote lengte.
In Hoofdstuk 9 worden de belangrijkste bevindingen van dit proefschrift samengevat en 
kritisch beoordeeld en worden toekomstperspectieven besproken. In de eerste plaats is 
gebleken dat de kandidaatgen aanpak succesvol kan zijn bij de diagnose van patiënten met 
een kleine lengte. Deze aanpak heeft echter ook nadelen. Het is zeer arbeidsintensief, vooral 
als het fenotype niet typisch is voor een bepaald gendefect, er kunnen geen nieuwe genen 
betrokken bij groei mee worden geïdentificeerd en wanneer het fenotype veroorzaakt 
door een genetisch defect heterogener is dan verwacht, dan wordt het niet altijd herkend. 
Vervolgens wordt een nieuwe strategie bediscussieerd die de kandidaatgen en genoom-
brede aanpak combineert. Deze heeft niet geleid tot de identificatie van nieuwe genen, 
maar heeft wel mutaties geïdentificeerd in de GH-IGF-I as. Tevens werden aanwijzingen 
gevonden dat kleine lengte ook kan worden veroorzaakt door een cumulatief effect van 
digene of oligogene defecten. Daarna wordt bediscussieerd dat een genoom-brede SNP 
array analyse een goede methode is om potentiële kandidaatgenen voor groeistoornissen 
te identificeren, hoewel aanvullende studies nodig zullen zijn om de mogelijke rol van deze 
genen bij de afwijkende lengtegroei te ondersteunen. Tenslotte wordt aan de hand van een 




nieuwe activerende NPR2 mutatie welke resulteert in zeer grote lengte geïllustreerd dat 
het gebruik van WES gecombineerd met functionele studies succesvol is in de identificatie 
en karakterisering van nieuwe mutaties in groei gerelateerde genen.
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